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Modelling prognostic trajectories in Alzheimer’s 
disease.  
Joseph Giorgio 
Abstract 
 
Progression to dementia due to Alzheimer’s Disease (AD) is a long and protracted process that 
involves multiple pathways of disease pathophysiology. Predicting these dynamic changes has 
major implications for timely and effective clinical management in AD.  There are two reasons 
why at present we lack appropriate tools to make such predictions. First, a key feature of AD 
is the interactive nature of the relationships between biomarkers, such as accumulation of β-
amyloid -a peptide that builds plaques between nerve cells-, tau -a protein found in the axons 
of nerve cells- and widespread neurodegeneration. Current models fail to capture these 
relationships because they are unable to successfully reduce the high dimensionality of 
biomarkers while exploiting informative multivariate relationships. Second, current models 
focus on simply predicting in a binary manner whether an individual will develop dementia 
due to AD or not, without informing clinicians about their predicted disease trajectory. This 
can result in administering inefficient treatment plans and hindering appropriate stratification 
for clinical trials. In this thesis, we overcome these challenges by using applied machine 
learning to build predictive models of patient disease trajectories in the earliest stages of AD. 
Specifically, to exploit the multi-dimensionality of biomarker data, we used a novel feature 
generation methodology Partial Least Squares regression with recursive feature elimination 
(PLSr-RFE). This method applies a hybrid-feature selection and feature construction method 
that captures co-morbidities in cognition and pathophysiology, resulting in an index of 
Alzheimer’s disease atrophy from structural MRI. We validated our choice of biomarker and 
the efficacy of our methodology by showing that the learnt pattern of grey matter atrophy is 
highly predictive of tau accumulation in an independent sample. Next, to go beyond predicting 
binary outcomes to deriving individualised prognostic scores of cognitive decline due to AD, 
we used a novel trajectory modelling approach (Generalised Metric Learning Vector 
Quantization – Scalar projection) that mines multimodal data from large AD research cohorts. 
Using this approach, we derive individualised prognostic scores of cognitive decline due to 
AD, revealing interactive cognitive, and biological factors that improve prediction accuracy. 
Next, we extended our machine learning framework to classify and stage early AD individuals 
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based on future pathological tau accumulation. Our results show that the characteristic 
spreading pattern of tau in early AD can be predicted by baseline biomarkers, particularly when 
stratifying groups using multimodal data. Further, we showed that our prognostic index 
predicts individualised rates of future tau accumulation with high accuracy and regional 
specificity in an independent sample of cognitively unimpaired individuals. Overall, our work 
used machine learning to combine continuous information from AD biomarkers predicting 
pathophysiological changes at different stages in the AD cascade.  The approaches presented 
in this thesis provide an excellent framework to support personalised clinical interventions and 
guide effective drug discovery trials.  
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1. Introduction 
Preamble   
Alzheimer’s Disease  
Alois Alzheimer in early November of 1906 gave a seminal lecture describing the 
neuropathological and clinical presentations of one of his patients, Auguste D. Alzheimer 
described the death of his patient as caused by the death of a dementing illness, describing 
clinical presentations of progressive dementia and the pathological presence of intracellular 
plaques and tangles (Alzheimer, 1907). This characteristic progressive dementia in the 
presence of plaques and tangles, termed Alzheimer’s disease (AD), now accounts for up to 
70% of the 50 million people living with dementia world-wide, at a global societal cost 
approaching 1 trillion US dollars (Patterson, 2018). However, these numbers are only a fraction 
of the projected diagnosis, with an anticipated 152 million cases by 2050 (Prince et al., 2015). 
The current societal and financial burden coupled with the anticipated increase in AD globally 
presents a critical need for treatment. Alarmingly, a pharmacological intervention still eludes 
the pharmaceutical industry with clinical trials failing to achieve FDA approval 99.6 percent 
of the time (Patterson, 2018). The long development time of 13 years with an average cost of 
5.6 billion US dollars (compared to on average 793.6 Million for a cancer drug) (Cummings, 
Reiber, & Kumar, 2018) has driven pharmaceutical giants out of the race with Pfizer pulling 
out of AD research in 2018. The increasing prevalence and lack of viable treatment makes AD 
one of the most debilitating diseases in the first world. This is evident when comparing the 
relative change in cause of death in the US between 2000 and 2015: 5 of the 6 leading causes 
of death declined(1% for breast cancer, up to 55% for HIV), while death due to AD (6th)  
increased by 123% (Alzheimer’s Association, 2018). 
Since 1906, however, the biological underpinnings of AD have been heavily studied and 
increasingly clear hypotheses have been proposed as to the pathological cascade that ultimately 
leads to dementia due to AD. This foundational neuroscientific inquiry coupled with robust 
biological definitions of AD provide a framework to study AD. Further, with the ingress of 
more computationally complex tools in neuroscience, predictive multivariate models can be 
built to elucidate pathophysiological interactions and prognostic trajectories in AD. These 
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multivariate approaches are well poised to combine multimodal biomarkers to stratify 
individuals at the earliest stages of AD, increasing the likelihood of effective clinical 
interventions. When considered together, these three facets of AD research can inform clinical 
trials and guide personalised interventions, ultimately alleviating the estimated 342.000 US 
dollar cost for a person living with dementia (Alzheimer’s Association, 2018).   
Machine learning in clinical decision making  
Machine learning is one such multivariate approach to integrate multimodal biomarkers to 
guide clinical decision-making. However, as of yet machine learning is yet to see widespread 
proliferation in clinical practice. Recently, deep learning has been lauded as the answer to this 
problem (Esteva et al., 2019). Deep learning attempts to model hidden interactions between 
input data with parameters tuned throughout the learning process (Lecun, Bengio, & Hinton, 
2015). In a typical application to neuroimaging data this parameter search space will often 
exceed the sample size by many orders of magnitude. The most efficient  designs still have 
1000 times more parameters than samples (Spasov, Passamonti, Duggento, Liò, & Toschi, 
2019). While deep learning has excelled at image recognition (Krizhevsky, Sutskever, & 
Hinton, 2012), access to labelled training data for image recognition dwarves labelled clinical 
data. Therefore, there is a drastic need to accurately validate these heavily parameterised 
approaches when making clinical decisions (Topol, 2019). Further, given the hidden 
architecture of deep learning models, internal decisions made by the model are largely blind; 
the machine learning practitioner often sees only a final output from the ‘black box’ 
architecture.  
This black box approach of deep learning seems at odds with clinical decision making. Clinical 
diagnosis is not blindly made, rather, informed from well categorised and interpretable 
biomarkers. Blind appraisal of data by deep leaning models is not the only feature at odds with 
a clinical decision maker. Throughout the learning process a deep learning model will multiply 
weights, fit non-linearities and -in some cases- model recurrent processes (Lecun et al., 2015). 
However, when tasked with making a clinical diagnosis the clinician is reminded “Entities 
should not be multiplied unnecessarily” (William of Occam, c. 1320). As a pillar of clinical 
science, Occam’s razor drives decision making, favouring diagnostic parsimony. These 
incongruities between a clinician and deep learning architectures (i.e. heavy parameterisation, 
poor interpretability and unnecessary complexity) question their current and potential clinical 
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utility in diagnosis. However, machine learning need not be so discordant with clinical ethos. 
In 1987 Blumer and colleagues showed when hypotheses of minimum complexity are applied 
to data in machine learning -so called Occam’s learner- a model can achieve optimal predictive 
performance (Blumer, Ehrenfeucht, Haussler, & Warmuth, 1987).  
For machine learning to become more accepted in clinical decision support, researchers must 
focus on developing models that are interpretable and generalisable without needless 
complexity. AD research is well poised to offer a course of inquiry where interpretable and 
robust machine learning can be deployed. Throughout the AD cascade there are well 
characterised pathophysiological processes. Under the recent biological definition of AD these 
measurable pathological processes can be reduced down to dynamic changes in β-amyloidosis, 
tau deposition, neurodegeneration and cognitive decline (Jack, Bennett, et al., 2018). 
Therefore, machine learning approaches that provide interpretable and intuitive predictions 
based within these categories of biomarker changes, can provide mechanistic insights into 
pathological processes while providing a clear and succinct clinical support tool.  
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Underlying pathology: the amyloid hypothesis  
The amyloid hypothesis is the most widely accepted series of pathological changes that lead to 
dementia due to AD. The amyloid hypothesis first put forward in the 1980’s, posits that the 
primary cause event of AD is the accumulation of β-amyloid plaques between neural cells 
(Glenner & Wong, 1984a). Similar work at the time showed that β-amyloid peptide, a biproduct 
of the amyloid precursor protein (APP), was the core chemical component of senile plaques 
(Masters et al., 1985) first proposed by Alois Alzheimer in 1906. These initial investigations 
showed that β-amyloid plaques found in patients with trisomy 21 (Down’s Syndrome) were 
the same as senile plaques characteristic of AD (Glenner & Wong, 1984b; Masters et al., 1985). 
When considering the invariable development of AD for older Down’s syndrome patients, this 
work suggested a genetic cause of AD. Subsequent work isolated a genetic deficit on 
chromosome 21 that leads to the accumulation of β-amyloid plaques (Goldgaber, Lerman, 
McBride, Saffiotti, & Gajdusek, 1987; Kang et al., 1987; Tanzi et al., 1987).These findings 
provided   a mechanistic understanding of how genetic mutations can alter the function of APP, 
resulting in AD (Goate et al., 1991; Mullan et al., 1992). 
Amyloid Precursor Protein (APP)  
β-amyloid is a fragment of the transmembrane amyloid precursor protein (APP). When β- then 
γ-secretases cleave APP in the amyloidogenic pathway, neurotoxic Aβ42 isoforms are formed. 
Due to the hydrophobic nature of Aβ42, these protein subunits self-aggregate to form β-amyloid 
fibrils and subsequent β-amyloid plaques (i.e. senile plaques) (Figure 1.1). While this process 
in itself does not cause dementia, familiarly inherited genetic mutations to the presenilin 1,2 
PSEN1, PSEN2) or BACE 1 gene invariably lead to Early Onset AD (EOAD). These mutations 
result in the favouring of proteolytic processing of APP by γ-secretase (PSEN1, PSEN2) or the 
adjacent β-secretase (BACE 1) subunit, which favours the production of the more fibrilogenic 
Aβ42 (over Aβ1-40) and subsequent β-amyloid plaques. Given the functional changes these 
mutations drive in APP processing, leading to accumulation of β-amyloid, and development of 
AD, these genetic studies provide strong evidence for the primary role of β-amyloid in AD 
(Hardy & Higgins, 1992; Selkoe, 1991). Additional support of the amyloid hypothesis comes 
from genetic studies investigating rare mutations on the 21st chromosome. These studies show 
that when the APP gene is duplicated individuals acquire AD in their 50s (Rovelet-Lecrux et 
al., 2006), while Downs syndrome individuals who only have the distal part of chromosome 
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21 replicated (not including the APP gene locus) do not get AD (Prasher et al., 1998). Similarly, 
several protective mutations to the APP gene show a decrease in β-amyloid accumulation and 
a lower risk or AD or age-related cognitive decline (Jonsson et al., 2012; Kero et al., 2013). 
ApoE 4 
While mutations to the APP gene are known to lead to EOAD, the major genetic risk factor for 
Late Onset AD (LOAD) is the epsilon 4 allele on the apolipoprotein E (ApoE) gene (Corder et 
al., 1993). The ApoE4 allele was identified as the major genetic risk factor for LOAD in the 
early 1990’s, where it was observed that individuals expressing the ApoE4 allele develop more 
β-amyloid deposits than those expressing only ApoE3 (Rebeck, Reiter, Strickland, & Hyman, 
1993). Subsequent work on transgenic mice has highlighted the influence of ApoE in the 
clearing of β-amyloid. Mice expressing the APP gene that are ApoE deficient show a 
significant decrease in β-amyloid accumulation, highlighting the role of ApoE in β-amyloid 
clearance not production (Castellano et al., 2011; Kim et al., 2013). Specifically, this work in 
transgenic mice showed that the epsilon 4 allele hindered β-amyloid clearance the greatest, 
with a decreased effect by ApoE4 > E3 > E2 (Castellano et al., 2011). These studies suggest a 
genetic link between β-amyloid dyshomeostasis (i.e. increased production and decreased 
clearance) and AD.  
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Figure 1.1 β-amyloid cascade 
 
Figure 1.1 adapted from (Castellani, Plascencia-Villa, & Perry, 2019) β-amyloid cascade 
hypothesis. β-amyloid precursor protein (APP) gene expression is followed by consecutive 
protease processing by β-secretase 1 (BACE1) and γ-secretase complex (PSEN1 (presenilin 
1), PSEN2 (presenilin 2), releasing the β-amyloid peptide, including pathogenic species 
Aβ42. Aβ42 undergoes conformational change, assembles into oligomers and protofibrils, 
and ultimately deposits as senile plaques 
 
Tau 
The second hallmark proteinopathy in AD is the formulation of neurofibrillary tangles.  
Tangles comprise filaments of the hyperphosphorylated forms of the microtubule binding 
protein tau (Grundke-Iqbal et al., 1986). These straight filaments twist around each other to 
form paired helical filaments initially appearing within the soma and dendritic processes of 
neurons. When these filaments aggregate, they combine into neuruofibrillary tangles and 
accumulate within dendrites, axons and cell bodies (Brion, 1998). 
The amyloid hypothesis is not without contention, with critics suggesting that deposition of tau 
not β-amyloid is the primary event in AD (Heiko Braak & Del Tredici, 2011). Histological 
work investigating the deposition of cortical tau across the lifespan shows subcortical tau 
deposition within the first decade of life (Heiko Braak & Del Tredici, 2011). Subsequent 
studies show that the subcortical deposition of tau as well as deposits in the medial temporal 
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lobe are commonly found in cognitively healthy amyloid negative older people (Heiko Braak 
& Del Tredici, 2012). While studies show that medial temporal tau in the absence of β-amyloid 
can lead to poorer episodic memory and medial temporal atrophy, this is referred to as primary 
age-related tauopathy (PART) and is distinct from AD (Crary et al., 2014). 
However, there are several lines of genetic evidence supporting β-amyloid as the primary driver 
of AD and not tau. When investigating the temporal order of events for individuals with the 
inherited mutations leading to EOAD and in Downs syndrome patients who acquire AD it has 
been shown that β-amyloid deposition precedes the accumulation of tangles (Bateman et al., 
2012; C. A. Lemere et al., 1996; Cynthia A. Lemere et al., 1996). Further, when investigating 
genetic mutations in the gene encoding tau (FTDP-17), these mutations lead to non-AD 
tauopathies such as frontal-temporal dementia and parkinsonism (Hutton et al., 1998; Poorkaj 
et al., 1998; Spillantini, Van Swieten, & Goedert, 2000). These genetic studies provide 
evidence that supports the upstream role of β-amyloid relative to tau accumulation.  
The AD Cascade 
The hypothetical model of the AD cascade proposed by Jack and colleagues presents a schema 
of the dynamic pathophysiological changes that lead to AD-dementia (Jack et al., 2013; Jack, 
Knopman, et al., 2010)  (Figure 1.2).  This model provides a sequence of pathological changes 
initiated by β-amyloid accumulation. The model extends the amyloid hypothesis, positing a 
series of pathological changes that are measurable in vivo. One critical aspect of the AD 
cascade is that while Aβ42 dysregulation that results in β-amyloid plaques is necessary, it is not 
sufficient to lead to AD. This is an important distinction as β-amyloid deposition is regularly 
seen in cognitively normal older adults, with approximately 30% of individuals being β-
amyloid positive by 80 (Jansen et al., 2015). The dynamic model of the AD pathological 
cascade shows upstream changes in β-amyloid and downstream neurodegeneration, with 
maximum rate of biomarker change moving from one pathophysiological domain to the next. 
The sequence of pathophysiological change has been widely supported in many international 
cohorts investigating in vivo changes in EOAD (Gordon et al., 2018). 
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Figure 1.2 The AD cascade 
 
Figure 1.2 adapted from (Jack, Knopman, et al., 2010). Dynamic biomarkers of the 
Alzheimer's pathological cascade: Aβ=β-amyloid. MCI=mild cognitive impairment. 
 
Dynamic Changes in β-amyloid Biomarkers Precedes Tau.  
The widespread cortical deposition of β-amyloid initiates the AD cascade. This rising 
deposition of β-amyloid has been shown in vivo using PET, with β-amyloid levels associated 
with tau deposition in coming years (Leal, Lockhart, Maass, Bell, & Jagust, 2018; Tosun et al., 
2017). Further, this deposition of β-amyloid precedes cognitive symptoms by up to 20 years 
and has a weak association with the cross-sectional severity of dementia symptoms (Furst et 
al., 2012; Klunk et al., 2004; Rowe et al., 2007). These studies support that β-amyloid is a 
prerequisite of both changes in tau and cognition in AD.  
Tau Deposition.  
The next key event s is tau deposition across the cortex. This deposition can be measured in 
vivo using flortaucipir PET and closely follows the characteristic spreading pattern of tau 
deposits across the cortex in AD, known as the Braak staging system (Schöll et al., 
2016)(Figure 1.3).  
The Braak staging describes the characteristic spreading pattern of tau deposits across the 
cortex in AD (H. Braak & Braak, 1991). The spreading pattern shows that neurofibrillary 
tangles and neuropil threads spread across the cortex at 6 different stages. Stages I and II are 
localised to transentorhinal regions. Stages III and IV are the limbic stages and involve the 
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spreading from the transentorhinal regions into the entorhinal cortex with no effect on 
neocortical regions. Stages V and VI are the neocortical stages, this involves the spreading of 
tau from the limbic regions throughout the neocortex.  
 
Figure 1.3 Braak staging system 
 
Figure 1.3 adapted from (Schöll et al., 2019) FTP Tau tracer deposition patterns 
resemble post mortem Braak stages. A. post mortem Braak stages of tau deposition 
throughout Alzheimer's disease. B. Voxel-wise two-sample t-tests on FTP SUVR images 
between subjects assigned to tau-PET based Braak stages. 
 
This spreading of tau in the presence of amyloid has been closely linked to cross sectional 
and longitudinal cortical atrophy and hypometabolism (Bischof et al., 2016; L. Wang et al., 
2016). Further, the deposition of tau is related to cognitive function in the presence of β-
amyloid, however this association is weaker in the absence of β-amyloid (Brier et al., 2016; 
Cho et al., 2016; Johnson et al., 2016; Schwarz et al., 2016).  
Cortical Atrophy and Hypometabolism.  
Closely following the changes in tau deposition, a characteristic pattern of hypometabolism 
and atrophic changes occur (Bradford C. Dickerson et al., 2009; Furst et al., 2012; V. Singh et 
al., 2006). Hypometabolism as measured by FDG-PET follows a signature pattern initially 
occurring in the posteromedial and lateral temporal parietal cortex, then spreading to other 
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temporal regions (W. J. Jagust et al., 2009). Structural MRI measures of individuals who 
transition from mild cognitive impairment to dementia show a pattern of atrophy that parallels 
the pattern of tau deposition (Whitwell et al., 2007). Further, whole brain measures of tau are 
closely related to temporoparietal atrophy both longitudinally and cross-sectionally (LaPoint 
et al., 2017), suggesting that tau spreads prior to medial temporal atrophy. These AD typical 
patterns of atrophy and hypometabolism lead to an increased risk of future cognitive decline in 
cognitively healthy individuals, particularly in individuals with β-amyloid (De Leon et al., 
2001; B. C. Dickerson et al., 2011; W. Jagust et al., 2006; Smith et al., 2007). However, similar 
patterns of atrophy can be observed in the absence of β-amyloid (Bakkour, Morris, Wolk, & 
Dickerson, 2013; Knopman et al., 2013) and this process of neurodegeneration is thought to be 
independent of AD, referred to as suspected non-Alzheimer pathophysiology (SNAP) (Jack, 
Knopman, et al., 2016). These studies highlight the lack of specificity of neurodegeneration, 
particularly in the medial temporal cortices when diagnosing AD. 
The large body of work that supports this hypothetical model of the AD cascade makes it an 
ideal framework to characterise an individual with AD. That is, this series of dependent 
changes throughout the AD cascade provides an elegant framework to classify and stage an 
individual with AD.  
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Biological Definition of AD 
Established by an international consortia of AD researchers, the 2018 NIA-AA Research 
Framework was developed to unify and guide AD researchers by formulating a biological 
definition of Alzheimer’s disease (Jack, Bennett, et al., 2018).   
The underlying principle of this framework is to provide a single classification scheme of AD 
across the disease spectrum. Given the reliance on biological markers and the relative infancy 
of the framework, the intent was not to guide clinical practice but to design longitudinal 
observational cohort studies and interventional studies. At the core of the research framework 
is the dissociation of syndromic definitions (i.e. defined by clinical labels) of AD that 
constituted the previous 2011 NIA-AA research framework (Albert et al., 2011; McKhann et 
al., 2011) from neuropathological changes that define a disease. However, the majority of 
ongoing longitudinal observational cohort studies were initiated prior to the introduction of the 
2018 NIA-AA diagnostic framework with the clinical categorisation of participants following 
the 2011 NIA-AA syndromic definitions of AD (R. C. Petersen et al., 2010). Therefore, 
research approaches and techniques that are amenable to both syndromic and biological 
diagnostic criterion are well suited to capitalise on decades of longitudinal AD research.  
Syndromic Definitions: Cognitively Normal, Mild Cognitive Impairment and 
Probable AD Dementia 
Under the previous classification schemes the AD continuum is defined as the transition from 
a preclinical cognitively unimpaired state to a state of mild cognitive impairment (MCI) to 
dementia (Ronald C. Petersen et al., 2001). Crucially the guidelines note that there are no sharp 
demarcations that separate MCI from cognitively normal or demented and subjective clinical 
judgement is required to make the final diagnostic decision.  
Mild Cognitive Impairment.  
MCI due to AD is a four-stage diagnostic process (Albert et al., 2011). First, the patient should 
have a declining state of cognition, which can be determined by a patient, person close to the 
patient or a trained clinician. Second, the patient should perform below education and age 
matched controls in one or more cognitive domains (i.e. memory, executive function 
visuospatial skills). If repeated longitudinal measurements are taken, then a decline in 
performance should be evident. Third, the patient should have only mild problems performing 
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everyday tasks and is able to function independently. Finally, the patient must not be demented; 
that is the symptoms are mild enough to not impair social or occupational functioning.      
Probable AD Dementia.  
The 2011 NIA-AA diagnoses probable AD dementia as a distinct subtype of all cause 
dementia, having all clinical presentations of all cause dementia in addition to several specific 
criterion (McKhann et al., 2011). All dementias require declining cognitive symptoms that 
interfere with the ability to work or maintain usual activities. These symptoms must not be 
explained by delirium or neuropsychiatric conditions. To be diagnosed as probable AD 
dementia the declining cognitive symptoms must include a minimum of two of the following: 
Impaired ability to acquire and remember new information, impaired reasoning and handling 
of complex tasks, impaired visuospatial abilities, impaired language functions and changes in 
personality. In addition to these symptoms a patient with probable AD dementia must have had 
an insidious onset of these symptoms as well as longitudinal data documenting the worsening 
of cognition. Finally, the diagnosis should not be applied when a patient has concomitant 
substantial cerebrovascular disease or features of other dementia causing illnesses (i.e dementia 
with Lewy bodies, Frontotemporal dementia, primary progressive aphasia).    
Sensitivity and Specificity of Syndromic Definitions.  
While these transitions take place in AD, they are not specific to AD. Similarly, the most 
common syndromic definition of AD dementia, multi-domain amnestic dementia, is not 
sensitive to atypical AD variants such as dysexecutive, visuospatial or language dementias 
(Murray et al., 2011; Ossenkoppele et al., 2015). Nor is multi-domain amnestic dementia 
specific to AD pathological change (Nelson et al., 2011; Serrano-Pozo et al., 2014). These 
inherent syndromic definitions therefore are unable to provide a sensitive and specific 
definition of AD. In light of this, a single biological framework to define AD across the 
Alzheimer’s continuum is preferable.  
A/T/N Classification Framework: A Biological Definition of AD 
The ATN classification framework was designed to be an unbiased classification scheme that 
codifies biomarkers commonly used in AD research. The scheme initially introduced by Jack 
et al (Jack, Bennett, et al., 2016)  provides a framework to classify individuals based on three 
categories of AD biomarkers that measure the underlying AD pathophysiology: fibrillary β-
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amyloid plaques (A), neurofibrillary tangles -tau- (T) and neurodegeneration/neuronal injury 
(N). This framework is appealing as it provides an objective classification framework across 
the AD spectrum.  
Amyloid Beta Plaques: A.  
As discussed previously, the hallmark pathological process in AD is the accumulation of β-
amyloid plaques. The presence of β-amyloid deposition can be measured in-vivo either with 
an increased uptake of β-amyloid PET tracers, or subthreshold levels of Aβ42 in the CSF, 
sampled via lumbar puncture. Biomarkers of β-amyloidosis are well targeted to the 
pathophysiological process in AD (Ikonomovic et al., 2008; Strozyk, Blennow, White, & 
Launer, 2003), although not specific to the disease. For example, following traumatic brain 
injuries it has been shown that there is a significant uptake in β-amyloid PET traces (Hong et 
al., 2014). Further, subthreshold levels of CSF Aβ42 have been reported due to atrophic 
(Holmberg, Johnels, Blennow, & Rosengren, 2003) or inflammatory responses (Krut et al., 
2013) un-related to AD pathophysiology. This lack of specificity can limit the diagnostic 
usefulness of this marker when measured in isolation (i.e. only diagnosing based on a β-
amyloid positive biomarker). 
Fibrillar Tau: T.  
The wide-spread accumulation of fibrillar tau is the second stage of the amyloid cascade 
hypothesis, however tau accumulation is also a hallmark of other primary tauopathies (i.e. 
frontotemporal dementia, progressive supranuclear palsy or cortical-basal syndrome) (B. Hall 
et al., 2017; Sander et al., 2016; Schöll et al., 2019). Several tau biomarkers do, however, have 
reasonably high specificity to AD. Using lumbar punctures to extract CSF markers, paired 
increases of t-tau (total-tau) and p-tau (phosphorylated tau) are indicative of AD (K. Blennow 
et al., 1995). Further, these CSF markers are not present in non-AD primary tauopathies (S. 
Hall et al., 2012), with p-tau correlating closely with the severity of AD tau pathology 
postmortem (Tapiola et al., 2009). However, elevated levels of t-tau do occur as a result of 
neuronal damage either due to traumatic brain injuries or underlying neuronal disease (Öst et 
al., 2006; T. et al., 2014). When taken together the two markers give an indication of the 
intensity of neurodegeneration (t-tau) and the accumulation of tau (p-tau) due to AD (Kaj 
Blennow & Hampel, 2003). With the introduction of the flortaucipir tau-PET ligands, the 
uptake and topology of fibrillar tau can be measured across the AD spectrum. tau-PET ligands 
have a reasonably high specificity to paired helical filament tau found in AD but a much lower 
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binding affinity to non-AD tauopathies with straight filament tangles (Marquié et al., 2015). 
Finally, the spatial topography of tau accumulation follows closely the Braak staging of AD 
related tau at autopsy (Schöll et al., 2016, 2019). The ability to accurately measure the 
pathological spread of tau in-vivo makes it a good candidate biomarker for biological 
diagnosis, particularly if an individual also has a positive β-amyloid biomarker. 
Neurodegeneration / Neuronal Injury: N.  
The final, but least specific, pathophysiological process in the amyloid cascade is 
neurodegeneration (Bakkour et al., 2013). Neurodegeneration / neuronal injury can be 
measured indirectly from t-tau levels in the CSF. Neuroimaging provides a more direct way to 
measure neurodegeneration / neuronal injury with FDG-PET used to measure hypometabolism 
and structural MRI to measure atrophy. However, abnormal levels of atrophy or 
hypometabolism are not specific to AD, even if there are concordant measures of AD-like 
signatures on both FGD-PET and structural MRI (i.e. SNAP) (Burnham, Bourgeat, Doré, 
Savage, Brown, Laws, Maruff, Salvado, Ames, Martins, Masters, Rowe, & Villemagne, 2016; 
Jack, Knopman, et al., 2016; Jack et al., 2012). While these neuroimaging markers are non-
specific, they both have a topology that is characteristic of typical AD (i.e. generally resulting 
in amnestic multidomain dementia). Atrophy measured using structural MRI shows atrophic 
patterns that initially occur within the medial temporal cortex extending to the basal lateral 
temporal cortex (Jack & Holtzman, 2013), whereas, FDG-PET hypometabolism initially 
occurs in the posteromedial and lateral temporal parietal cortex (W. J. Jagust et al., 2009).  
Defining AD With The ATN Classification Scheme: The Alzheimer’s Continuum.  
The 2018 NIA-AA framework establishes a set of definitions of AD without the need of clinical 
diagnosis (Table 1.1). As β-amyloidosis is a specific pathophysiological process to AD, an 
individual with a positive biomarker for β-amyloid (notated A+) is defined as AD continuum. 
While non-specific to AD, tau is the second proteinopathy that is a hallmark of AD. Therefore, 
an individual with a positive biomarker for amyloid (A+) and a positive biomarker for tau 
(notated T+) is defined as having Alzheimer’s Disease (i.e. A+T+). An individual with a 
positive biomarker for β-amyloid (A+) but a negative biomarker for tau (T-), is at an earlier 
stage of the AD continuum compared to an individual with A+T+ and is defined as presenting 
Alzheimer’s pathological change (i.e. A+T-).  
As a non-specific biomarker for AD, neurodegeneration / neuronal injury is not used to define 
AD within the NIA-AA framework. However, the presence of a positive biomarker for 
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neurodegeneration / neuronal injury (notated as N+) is used to stage an individual with AD. As 
neurodegeneration / neuronal injury is the last stage of the amyloid cascade, an individual with 
the biomarker profile A+T+N+ is in a more advanced stage of AD compared to an individual 
with A+T+N-.  
 
Table 1.1 ATN classification scheme 
 
Table 1.1 adapted from (Jack, Bennett, et al., 2018) describes the biomarker profiles that are 
associated with different diagnostic classification in the 2018 research framework. 
 
Biomarker cut-offs: Amyloid Positivity.  
Within the ATN classification system all biomarkers exist on a continuous scale. However, 
under the NIA-AA classification framework a binary indication of biomarker positivity is 
required to make a diagnosis. The appropriate discretisation of these continuous biomarkers is 
crucial for informing clinical decision making or determining inclusion in a clinical trial. As 
β-amyloid biomarkers are one of the most heavily studied in AD, binary categorisation 
approaches exist for determining β-amyloid positivity (i.e. A+). Large AD cohort studies have 
observed that β-amyloid PET is distributed bimodally (Palmqvist et al., 2015). This has led to 
deriving β-amyloid PET cut off values that denote if an individual is A+ vs A- (Jack et al., 
2017). Similarly, when investigating CSF Aβ42, researchers have been able to determine the 
abnormal level indicating that cortical β-amyloid is not being sufficiently cleared (Palmqvist 
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et al., 2014).  These discretisation approaches have proven robust however they do not account 
for individuals who are on the boundary of β-amyloid positivity.  
Biomarker Cut-Offs: Tau and Neurodegeneration / Neuronal Injury.  
Unlike β-amyloid biomarkers, there is no clear discretisation approach to determining a 
categorical classification of in vivo tau (i.e. T+) and neurodegeneration / neuronal injury (N+). 
The most applicable way of categorising these biomarkers is using topographical staging. The 
topographic accumulation of tau PET closely follows the Braak neurofibrillary tangle staging 
topography (Schöll et al., 2016). This classification scheme would mirror the Braak postmorten 
staging based on the location of tau PET uptake. A recent approach measures the accumulation 
of tau in meta regions with stages closely aligned with cognitive decline (Jack, Wiste, et al., 
2018). A similar approach could be used for structural MRI as patterns of cortical atrophy have 
been shown to mirror the progressive Braak staging (Jack et al., 2017). 
Combining ATN Biomarkers To Make Prognostic Decisions In AD.  
Many studies on independent cohorts show that the combination of ATN biomarkers provide 
a fine stratification of individuals on the AD continuum based on prognostic trajectories of 
cognitive decline (Allison et al., 2019; Bilgel et al., 2018; Burnham, Bourgeat, Doré, Savage, 
Brown, Laws, Maruff, Salvado, Ames, Martins, Masters, Rowe, Villemagne, et al., 2016; 
Dumurgier et al., 2017; Insel et al., 2015; Jansen et al., 2018; van Maurik et al., 2019). While 
the NIA-AA proposed that a numeric scale could be used to define normal vs abnormal 
biomarkers to inform clinical decision making, there is no widely accepted approach used. The 
inherent continuous nature of these biomarkers and the reliable biomarker trajectories make 
multivariate methods, such as machine learning, optimal for combining ATN biomarkers to 
make prognostic decisions. 
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Predictive Models in AD 
Machine learning techniques have become one of the most favoured means of analysing 
neuroimaging data. Annual publications involving both neuroimaging and machine learning 
have increased nearly exponentially since 2003 (Christos Davatzikos, 2019). The application 
of machine learning approaches in AD is prevalent and accordingly has been extensively 
reviewed (Arbabshirani, Plis, Sui, & Calhoun, 2017; Maroco et al., 2011; Pellegrini et al., 2018; 
Rathore, Habes, Iftikhar, Shacklett, & Davatzikos, 2017; Tanveer et al., 2020). In particular, 
machine learning approaches are commonly used for a) classifying individuals as  cognitively 
normal (CN) vs. AD patients, achieving accuracies ranging from 60-90% or b) predicting 
conversion to dementia due to AD from MCI (i.e. stable MCI vs progressive MCI) achieving 
accuracies ranging from 50-85% (Pellegrini et al., 2018). The most common and arguably most 
simple classification frameworks rely on Support Vector Machines (Arbabshirani et al., 2017; 
Pellegrini et al., 2018; Rathore et al., 2017). However, large publicly available longitudinal 
research cohorts have encouraged more complex learning approaches to be used (for example; 
elastic nets, random forests, gaussian process regressions, multiple kernel learning, artificial 
neural networks and deep learning) ) (Ebrahimighahnavieh, Luo, & Chiong, 2020; Jo, Nho, & 
Saykin, 2019; Jollans et al., 2019; Tanveer et al., 2020). Attempts have been made to compare 
the performance of different modelling approaches (Jollans et al., 2019; Maroco et al., 2011; 
Samper-González et al., 2018). However, comparison of modelling techniques is difficult as 
cross validation approaches, sample sizes and sample heterogeneity have a significant effect 
on model performance metrics (i.e. accuracy or receiver operator characteristics) (Jollans et al., 
2019).  
Further, when concluding that a given algorithm is best for making predictions across the AD 
continuum the machine learning approach must be able to capture changes in pathology, 
cognition and diagnosis. However, in trying to achieve optimal performance across a set of 
different prediction problems the machine learning practitioner should refer to the no free lunch 
theorem. The no free lunch theorem (Wolpert & Macready, 1997) is an empirically assessed 
theorem that states that over all possible predictions all machine learning approaches average 
out to have the same performance. This occurs because a machine learning approach is 
commonly designed to achieve optimal performance for a specific task (i.e. predicting change 
in diagnosis). In constraining the algorithm to perform optimally in this task the same machine 
learning algorithm is therefore limited to solve a new task (i.e. predicting change in cognitive 
scores). Therefore, even though prediction tasks may be associated, the same algorithm with 
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optimal performance on the first task will sacrifice prediction performance on the second task 
(i.e. better performance in predicting change in diagnosis will likely decrease performance in 
predicting change in cognitive scores). With this in mind it is perhaps better to not ask which 
algorithm is best for making a specific prediction related to AD, but rather, which algorithm is 
able to make a range of predictions related to AD. In light of this a potential way to compare 
modelling frameworks is to test models on the same hold out data set across a set of different 
problems (i.e. changes in diagnosis and change in cognitive scores). These prediction 
challenges offer a more unbiased and potentially more relevant approach to determining the 
efficacy of prediction algorithms (e.g. TADPOLE (Marinescu et al., 2018)). This is particularly 
relevant in classification of cognitively normal vs AD or sMCI vs pMCI, these classes are 
discriminated with similar accuracies using simple linear discriminant analysis (i.e. LDA) or 
complex and heavily optimised nonlinear models (i.e deep learning) (Pellegrini et al., 2018). 
Given that heavily constrained models (i.e. deep learning) will be less effective at multiple 
prediction tasks (i.e. no free lunch) and offer no predictive benefit, simpler and less 
parameterised machine learning approaches may be optimal to predict a range of AD related 
changes while achieving benchmark performance. 
Alternatively, insights can be gained by approaches that compare performance within the same 
framework. That is, research that uses the same sample and modelling approach to classify 
patients but alters training features can provide information on the predictive nature data 
modalities. By doing this neuroscientists and clinicians alike can optimise their data collection 
to be as predictive as possible. 
Data modalities used for classification  
Cognitive Data 
Several studies have used only cognitive variables to make predictions in AD (Belleville, 
Fouquet, Hudon, Zomahoun, & Croteau, 2017; Chapman et al., 2011; Donovan et al., 2014; 
Gallucci et al., 2018; Pereira et al., 2018, 2017; Silva et al., 2013; Tabert et al., 2006). These 
models have reasonable performance separating sMCI vs pMCI, achieving classification 
accuracies up to 84% (Chapman et al., 2011). Of these cognitive variables, those that relate to 
memory are often the most heavily weighted (i.e. are more informative for the classification) 
particularly when predicting conversion from MCI to AD (Silva et al., 2013; Tabert et al., 
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2006).  However, multivariate models that combine cognitive data across several domains are 
favourable to single domain models (Chapman et al., 2011).  
Clinical Information 
In addition, several studies have investigated whether clinical variables associated with 
affective disturbance (i.e. depression and anxiety) are predictive of conversion to dementia 
due to AD (Chen et al., 2008; Defrancesco et al., 2017; Donovan et al., 2014).  These studies 
show that moderate to severe depressive symptoms are predictive of conversion to dementia, 
(Defrancesco et al., 2017) while mild depressive symptoms, which are frequent in individuals 
with MCI, do not increase the risk of conversion (Chen et al., 2008; Defrancesco et al., 
2017).  
Clinical Neuroimaging Data 
Different approaches have been used to perform discrete classifications using neuroimaging 
data (for reviews: (Arbabshirani et al., 2017; Maroco et al., 2011; Pellegrini et al., 2018; 
Rathore et al., 2017; Tanveer et al., 2020)). However, alternate continuous approaches have 
also been used to reduce neuroimaging data into an AD index or indices (Christos Davatzikos 
et al., 2019). These studies look for latent disease markers within structural MRI scans, often 
observing that the heavily weighted regions in these latent structures are in the hippocampal 
and parietal lobes (C. Davatzikos, Xu, An, Fan, & Resnick, 2009; Y. Fan, Batmanghelich, 
Clark, & Davatzikos, 2008). Further, using these data reduction approaches, several AD 
atrophy signatures have been discovered, often relating to separable cognitive trajectories 
(Dong et al., 2017; Young et al., 2018).  
Multimodal Data 
Given the interactive pathophysiological processes that occur in AD, models have been built 
to combine multimodal data to make predictions in AD commonly combining; genetic, 
cognitive, CSF and neuroimaging data (Cui et al., 2011; Devanand et al., 2007; Frölich et al., 
2017; Hinrichs, Singh, Xu, & Johnson, 2011; Mazzeo et al., 2016; K. H. Thung, Yap, Adeli, 
Lee, & Shen, 2018; Zhou et al., 2018; Zhu, Suk, Lee, & Shen, 2016). There is general 
agreement that the combination of multimodal data improves model prediction performance, 
with varied improvements in classification accuracies (Rathore et al., 2017). 
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Binary Classification Of Disease vs Predicting Disease Trajectories 
Most modelling approaches thus far have focussed on binary classifications. These assign class 
labels based on changes in diagnosis that largely correspond to the NIA-AA 2011 diagnostic 
criterion. Accordingly, methodological frameworks for mining neuroimaging data (Jollans et 
al., 2019) and predicting progression to AD (Samper-González et al., 2018) have been 
introduced. These approaches generally focus on binary classifications that are based on 
discrete clinical labels (i.e. stable vs. progressive MCI), as determined by arbitrary criteria (e.g. 
within a 3 year period of clinical assessment). However, these class labels (or targets) are poor 
ground truths for building and testing the performance of classification models (i.e. target 
uncertainty). One issue is that by discretising patients in two broad categories (i.e. sMCI vs 
pMCI) the model ignores the continuous nature of AD progression. Take for example patients 
at either side of the class boundary with very different disease trajectories; patient who 
progresses to AD within 1 day from clinical assessment and a patient who converts in 3 years 
will both be classified as pMCI. Similarly, patients with similar disease trajectories may be 
classified in different groups; a patient who converts in 3 years will be classified as pMCI, 
while a patient who remains stable for 3 years and progresses to dementia 1 day after the 
clinical assessment will be classified as sMCI. As a result, crucial continuous prognostic 
information is ignored, and models can easily misclassify patients based on arbitrary decision 
boundaries. To overcome this limitation and make meaningful predictions in AD, modelling 
approaches need to capture continuous information in prognostic trajectories.  
Some models have achieved prediction of individual variability in disease progression (for 
review (Tang et al., 2015; Woo, Chang, Lindquist, & Wager, 2017)).  A common approach to 
account for individual variability is to generate predictions using time-to-event models. These 
approaches assign a probability that a person will convert from MCI to dementia due to AD 
within a certain period of time (Alsaedi, Abdel-Qader, Mohammad, & Fong, 2018; Casanova 
et al., 2013; Desikan et al., 2010; Jack, Jr, et al., 2010; S. M. Landau et al., 2010; K. Liu, Chen, 
Yao, & Guo, 2017; Michaud, Su, Siahpush, & Murman, 2017; Oulhaj, Wilcock, Smith, & De 
Jager, 2009; Young et al., 2014), while others aim to predict exact time to conversion (Dukart, 
Sambataro, & Bertolino, 2015; K.-H. Thung, Yap, Adeli, Lee, & Shen, 2018; Vogel et al., 
2018). 
Although time-to-event models (e.g. survival analysis models predicting time to conversion) 
capture continuous information in patient trajectories, they are limited by target uncertainty. 
One source of uncertainty is the limited and variable frequency of clinical follow-ups, with 
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many studies interpolating the exact ‘time to conversion’ between clinical diagnoses. While 
this approach is common it has been shown to adversely affect model reliability (Li, Iddi, 
Aisen, Thompson, & Donohue, 2019). A further source of target uncertainty in models that 
rely on syndromic definitions is the poor inter-rater reliability in AD diagnosis (i.e. diagnoses 
may differ across clinicians). This issue is not limited to just AD prediction but most 
classification tasks in clinical neuroscience using diagnosis as class labels (for review (Woo et 
al., 2017)).  
While these are clear limitations to using diagnostic labels as training targets, these types of 
predictions do fit well under the 2011 NIA-AA diagnostic recommendations for preclinical, 
mild cognitive impairment or dementia stages in AD. Accordingly, most large research cohorts 
focus heavily on changes in syndromic labelling as outcome variables (R. C. Petersen et al., 
2010). However, the 2018 NIA-AA research framework has transitioned to defining AD as a 
continuum; that is, in this framework cognitive staging is achieved using continuous measures. 
Therefore, for predictive models to be of use within the current AD research framework, 
predictions need to move beyond discrete classifications based on noisy labels and predict 
continuous trajectories of more objective measures (i.e. cognitive scores). 
Modelling Trajectories in MCI: 
Several approaches predict future changes in cognitive scores by grouping longitudinal 
cognitive scores into discrete trajectories (Bhagwat, Viviano, Voineskos, Chakravarty, & 
Initiative, 2018; Hochstetler et al., 2015; Y. Wang et al., 2019; Wilkosz et al., 2010). These 
approaches have used various data driven ways to define prototypical patterns of cognitive 
change based on future changes of MMSE or ADAS-Cog. (Bhagwat et al., 2018) used a 
novel learning approach to fuse baseline and follow up imaging and clinical scores to predict 
if an individual will decline fast or slow (MMSE) or fast, moderate or slow (ADAS-cog) on 
cognitive scores. (Hochstetler et al., 2015) used classification and regression trees to 
determine if baseline variables can predict from three latent classes who had similar growth 
patterns of cognitive and functional changes. (Wilkosz et al., 2010) derived a much larger set 
of outcome labels discovering six different trajectories for cognitive decline due to AD. 
Recently, the generalisability and interoperability of this type of approach have been 
questioned (Y. Wang et al., 2019). Here, Wang et al. investigated the interoperability of 
defining broad latent trajectories of cognitive decline in two separate longitudinal studies. 
While they found that both cohorts had trajectories of slow and rapid dementia progression, 
 34 
the number of latent classes and relative class size could not be replicated across the two 
datasets when identical statistical approaches were used. Moving away from discrete 
trajectories approaches have been proposed to predict exact changes in MMSE or ADAS-Cog 
scores (Y. Fan et al., 2008). (Zhang, Shen, & Initiative, 2012) used baseline and follow-up 
data to predict future scores on cognitive tests at different time intervals, while (Y. Fan et al., 
2008) used structural MRI to predict the rate of change in MMSE score. While these two 
studies don’t assume latent classes, their predictions are based on measures with low 
resolution and sensitivity to change (i.e. MMSE).  
Modelling trajectories in preclinical AD  
The work discussed so far primarily focused on predicting changes from a baseline state of 
MCI. However, determining biological predictors of future pathological change for cognitively 
normal individuals is of crucial importance particularly as clinical trials move to less severely 
AD affected individuals. Several studies using primarily mixed effects models have studied the 
association of cortical β-amyloid and cognitive trajectories in cognitively normal populations 
(Allison et al., 2019; Bilgel et al., 2018; Burnham, Bourgeat, Doré, Savage, Brown, Laws, 
Maruff, Salvado, Ames, Martins, Masters, Rowe, & Villemagne, 2016; Dumurgier et al., 2017; 
Insel et al., 2015; Jansen et al., 2018). These studies have shown that when considering both 
atrophy and cortical amyloid burden separable patterns of cognitive decline are observed 
(Bilgel et al., 2018; Burnham, Bourgeat, Doré, Savage, Brown, Laws, Maruff, Salvado, Ames, 
Martins, Masters, Rowe, & Villemagne, 2016; Dumurgier et al., 2017; Insel et al., 2015), 
concluding that for optimal predictive performance both amyloid and atrophy should be 
considered. Further, it has been shown that there is a dose dependent relationship of amyloid 
and cognitive decline (Bilgel et al., 2018). As more longitudinal data from preclinical research 
cohorts become available, machine learning approaches that accurately predict prognostic 
trajectories in preclinical AD will have the most utility in clinical trial design.  
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Thesis Motivation and summary 
The work presented in this thesis contains novel adaptations to machine learning tools for 
prediction in AD. However, these tools were designed to be fit for purpose, that is, biological 
and clinical characteristics of the data necessitated computational innovation and not the 
inverse. Accordingly, the motivation of the thesis is not methodological but demonstrates an 
integration of multivariate prediction techniques to make clinically relevant predictions in a 
well-defined biological problem. The methods section introduces two approaches to capitalise 
on the characteristics of the data used for prediction in AD. The first section, Partial Least 
Squares regression – Recursive Feature Elimination (PLSr-RFE), introduces a new technique 
to reduce high dimensional collinear neuroimaging data into a single disease related index. The 
second section, Generalised Matrix Learning Vector Quantisation -Scalar Projection 
(GMLVQ-Scalar projection), introduces a trajectory modelling approach that derives a 
continuous prognostic index from a model trained on diagnostic labels with high target 
uncertainty. We then deploy these tools in three separate experiments, described in respective 
chapters. The first derives a single index of grey matter atrophy that is predictive of AD 
biomarkers across modalities. The second generates prognostic trajectories of cognitive decline 
for individuals who are MCI at baseline. The third generates prognostic trajectories of tau 
accumulation for individuals who are cognitively normal at baseline. For all models we validate 
using independent data, not only testing the performance on the task the model was trained on, 
but also making predictions of other markers in line with the model of the AD pathological 
cascade. For example, we validate our atrophic maker by relating it to tau burden and cognition, 
which are immediately upstream and downstream, respectively, to atrophy. We generate 
prognostic trajectories and associate these to cognitive decline for MCI individuals, as this 
measure is hypothesised to have the maximum rate of change for this population. Similarly, 
for cognitively normal individuals, we generate prognostic trajectories and associate these with 
tau accumulation, which is hypothesised to have maximum rate of change prior to cognitive 
deficits.  
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2. Methods 
Introduction 
Machine learning has emerged as one of the most common approaches to analyse 
neuroimaging data (Christos Davatzikos, 2019). Within the context of using neuroimaging data 
to make predictions in AD many machine learning approaches have been proposed 
(Ebrahimighahnavieh et al., 2020; Jo et al., 2019; Jollans et al., 2019; Tanveer et al., 2020). 
Broadly, machine learning can be separated into two categories, a.) machine learning 
approaches that require independent feature creation or feature selection or b.) approaches that 
do not require separate feature creation and prediction stages (i.e. deep learning). Approaches 
like deep learning operate in a way where a subspace within the entire image is learnt and 
within this hidden subspace a prediction is made. However, in neuroimaging as the number of 
features (e.g. grey matter voxels) is far greater than the number of observations (e.g. number 
of voxels >300,000, number of observations <1000), these approaches are heavily susceptible 
to overfitting. Further, as the learnt subspace is within hidden layers, it can be difficult to 
determine how the algorithm makes a prediction and what are the important signatures within 
the image. Machine learning in contrast to deep learning approaches often requires a separate 
feature selection or feature creation stage and model prediction stage. Successful feature 
selection is a critical determinant of model success in making accurate and robust predictions 
(Chu, Hsu, Chou, Bandettini, & Lin, 2012). Common approaches for selecting neuroimaging 
features involve exhaustively searching through a reduced set of possible predictors from 
structural MRI. Alternatively, unsupervised feature creation approaches (i.e. PCA) are often 
deployed to reduce dimensionality and remove collinearity between features (Rathore et al., 
2017).  
In this work we performed supervised feature set construction using PLS and feature reduction 
using recursive feature elimination. PLSr determines multivariate relationships between 
predictor variables to best describe response variables. These multivariate relationships 
decompose the neuroimaging into a subset of orthogonal latent variables with maximum 
covariance with the response variable(s) (Krishnan, Williams, McIntosh, & Abdi, 2011; 
McIntosh & Lobaugh, 2004). Further, we use recursive feature elimination to remove voxels 
with poor predictive utility so as to reduce the likelihood of the resultant feature being overfit. 
The result of this process is in an easily interpretable sparse set of voxels that can be used to 
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make robust predictions. The PLS regression algorithm -plsregress.m- used is part of the 
MATLAB statistics and machine learning toolbox. All additional analysis steps were built 
using custom code in MATLAB and developed for the purpose of the work presented in this 
thesis. 
 
Following the feature selection process predictions within the machine learning framework are 
then made. The most common machine learning frameworks are classification, with the model 
assigning each individual a specific class label based on the multivariate relationship between 
predictor features. Alternatively, a machine learning approach can be developed to predict an 
outcome measure which may be discrete or continuous within a regression framework. The 
most common approach to performing binary classifications in AD is the support vector 
machine (SVM) (Rathore et al., 2017). While this approach has been successful at classifying 
cognitively normal vs AD and sMCI vs pMCI the approach is limited in several aspects. The 
first, SVMs are not well suited to handling correlated features. Correlated features may hinder 
interpretability of model outputs as predictor weights within the SVM may oscillate between 
the correlated features. In addition, these pairwise interactions within the feature space (e.g. 
feature covariance) may be useful in the prediction and may not be accounted for in model 
formulation. In this work we use the GMLVQ classification framework to perform binary 
classifications (Schneider, Biehl, & Hammer, 2009). The GMLVQ classification model learns 
the multivariate relationship between the baseline predictors (metric tensor) and the location in 
multidimensional space (prototype) that best discriminates between the two classes. 
GMLVQ is well suited to classification in AD as the model induces univariate and multivariate 
feature scaling via a highly interpretable metric tensor to improve classification performance.  
Despite the high prediction accuracies achieved by machine learning algorithms, binary 
classification approaches are poorly constrained, as they are based on clinical labels rather than 
capturing information in longitudinal patient trajectories. To derive a continuous prediction for 
each individual we introduce the GMLVQ-scalar projection methodology. This approach 
extends the GMLVQ classification framework to derive a distance to a given class prototype 
along the predictive axis for each individual. The GMLVQ algorithm described by Schneider 
et al (Schneider et al., 2009) was implemented in MATLAB by collaborators in the school of 
computer science at the University of Birmingham.  The extension of the GMLVQ framework 
was derived and implemented using custom code in MATLAB and was developed for the 
purpose of the work presented in this thesis. 
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Partial Least Square Regression 
To extract a predictive AD index from grey matter voxels we used PLS regression (PLSr). 
PLSr is a technique that determines multivariate relationships between predictor variables to 
best describe response variables. PLSr applies a decomposition on a set of predictors to create 
latent variables that show the maximum covariance with the response variables (Krishnan et 
al., 2011; McIntosh & Lobaugh, 2004).  
These latent variables are derived by performing a decomposition of both the predictor 
variables and the response variables. In our case, we only use a single response variable 
therefore only the predictor variables are decomposed into latent variables. This decomposition 
process iteratively computes a vector of weights so that the projections of the predictors (i.e. 
latent variables) have maximum covariance with the response variable. After the first weights 
vector is computed, the reconstructed predictor data is subtracted from the original predictor 
data resulting in a deflated predictor matrix. This process is then repeated on the deflated 
predictor data to generate a second weights vector and latent variable and it can be further 
repeated to derive as many dimensions as the user specifies.   
For our case the PLSr model is set up as such: 
For each individual, the predictor variables are values of grey matter density from a structural 
MRI scan and the response variable is a cognitive score (Figure 2.1). 
The 3-dimensional structural scan is vectorized so that the predictor matrix (denoted as X) is 
subjects (rows) by voxels (columns) and the response variable (denoted as Y) is subjects (rows) 
by 1 (cognitive score).  
 
Figure 2.1 PLSr model 
 
Figure 2.1 shows a visual representation of the PLSr model, the column on the left is the 
response variable Y, the row on the right is the vectorized structural MRI for a single subject. 
 
The PLSr method will decompose the predictor variables X into T latent projections.  
Such that:  
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T =XW, so that the cov(T,Y)=max 
Where X is the matrix of grey matter voxels, T is a subjects by L (number of dimensions) 
matrix of projections, W is a voxels by L matrix of voxel weights and Y is the response 
variable.  
Voxel weight stability 
Given that neuroimaging data often has many more predictors (i.e. voxels) than samples (i.e. 
patients), it is highly likely that the PLSr approach will overfit the data rendering interpretation 
of the voxel weights matrix unreliable. Therefore, it is ideal to assess the predictive nature of a 
given voxel. One way of doing this is to determine the stability of the weight assigned to each 
voxel. A common approach is to use bootstrapping to assess this, where stability is assessed 
by generating n sets of bootstraped samples from the data set. Then for each bootstrapped 
sample a PLSr is performed resulting in a distribution of weights per voxel. Across bootstraps 
axis rotation and reflection can occur, this is corrected for using Procrustes rotation (Milan & 
Whittaker, 1995). To summarise the resultant distributions for each weights vector, we 
calculated a variance-normalised weight for each voxel 𝑍𝑤#$%,'() akin to a z-statistic. 𝑍𝑤#$%,'() = 	 ,(.$$/0/123)5(.$$/0/123)  where the voxel location is indexed by 𝑣𝑜𝑥 ∈ {1,… , 𝑉} , the PLSr 
dimension is indexed by	𝑑𝑖𝑚 ∈ {1,… , 𝐷} and 𝑏𝑜𝑜𝑡𝑠𝑡𝑟𝑎𝑝 is the distribution of weights for the 
given voxel and dimension across bootstrapped samples. i.e. The mean weight across all 
bootstrap samples was normalised by the corresponding standard deviation.  
PLSr Recursive Feature Elimination (PLSr-RFE) 
While PLSr is robust so that the number of predictors can be more than the number of 
observations, the high variance explained by the complete model can show that merely having 
many predictors can explain “erroneous” variance in the outcome variable. To account for this, 
we performed recursive feature elimination, whereby we iteratively removed voxels (original 
input features) that have weak predictive value. While recursive feature elimination is generally 
used for feature selection, we performed a simultaneous feature selection and feature 
construction method using the PLSr recursive elimination framework.  
Using the variance normalised weight (i.e. 𝑍𝑤#$%,'() ) we determined how stable the predictive 
power of each voxel is by summing the variance normalised weight across PLSr dimensions. 
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As the weights can be either negative or positive, we calculated the stability 𝑆𝑤#$% of a voxel 
by the sum of the absolute z values across the PLSr dimensions. 
𝑆𝑤#$% = J K𝑍𝑤#$%,'()KL'()MN  
 
In order to determine the least stable voxels to be eliminated in each iteration, we ranked each 
voxel by its stability from lowest to highest and removed the lowest 25th percentile. We then 
repeated this process iteratively removing the least stable 25th percentile of voxels. After each 
reduction, we tested how well the model using the remaining voxels predicts the response 
variable. This value was generated using a nested cross validation framework. To determine 
the optimal number of voxels, we implemented an early stopping paradigm, where we tested 
after each iteration of the recursive feature elimination loop the generalisation performance of 
the learnt PLSr dimensions generated from the voxel subset. We simultaneously assessed the 
performance of each PLSr dimension to generalise out-of-sample and the “optimal” number of 
voxels required to generate these dimensions. 
k-Fold Nested Cross Validation 
Standard methods to test for model acceptance involve permutation testing to generate a null 
hypothesis (McIntosh & Lobaugh, 2004). Here, we use k-fold cross validation to asses model 
performance (Figure 2.2a). Within each of the cross folds we first need to determine the 
optimal number of voxels and PLSr dimensions to retain. Here, we accepted a model, 
specifically a given PLSr dimension and the number of voxels retained, using nested cross 
validation. Nested cross validation is an approach of determining hyperparameters (i.e. PLSr 
dimension and the number of voxels retained) by assessing the generalisation performance 
across a set of hyperparameters (Figure 2.2b).  
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Figure 2.2 Data splitting for cross validation framework. 
Figure 2.2a K-fold cross validation example, where k=5. 
COMPLETE SAMPLE 
  
   
   
   
TEST Cross Fold X Training Data Cross Fold X 
Figure 2.2a shows an example of splitting a data set for 5-fold cross validation. The data is 
split into 5 non overlapping sets of test data (yellow box) and 5 sets of training data. 
 
Figure 2.2b Nested k fold cross validation, where number of nested loops nk = 5. 
Training Data Cross Fold X 
Nested cross validation training data x Nested cross 
validation test data x 
   
   
   
  
Figure 2.2b shows an example of splitting one training set (Training Set Data Cross Fold X) 
from figure 1a into 5 nested cross validation folds. The training set from figure 1a is split into 
5 non overlapping sets of nested cross validation test data (orange box) and 5 sets of nested 
cross validation training data (green box). 
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Recursive feature elimination within nested cross folds. 
We assessed the generalisation performance of different hyperparameters by learning a voxel 
weights matrix on a nested training data set that is iteratively reduced (i.e. voxels removed). 
Within each recursive loop, we learned the weights matrix from the remaining cross validation 
training data and then generated the latent dimensions for a cross validation test set by 
multiplying the voxel weights matrix by the cross-validation test data. We then tested the 
variance that can be explained by each of these latent dimensions in our predictor variable. 
Following this we assessed and ranked the stability of how predictive each voxel is, removing 
the least stable 25%. We then repeated this process, iteratively removing voxels from the cross-
validation training set. We determined the optimal number of voxels by assessing when 
prediction performance starts to decrease on the cross-validation test set (i.e. too few voxels 
remaining). Simultaneously, we determined how many PLSr dimensions to retain by assessing 
the difference between cross validation training variance and test variance explained in the 
response variable.    
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Algorithm 2.1. PLSr-RFE implementation 
 PLSr-RFE algorithm  
1 For each 1:k cross-fold resampling do 
2  For each 1:nk nested cross fold resampling do 
3   For each recursive loop  
4 	 	 	 generate PLSr weights for a set of latent dimensions for nested training 
data.  T(Nested	Training	x)	=	X(Nested	Training	x)	W(Nested	Training	x),			
Where,		Cov(T(Nested	Training	x),Y(Nested	Training	x))	=	max	
5 	 	 	 project the nested test data onto the training weights matrix to derive 
a set of latent variables for the nested test data.		T(Nested	Test	x)	=	X(Nested	Test	x)	W(Nested	Training	x)	
6 	 	 	 calculate the shared variance (R2) between the nested test latent 
variables and the nested test set response variable 
7 	 	 	 determine predictive stability of each voxel			
𝑆𝑤#$% = J K𝑍𝑤#$%,'()KL'()MN 	
8 	 	 	 rank and remove the least stable 25% of voxels 
9 	  end 
10 	 end 
11 	 Set number of voxels retained(nLoops) and PLSr dimensions (nPLSdim) 
12 	 For 1:nLoops 
13 	 	 generate PLSr weights for a set of latent dimensions for cross-fold 
training data T(Training	Data	Cross	Fold	X)=	X(Training	Data	Cross	Fold	X)	W(Training	Data	Cross	Fold	X),		
Where,	Cov(T(Training	Data	Cross	Fold	X),Y(Training	Data	Cross	Fold	X))	=	max	
14 	 	 determine predictive stability of each voxel		
𝑆𝑤#$% = J K𝑍𝑤#$%,'()KL'()MN 	
15 	 	 rank and remove the least stable 25% of voxels 
16 	 end 
17 	 project the cross-fold test data onto the training weights matrix to derive 
a set of latent variables for the cross-fold test data.	T(TEST	Cross	Fold	X)	=	X(TEST	Cross	Fold	X)	W(Training	Data	Cross	Fold	X)	
18 	 calculate the R2 between the cross-fold test data nPLSdim latent dimensions 
and the cross-fold test data response variable.  
19  end 
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PLSr-RFE: Summary/Conclusion 
The PLSr-RFE process was designed to alleviate two issues with PLSr when applied to 
neuroimaging data. The first is, by determining the optimal model by nested cross validation, 
we increase the likelihood of the model to generalise out of sample. That is, the resultant sparse 
voxel weights matrix is likely to extract a predictive latent score in a new representative 
population. This is critical for neuroimaging data as the number of voxels in a scan (in the order 
of 105-106) will often be far greater than the number of observations, increasing the chance of 
overfitting the data. The second benefit of this approach is that the resultant sparse weights 
matrix is easily interpretable, giving a strong indication of the regionally specific multivariate 
relationships between grey matter density and the response variable (i.e. cognitive score). 
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Generalised Matrix Learning Vector Quantisation 
Learning Vector Quantisation (LVQ) 
Learning Vector Quantisation (LVQ) comprises classifiers that operate in a supervised manner 
to iteratively modify class-specific prototypes to find boundaries of discrete classes. In 
particular, LVQ classifiers are defined by a set of vectors (prototypes) that represent classes 
within the input space. These prototypes are updated iteratively throughout the training phase, 
resulting in changes in class boundaries. For each training example, the closest prototype for 
each class is determined. These prototypes are then updated so that the closest prototype 
representing the same class as the input example is moved towards the input example and those 
representing different classes are moved further away. 
Training data sample of size n is denoted by (𝑥(, 𝑦() 	 ∈ 	ℝ) 	× {1, … , 𝐾}, 𝑖 = 1,2, … , 𝑛, where 
m denotes data dimensionality and K the number of different classes. In this instance the LVQ 
network comprises L prototypes 𝑤n ∈ 	ℝ), 𝑞 = 1,2, … , 𝐿	defined by their location in the input 
space and their class label 𝑐r𝑤ns 	∈ {1, … , 𝐾}. 
Prototypes are adapted automatically throughout training so that distances between points of 
class 𝑐 ∈ {1, … , 𝐾} and their corresponding prototypes sharing the same label c is minimised, 
while keeping the prototypes of other classes as far as possible. Classification is then performed 
on test data based on a winner-takes-all process, whereby a previously unseen input vector 𝑥( 	∈ 	ℝ) is assigned the class label 𝑐r𝑤ns of the closest prototype r𝑤ns. 
The Generalised Matrix LVQ (GMLVQ) 
The Generalised Matrix LVQ (GMLVQ) (Schneider et al., 2009) extends the LVQ utilising a 
full metric-tensor for a more robust (with respect to the classification task) distance measure in 
the input space. To do this, the metric tensor induces feature scaling in its diagonal elements, 
while accounting for task conditional interactions between pairs of features (co-ordinates of 
the input space). 
Given a positive definite matrix 𝛬	, 𝛬	 ≻ 0, the generalised form of the squared distance is 
calculated as 𝑑w(𝑥, 𝑤) = (𝑥 − 𝑤)y𝛬(𝑥 − 𝑤). 
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Positive definiteness of 𝛬 can be ensured by defining  𝛬 = ΩyΩ where Ω	 ∈ 	ℝ)	×) is a full 
rank matrix. Note that only relative distances of input points to the prototypes are important. 
Hence, the metric tensor can be multiplied by any positive real number without effecting the 
classifier performance in any way. To account for this inherently ill-posed nature of the model 
fitting and hence to ensure the stability of the algorithm,  𝛬 must be normalised following each 
learning step e.g. by making sure that  ∑ 𝛬(,( = 1( , fixing the trace throughout learning. 
Using the steepest descent method, the cost function to be minimised through online learning 
is 𝑓}~ =Jφ(𝜇w(𝑥())(MN  
where 𝜇w(𝑥() = 𝑑w(𝑥(, 𝑤) − 𝑑w(𝑥(, 𝑤)𝑑w(𝑥(, 𝑤) + 𝑑w(𝑥(, 𝑤) 
In this instance φ is a monotonic identity function	φ(ℓ) = ℓ, 𝑑w(𝑥(, 𝑤) is the distance 
between the sample vector 𝑥( from the closest prototype with the same class label 𝑐(𝑤) =𝑐(𝑥() and 𝑑w(𝑥(, 𝑤)	is the distance from  𝑥( to the closest prototype of a different class. We 
assessed model performance by classification accuracy, true positive rate, true negative rate 
and averaged error (i.e. average error of false positive and false negative). 
Interrogating the Metric Tensor Matrix:  
The metric tensor provides a way to determine how predictive different data is in the 
classification task. Below are toy examples highlighting how the elements of the metric tensor 
transform the feature space by weighting univariate and pairwise features. The examples show 
a hypothetical binary classification task. The data and metric tensor are shown in the original 
space and in the learnt space (i.e. after feature scaling by the metric tensor). The metric tensor 
is learnt to ensure that all points have a neighbour of the same class, that is, the shortest pairwise 
distance for all points is with a point from the same class. 
Here, we provide 3 examples of how the elements of the metric tensor scales the data in the 
input space and the interpretation of the metric tensor.  
Panel a: All examples show the initialised metric tensor on the left panel, where the diagonal 
values are both equal to 0.5 and the off diagonals are equal to 0. The panel on the right gives 
an example of the data distribution in the original space, where red circles are training data of 
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class 1 and blue dots are of class 2. The solid black line represents the X and Y axis in the 
original space. 
Panel b: All examples show the learnt metric tensor following the GMLVQ process on the left 
panel, note the diagonal terms sum to 1 and the off diagonals can be either negative of positive. 
The right panel shows the transformed space when scaled by the learnt metric tensor: the red 
circles and the blue dots are the same individuals from Panel a in the transformed space 
following the GMLVQ process and the solid black lines show the transformation of the X and 
Y axis into the learnt space. 
 
 
Example 2.1: Univariate weights 
 
Example 2.1 shows that for all data have a neighbour of the same class the diagonals need to 
be scaled so that the term for Feature Y has to be increased relative to Feature X The conclusion 
that is drawn from the metric tensor is that Feature Y is the most relevant feature. 
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Example 2.2 Multivariate weights (positive) 
 
Example 2.2, the interaction between Feature X and Feature Y is highly relevant to group 
training samples of the same class (Note that the off-diagonal terms are positive). This 
interaction term collapses the angle between the two dimensions causing data of the same class 
to group together. 
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Example 2.3 Multivariate weights (negative) 
 
Example 2.3 shows that for all data to have a neighbour of the same class the interaction 
between Feature X and Feature Y is relevant; however, as this term is negative it increases the 
angle between the two dimensions. Thus, we conclude that these two features separate points 
from different classes. 
 
To interpret these examples mathematically, note that the squared distance can be written as 𝑑w(𝑥, 𝑤) = (𝑥 − 𝑤)y𝛬(𝑥 − 𝑤) = 	 (𝑋 −𝑊)y(𝑋 −𝑊) = 	𝑑(𝑋,𝑊), 
where 𝑑(. , . ) denotes the squared Euclidean distance and 𝑋 = 𝛬N/𝑥, 𝑊 = 𝛬N/𝑤. Hence, the 
original vectors (including the unit directional vectors of the standard axis) are transformed by 
the linear operator equal to the square root of the symmetric positive-definite metric tensor 𝛬 
into a space where the new distance (defined by 𝛬) can be re-interpreted as the usual Euclidean 
distance. 
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GMLVQ – Scalar Projection 
Let’s assume that our class labels are defined by a longitudinal change in diagnostic category, 
where someone who has a change of diagnosis attributed to a deteriorating condition is classed 
progressive, whereas someone with a stable diagnosis and condition is classed stable. 
The GMLVQ- Scalar Projection method extends the GMLVQ framework to extract specific 
distance information from the sample vector 𝑥( and the learnt prototypes	𝑤(0/2.,31$100(#). 
Specifically, we determine the distance in the learnt space (i.e. after applying the learnt metric 
tensor) between an individual with sample vector 𝑥(	and the learnt prototype 𝑤0/2. along the 
vector separating 𝑤0/2. and 𝑤31$100(# 
Following the learning process in GMLVQ we transformed the sample vector 𝑥( and prototypes 𝑤(0/2.,31$100(#)	into the learnt space via the metric tensor	𝛬. 𝑋( = 𝛬N/	𝑥( 𝑊(0/2.,31$100(#) = 𝛬N/𝑤(0/2.,31$100(#) 
As the metric tensor 𝛬 is learnt in the non-Euclidean space:𝑑w(𝑥, 𝑤) = (𝑥 − 𝑤)y𝛬(𝑥 − 𝑤), 
we applied the square root of this tensor to re-represent the data so that the squared norm of a 
vector in the non-Euclidian space is equal to the squared Euclidean norm of the transformed 
space. 
We centred the coordinate system on 𝑊(0/2.) and calculated the orthogonal projection of each 
vector 𝑋( onto the vector 𝑊(31$100(#), in this co-ordinate system. 𝑃𝑟𝑜𝑗𝑒𝑐𝑡𝑖𝑜𝑛 = 𝑋𝑊0/2.⃑ .𝑊31$100#𝑊0/2.⃑K𝑊31$100#𝑊0/2.⃑ K  
To normalise the projections with respect to the position of the prototype 𝑊(31$100(#), we 
divided the projection by the norm of 𝑊(31$100(#): 𝑆𝑐𝑎𝑙𝑎𝑟	𝑃𝑟𝑜𝑗𝑒𝑐𝑡𝑖𝑜𝑛 = 𝑋𝑊0/2.⃑ .𝑊31$100#𝑊0/2.⃑K𝑊31$100#𝑊0/2.⃑ K  
The resultant value indicates the separation of a test point from prototype 𝑊0/2. along the 
direction of 𝑊31$100#𝑊0/2.⃑ . To determine the relative separation from the stable 
prototype, we normalised the projection by the distance between each prototype 𝑊31$100(#,𝑊0/2., as indicated by squaring the norm of vector 𝑊31$100#𝑊0/2.⃑ . A large 
positive projection indicates a large separation from 𝑊0/2.  in direction 𝑊31$100#𝑊0/2.⃑  
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and a large negative projection indicates a large separation from 𝑊0/2.	in the opposite 
direction i.e. 𝑊0/2.𝑊31$100#⃑ . In particular, a value of 1 indicates that a sample is incident 
to prototype 𝑊31$100(#,	whereas a value of 0 indicates that a sample is incident to prototype 𝑊0/2.. A value of 0.5 is the decision boundary separating the two classes within the binary 
classification framework. That is, the scalar projection has a large positive value for 
progressive individuals and zero or negative value for stable individuals. 
Deriving the GMLVQ – Scalar Projection: Prototype Vector 
The figure below uses the data from Example 2 above to graphically derive the Prototype 
Vector (𝑊n𝑊⃑ ) that is generated following the GMLVQ learning process. Note: Here we return 
to general notation, where class 1 is progressive and class 2 is stable in the description above. 
 
Figure 2.3 Prototype vector 
 
Figure 2.3 The left panel shows the vector 𝑊n𝑊⃑  represented by the black arrow connecting 
prototypes for class 1 and class 2. The dashed lines show the transformed axis from the 
original space. The right panel is the learnt metric tensor used to transform the data from the 
original space into the learnt space. 
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Deriving the GMLVQ – Scalar Projection: Test Projections 
Here, we use the data and learnt metric tensor from Example 2.2 in Interrogating the Metric 
Tensor Matrix to show three scenarios where values for the scalar projection are calculated 
and interpreted in a general sense. 
The left panel shows a possible test point in the original data space of Example 2.2. The red 
dots are the training sample for class 1, the blue dots are the training sample for class 2 and the 
black X is the test point in the original space. 
The right panel shows the graphical derivation of the scalar projection in the learnt space for 
the test data point X. Here, the red dots are the training sample for class 1 and the blue dots are 
the training sample for class 2, the black X is the test point in the learnt space (i.e. after the 
GMLVQ learning process) and the dashed black lines show the transformation of the X and Y 
axis into the learnt space. 
The red square is the prototype for class 1 in the learnt space, the blue square is the prototype 
for class 2 in the learnt space. The vector WW⃑  connects the prototypes for class 1 and class 
2, and vector XW⃑  connects the test point in the learnt space with the prototype for class 2. The 
dashed blue line is the orthogonal projection from the test point in the learnt space to vector WW⃑ . The solid blue line represents the scalar projection from the test point in the learnt space 
to the class 2 prototype along the vector WW⃑ . 
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Example 2.4 Between two classes 
 
Example 2.4 shows an example of a scalar projection that has a length between 0 and 1. Within 
the binary classification framework a decision boundary exists at 0.5, where a value below this 
will cause the point to be labelled as class 2 and a value beyond this will cause the point to be 
labelled class 1. This is interpreted as an individual that is between the two classes. 
Example 2.5 Positive value greater than one 
 
Example 2.5 is given where the length of the scalar projection is larger than 1, in this example 
the individual is further away from class 2 prototype along the prototype vector than the class 
1 prototype. This is interpreted as being further away from the class 2 prototype than the 
majority of class 1 individuals.   
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Example 2.6 Negative value 
 
Example 2.6 shows an example where the length of the scalar projection is negative. In this 
example the individual is further away from the class 1 prototype than the class 2 prototype 
along the prototype vector. This is interpreted as being further away from the class 1 prototype 
than the majority of class 2 individuals. 
 
GMLVQ – Scalar Projection: Summary/Conclusion 
The GMLVQ-scalar projection approach is a method for deriving a continuous predictive 
variable from the GMLVQ classification framework. Our methodology defines a novel way of 
learning a continuous prognostic metric while training using ‘noisy’ diagnostic labels. The 
development of this approach was motivated to capitalise on broad class labels to train a model 
and derive an individual continuous score. By building a model to separate two continuous 
target values into two general categories (i.e. stable or progressive), we have forced the model 
to concentrate on the main structures in the data that lie between distinguishing the higher and 
lower target values. As our model has relatively - compared to deep learning approaches- few 
degrees of freedom (DOF), the model is unlikely to overfit the training data.   
Where DOF for the model is DOF for prototypes + DOF for metric tensor. 
DOF for the prototypes = D*C*P, and, metric tensor = D2- (D2-D)/2 
D = number of original input features (input dimensions) 
C = number of classes 
P = number of prototypes per class 
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The GMLVQ-scalar projection approach addresses three inherent issues with prognostic 
models in AD research. 1.) The GMLVQ-scalar projection approach is able to account for 
target uncertainty. This is achieved by having a model that learns a low-parameter task-
dependent scaling matrix (metric tensor), and only two locations in hyperdimensional space 
(prototypes). These univariate (diagonal) and multivariate (off diagonal) relationships are 
learnt to separate the two classes (stable vs progressive) as best possible from a global 
perspective (vs local metric tensors) without over constraining the predictor data. Similarly, by 
defining only one position in this learnt space that best determines if a person is stable or 
progressive, the model must ignore subtle differences for any given target, learning a broad 
location that best describes stable / progressive populations. By not over constraining the data, 
this type of model will not be sensitive enough to overfit based on subtle difference in 
diagnostic criteria or by patients on the class boarder. 2.) The GMLVQ-scalar projection 
approach is able to derive a continuous metric of how far an individual is from the stable 
prototype along the dimension that best separates stable and progressive training samples. This 
allows the model to learn implicitly a continuous prognostic trajectory for an individual that 
may be predictive of underlying pathophysiological change that leads to a deteriorating 
condition (i.e. progressive pathophysiology). 3.) The GMLVQ-scalar projection approach is 
perfectly suited to harmonise data that was collected using diagnostic criteria based on 
syndromic definitions with inherently poor sensitivity and specificity to extract a highly 
sensitive continuous prognostic index.  
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3. Experimental Chapters Overview.  
Related publications and presentations 
Publications 
Giorgio, J., Landau, S. M., Jagust, W. J., Tino, P., Kourtzi, Z., & Alzheimer's Disease 
Neuroimaging Initiative. (2020). Modelling prognostic trajectories of cognitive decline due to 
Alzheimer's disease. NeuroImage: Clinical, 26, 102199 (Joseph Giorgio, Landau, Jagust, 
Tino, & Kourtzi, 2020). 
Giorgio, J., Jagust, W. J., Baker, S. L, Landau, S. M., Tino, P., Kourtzi, Z., & Alzheimer's 
Disease Neuroimaging Initiative. (in review). Predicting future tau accumulation in 
asymptomatic and early Alzheimer’s disease (Joseph Giorgio, Jagust, et al., 2020).  
Presentations 
Alzheimer's Imaging Consortium 2020 
Giorgio, J., Jagust, W. J., Baker, S. L, Landau, S. M., Tino, P., Kourtzi, Z. (2020) (POSTER):  
Predicting future regional tau accumulation in preclinical Alzheimer’s disease 
Alzheimer’s Association International Conference 2020 
Giorgio, J., Jagust, W. J., Baker, S. L, Landau, S. M., Tino, P., Kourtzi, Z. (2020) (ORAL):  
Predicting future regional tau accumulation in preclinical Alzheimer’s disease 
Alzheimer’s Association International Conference 2019 
Giorgio, J., Landau, S. M., Jagust, W. J., Tino, P., & Kourtzi, Z. (2019). (POSTER): 
PREDICTING FUTURE RATE OF COGNITIVE DECLINE DUE TO ALZHEIMER'S 
DISEASE. Alzheimer's & Dementia, 15, P228-P228. 
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Experiment Chapter 1. Deriving an interpretable and 
interoperable score of Alzheimer’s related atrophy  
Here we use the novel feature generation methodology procedure introduced in Methods: 
PLSr Recursive Feature Elimination (PLSr-RFE) to generate an index of Alzheimer’s 
disease atrophy from structural MRI. PLSr-RFE is a hybrid-feature selection and feature 
construction method that captures co-morbidities in cognition and pathology. Using 
predictive, study specific information (cognitive composites) we generate a highly 
interpretable disease related biomarker (i.e medial temporal atrophy due to AD). This 
biomarker can then be used across studies, transferring information rich study specific 
information between cohorts and modalities (i.e. interoperation). Here, we confirm the 
interoperability of our methodology and biomarker showing that the learnt pattern of grey 
matter atrophy is highly predictive of tau burden in an independent sample. 
 
Experimental Chapter 2. Modelling prognostic 
trajectories of cognitive decline due to Alzheimer’s 
disease 
Here, we use the novel trajectory modelling approach presented in Methods: GMLVQ-Scalar 
Projection to mine multimodal data from MCI patients in the Alzheimer’s disease 
Neuroimaging Initiative (ADNI) cohort, deriving individualised prognostic scores of cognitive 
decline due to AD. We integrate the biomarker generated from the PLSr-RFE procedure 
(Experiment Chapter 1: Deriving an interpretable and interoperable score of 
Alzheimer’s related atrophy) into the machine learning methodology that extends beyond 
binary patient classification into discrete subgroups (i.e. stable vs. progressive MCI), 
determining individual profiles from baseline (i.e. cognitive or biological) data that are 
predictive of individual cognitive trajectories (i.e. change in memory scores from baseline). 
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Experimental Chapter 3. Predicting future regional tau 
accumulation in early Alzheimer’s disease 
Here, we extended previous work modelling cognitive trajectories for MCI individuals 
(Experimental Chapter 2. Modelling prognostic trajectories of cognitive decline due to 
Alzheimer’s disease) to preclinical AD samples. We use our machine learning framework 
(Methods: GMLVQ-Scalar Projection) to test whether a prognostic index derived from 
baseline data can classify and stage preclinical AD individuals based on future pathological tau 
accumulation. Our results show that the characteristic spreading pattern of tau in preclinical 
AD is predictable using baseline biomarkers, particularly when stratifying groups using 
multimodal data. Finally, we are able to predict spatially specific individualised changes in tau 
accumulation in an out-of-sample group of cognitively normal people, highlighting the strong 
predictive ability of this metric and prediction framework.  
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4. Experimental Chapter 1: Deriving an 
interpretable and interoperable score of 
Alzheimer’s related atrophy  
Introduction 
With the introduction of MRI in clinical research, atrophic patterns characteristic of AD can 
be reliably measured in-situ (W. Jagust, 2018). However, there is no single measure that 
quantifies the degree of AD related atrophy. Nor, is there a single measure of cognitive 
dysfunction due to AD. Therefore, it is critical to generate scores for AD related atrophy and 
cognitive decline that can be used within the ATN diagnostic framework to support effective 
stratification. Through the use of longitudinal databases such as the Alzheimer’s Disease 
Neuroimaging Initiative (ADNI) researchers are able to derive informative biological and 
cognitive composite scores. These composites are generated from many variables and crucially 
avoid the so called “curse of dimensionality” when building models of disease progression. 
Cognitive composites have rapidly become the norm for generating summative measures when 
investigating AD (Ayutyanont et al., 2014; Donohue et al., 2014; Jutten et al., 2017, 2018; 
Langbaum et al., 2014), with measures of memory (i.e., ADNI- Mem (Crane et al., 2012))) and 
executive function (i.e., ADNI EF (Gibbons et al., 2012)) proving highly effective for 
diagnosing ADNI individuals with MCI. However, these cognitive composite scores may not 
generalise across studies as scores are often within-sample normalised and generated using 
cohort specific cognitive batteries.  
Here, we aim to create biomarkers from data that is readily transferable across studies (i.e. 
structural MRI) that can predict a cohort specific cognitive composite measure (i.e. ADNI- 
mem). Our aim is to move beyond correlational analysis of ADNI-Mem (i.e. (Nho et al., 
2012)), in doing so we will derive a score that allows us to transfer information from study to 
study via structural MRI (i.e. interoperation).  While many studies in AD use structural MRI 
to separate sMCI vs. pMCI within a binary classification framework (for reviews: (Pellegrini 
et al., 2018; Rathore et al., 2017)) we aim to capture continuous information that directly 
predicts cognition. Further, given the close link between memory, medial temporal lobe 
atrophy, and regional deposition of tau (Cho et al., 2016; Harrison et al., 2019; Johnson et al., 
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2016; Knopman et al., 2019; Schöll et al., 2016) this continuous structural MRI score should 
relate to both memory dysfunction and cortical tau deposition.  
Using the novel, hybrid feature selection and feature construction method presented in 
(Methods: PLSr Recursive Feature Elimination (PLSr-RFE)) we generate an 
interpretable feature that can transfer pathological information from behavioural composite 
measures through structural MRI (i.e grey matter atrophy due to Alzheimer’s Disease). We 
highlight the efficacy of our methodology and validate our biomarker using two approaches. 
First, we generate and test predictions of ADNI Mem using structural MRI in an independent 
ADNI sample. Next, we show that our approach is able to transfer information from one 
domain (cognitive) to another (cortical tau burden) via structural MRI in an independent 
sample.   
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Methods and materials 
ADNI Participants 
Data were obtained from the Alzheimer’s disease Neuroimaging Initiative (ADNI) database 
(adni.loni.usc.edu). ADNI was launched in 2003 as a public-private partnership, led by 
Principal Investigator Michael W. Weiner, MD. A major goal of ADNI has been to examine 
biomarkers including serial magnetic resonance imaging (MRI), and positron emission 
tomography (PET), with clinical and neuropsychological assessment to predict outcomes in 
mild cognitive impairment (MCI) and early Alzheimer’s disease (AD). Data samples are 
defined as: (1) Development data samples used for model formulation and within-sample 
validation, (2) independent validation data samples used for out-of-sample validation. Below 
we provide details for each data sample: 
1. Development Sample:  
Data from 589 individuals (baseline diagnoses: Normal =317, MCI=272) from ADNI-GO and 
ADNI-2 were used for model formulation and within-sample validation. All individuals had 
cognitive measurements and 3T structural MRI. All individuals were included in this cross-
sectional sample independent of their future diagnosis (i.e. whether following baseline an 
individual’s diagnosis changed from cognitively normal to MCI/AD). 
2. Cross-modal associations validation sample:  
To out-of-sample-validate the model that predicted cross-modality associations (e.g. predict 
ADNI-Mem scores from grey-matter), we drew an independent validation sample comprised 
of 446 individuals (Normal=263, MCI=172, AD=11) from ADNI-3. These individuals have a 
3T structural MRI, and cognitive measures in addition to a flortaucipir (FTP) PET scan for 
measuring cortical tau.   
2. Cross-modal associations validation sample I:  
We selected 219 individuals from the Cross-modal associations validation sample 
(Normal=122, MCI=89, AD=8), excluding individuals with an FTP-PET scan who were part 
of the Development Sample. Individuals in the Cross-modal associations validation sample I 
were newly recruited into ADNI-3, that is they had not been enrolled in ADNI-GO or ADNI-
2 prior to enrolling in ADNI-3. This independent sample was used to validate cross-modal 
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associations of grey matter and ADNI-Mem scores. All data from the Cross-modal associations 
validation sample were taken from assessments closest in time to the FTP-PET scan.  
Brain Imaging data 
MRI Acquisition 
Structural MRIs were acquired at ADNI-GO, ADNI-2 and ADNI-3 sites equipped with 3 T 
MRI scanners using a 3D MP-RAGE or IR-SPGR T1-weighted sequences, as described online 
(http://adni.loni.usc.edu/methods/documents/mri-protocols). 
PET Acquisition 
The FTP-PET protocol entailed the injection of 10 mCi of tracer followed by acquisition of 30 
min of emission data from 75-105 min post injection. For each participant FTP-PET scans were 
acquired in close proximity to the structural MRI scan (mean =0.21 +- std=0.51 years). 
Image Analysis: FTP (Flortaucipir PET) Tau 
FTP data were realigned, and the mean of all frames was used to coregister FTP to each 
participant’s MRI acquired closest to the time of the FTP-PET. FTP standardised uptake 
value ratio (SUVR) images were normalised to inferior cerebellar grey matter  
(Baker, Maass, & Jagust, 2017). MR images were segmented and parcellated using 
Freesurfer (V5.3) and regions of interest were used to extract cerebellar-normalised regional 
SUVR data. SUVR data was summarised for three Braak staging regions 12 (medial 
temporal), 34 (inferolateral temporal) and 56 (extra-temporal neocortical) by averaging 
uptake across individual Freesurfer region of interests (ROIs) comprising each Braak region 
(Maass et al., 2017).  Finally, we assigned individuals as tau positive for each Braak stage if 
their SUVR value was greater than the 90th percentile of amyloid-negative, cognitively 
normal individuals. 
Image Analysis Voxel Based Morphometry (VBM) 
Structural scans were segmented into grey matter, white matter and CSF (Cerebrospinal 
Fluid). The DARTEL toolbox (Ashburner, 2007) was then used to generate a study specific 
template to which all scans were normalised. Following this, individual grey matter 
segmentation volumes were normalised to MNI space without modulation. The unmodulated 
values for each voxel represent grey matter density at the voxel location. We chose to use the 
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unmodulated grey matter data as it has been shown that there is a marked decrease in 
sensitivity to detecting abnormal regions within grey matter when the data is modulated 
(Radua, Canales-Rodríguez, Pomarol-Clotet, & Salvador, 2014). We repeated the PLSr-RFE 
procedure with modulated data to confirm that unmodulated data is preferred when 
generating AD related biomarkers. All images were then smoothed using a 3mm3 isotropic 
kernel and resliced to MNI resolution 1.5x1.5x1.5 mm voxel size. We used a small kernel 
size, as topographically complex and relatively small cortical regions are likely to be affected 
in AD (i.e. structures within the medial temporal cortex; e.g. hippocampus, entorhinal 
cortex). It has been suggested that smoothing beyond a 3mm kernel may artificially link 
small but discrete clusters of voxels, reducing topographic sensitivity (Radua et al., 2014).  
Further, our analysis applies a spatial decomposition across voxels. By sampling the spatial 
covariance structure across voxels, disease related non-parametric variations at the voxel 
level (that are mitigated using larger smoothing kernels in parametric statistical tests across 
participants) are preserved when using smaller kernel sizes, improving the efficacy of the 
analysis method.  All structural MRI pre-processing was performed using Statistical 
Parametric Mapping 12 (http://www.fil.ion.ucl.ac.uk/spm/). 
Partial Least Squares Regression with Recursive Feature Elimination (PLSr-
RFE) 
We implemented Partial Least Squares Regression with Recursive Feature Elimination 
(PLSr-RFE) (Methods: PLSr Recursive Feature Elimination (PLSr-RFE)) to generate a 
grey matter density feature based on data from the Development sample (cognitively normal 
and MCI individuals).  In particular, we used grey matter density measured by structural MRI 
as a predictor variable to determine multivariate relationships between grey matter voxels 
that best predict ADNI-Mem. We performed feature set construction using PLSr and feature 
reduction using recursive feature elimination. PLSr determines multivariate relationships 
between predictor variables to best describe response variables. In particular, PLSr applies a 
decomposition on a set of predictors to create orthogonal latent variables that show the 
maximum covariance with the response variables (Krishnan, Williams, McIntosh, & Abdi, 
2011b; McIntosh & Lobaugh, 2004). In our study, we used PLSr to generate a set of latent 
predictor variables from structural MRI data, where a) the number of features (i.e. grey 
matter voxels) is far greater than the number of observations (e.g. number of voxels 
>300,000, number of observations <1000), b) there is high degree of multi-collinearity 
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between voxels. PLSr reduces redundant information and maximises the amount of variance 
that the latent variables predict in the response variable. Further, we performed recursive 
feature elimination by iteratively removing voxels that have weak predictive value to reduce 
the chance of over fitting.  
Methods Cross Validation Framework 
Within-sample validation: k-fold cross-validation (PLSr-RFE) 
Within-sample generalisation for PLSr-RFE (Development Sample) frameworks was assessed 
using k -fold cross validation (k=5). In brief, data was split into a series of training and test 
sets, whereby each sample point is present once in a test set. To select hyper-parameters for a 
given training sample, we used nested cross-validation. To assess model generalisation 
performance, we averaged variance explained in ADNI-Mem from the test set across all cross 
folds. 
Resampling PLSr-RFE 
To generate our test cross-folds and validation cross-folds, we performed a stratified 
permutation. As we have a priori knowledge of the distribution of the ADNI-Mem score within 
our complete sample, we respected this distribution within each fold of the data. To do this we 
ordered our sample by ADNI-Mem and resampled the data to have population representative 
distributions relative to this metric. 
Out-of-Sample validation: Cross-modal associations (PLSr-RFE) 
To test the out-of-sample association of the PLS derived grey matter feature (represented by 
the voxel weight matrix) with memory and cortical tau we used an independent sample of 
individuals from ADNI 3 (Cross modal associations validation sample I). We pre-processed 
the structural MRI scans independent of the Development sample used for model formulation 
following the same VBM methodology. We derived a grey matter score for the validation 
sample by multiplying the weight matrix generated from the PLSr-RFE trained on 
Development sample by the grey matter voxel values of the Cross-modal associations 
validation sample. We then correlated the grey matter score from the Cross-modal associations 
validation sample I with the ADNI-Mem composite score to test the generalisability of the grey 
matter score across data samples. Further, we tested the cross-modal association of the PLS 
derived grey matter score with cortical tau burden (measured with FTP-PET) (Cross-modal 
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associations validation sample). Using independent sample t-tests, we tested whether there is a 
significant difference in PLS derived grey matter score between tau positive and tau negative 
individuals across 3 different Braak staging regions: 12, 34 and 56. We then tested whether 
individual variability in the PLS derived grey matter score relates to individual variability in 
cortical tau burden across each of the Braak staging regions (Pearson’s Correlation). 
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Results 
Nested Cross Validation Results Modulated vs Un-modulated structural MRI 
Optimising Number of Remaining Voxels 
To determine the optimal number of voxels to retain in the PLSr-RFE model, we used a nested 
cross validation framework. Our acceptance criterion is the amount of variance explained in 
the ADNI-Mem score from the cross validation hold out set. We folded our training set 5 times 
to tune the parameter of number of retained voxels. Further, we investigated how the PLSr-
RFE model performs when the same grey matter data is modulated in the VBM process. 
PLS 1 on un-modulated grey matter:  
For the first PLS dimension across cross validation runs we observed a decline in test variance 
explained after the 21st recursive loop iteration corresponding to 902 remaining voxels. Figure 
4.1 shows the converging performance of the training and test sets throughout the recursive 
elimination process. Here, we show that generalisation performance approximately doubles 
when eliminating variant (un-stable) voxels. 
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Figure 4.1 PLS 1 on un-modulated grey matter early stopping generalisation 
 
Figure 4.1 shows the training and test performance of PLS 1 derived from un-modulated 
data across each recursive elimination iteration. The black dots and error bars show the 
mean and standard deviation of the variance explained in the ADNI-Mem score by PLS1 for 
the training sample across all nested validation loops. The red dots and error bars show the 
mean and standard deviation of the variance explained in the ADNI-Mem score by PLS1 for 
the test sample across all nested validation loops. 
PLS 2-5 on un-modulated grey matter:  
For the remaining PLS features we observe that the training variance explained is far greater 
than the cross-validation test variance as seen in Figure 4.2. Thus, we conclude that all 
remaining dimensions are fitting noise / over fitting the training sample. We therefore reject 
these components from further analysis.  
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Figure 4.2 PLS 2-5 on un-modulated grey matter early stopping generalisation 
performance 
 
Figure 4.2 shows the training and test performance for the remaining PLS dimensions (2-5) 
for unmodulated data across each recursive elimination iteration. The black dots and error 
bars show the mean and standard deviation of the variance explained in the ADNI-Mem 
score by PLS dimensions for the training sample across all nested validation loops. The red 
dots and error bars show the mean and standard deviation of the variance explained in the 
ADNI-Mem score by the PLS dimensions for the test sample across all nested validation 
loops. Given the last few dimensions are capturing noise that describe small amounts of 
variance in ADNI-Mem, their order across recursive loops may vary. This can be seen by the 
out of phase oscillatory behaviour of PLS 4 and PLS 5. 
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Generalisation Performance un-modulated data:  
To determine the efficacy of the PLS derived voxel weights matrix to generalise, we performed 
the matrix multiplication of the hold-out grey matter and the voxel weights matrix within each 
cross fold following the recursive elimination process. Table 4.1 shows the hold out 
performance for each of the five cross folds using un-modulated data. The high correspondence 
between the training and test variance across the cross folds suggests that the PLS derived 
voxel weights matrix generated is robust. 
 
Table 4.1: PLS 1 un-modulated data cross fold performance 
 
train variance test variance 
cross fold ADNI-Mem ADNI-Mem 
1 0.16 0.28 
2 0.18 0.18 
3 0.18 0.18 
4 0.21 0.09 
5 0.20 0.14 
MEAN 0.19 0.18 
Table 4.1 shows the training and test variance explained in the ADNI Mem score by PLS 
derived grey matter score for the un-modulated data from the individual cross folds and the 
mean performance across all cross folds. 
 
PLS 1 on modulated grey matter:  
For the first PLS dimension across cross validation runs we observed a decline in test variance 
explained after the 16th recursive loop iteration corresponding to 3799 remaining voxels. 
Figure 3 shows a different profile to that of the un-modulated data (Figure 4.2) on the training 
and test sets throughout the recursive elimination process. Here, we show that generalisation 
performance peaks with approximately 4 times the amount of voxels retained than the un-
modulated data. 
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Figure 4.3: PLS 1 on modulated grey matter early stopping generalisation performance 
 
Figure 4.3 shows the training and test performance of PLS 1 derived from modulated data 
across each recursive elimination iteration. The black dots and error bars show the mean 
and standard deviation of the variance explained in the ADNI-Mem score by PLS1 for the 
training sample across all nested validation loops. The red dots and error bars show the 
mean and standard deviation of the variance explained in the ADNI-Mem score by PLS1 for 
the test sample across all nested validation loops. 
 
Generalisation Performance, modulated data:  
To determine the efficacy of the PLS derived voxel weights matrix to generalise to another 
sample, we performed the matrix multiplication of the hold-out grey matter and the voxel 
weights matrix within each cross fold following the recursive elimination process. Table 4.2 
shows the hold out performance for each of the five cross folds using modulated data. The low 
correspondence between the training and test variance across the cross folds suggests that the 
PLS derived voxel weights matrix generated is not robust to the cognitive measure ADNI-
Mem. Suggesting that when investigating the spatial correlates of AD related atrophy, un-
modulated data may be more appropriate. Given the lack of within sample generalisability 
when using modulated grey matter we do not continue to use these data in further analysis. 
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Table 4.2: PLS 1 modulated data cross fold performance 
 
train variance test variance 
cross fold ADNI-Mem ADNI-Mem 
1 0.15 0.07 
2 0.13 0.05 
3 0.13 0.05 
4 0.13 0.06 
5 0.12 0.04 
MEAN 0.13 0.05 
Table 4.2 shows the training and test variance explained in the ADNI Mem score by PLS 
derived grey matter score for the modulated data from the individual cross folds and the 
mean performance across all cross folds. 
 
Spatial Organisation of Voxel Weights Matrix: Figure 4.4 and Table 4.3 show the ‘z-
value’ for each cluster contained within a given anatomical region within the average voxel 
weights matrix across cross folds using unmodulated data. We show that the voxels cluster 
within the medial temporal cortex covering regions in the bi-lateral hippocampus and 
amygdala. Reference regions of interest (ROIs) are extracted from the Brainnetome Atlas (L. 
Fan et al., 2016). 
Figure 4.4 PLS voxel weights matrix 
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Table 4.3: PLS 1 voxel weights 
%Overlap Max Z Mean Z nVoxels ROI 
(Left/Right) 
Anatomical Description 
(BA Area) 
0.55 9.8 9.08 13 FuG L rostroventral (area 20) 
6.2 10.29 9.67 24 PhG L rostral (area 35/36) 
17.2 15.22 11.76 66 Amyg L medial amygdala 
18.3 15.2 11.89 90 Amyg R medial amygdala 
21.29 16.44 12.71 43 Amyg L lateral amygdala 
14.29 15.7 13.09 45 Amyg R lateral amygdala 
18.28 17.69 12.49 247 Hipp L rostral hippocampus 
6.59 13.87 11.59 73 Hipp R rostral hippocampus 
6 14.64 11.88 82 Hipp L caudal hippocampus 
10.09 12.81 10.88 144 Hipp R caudal hippocampus 
Figure 4.3 and Table 4.3 reports brain regions within the mean PLS 1 voxel weights matrix 
across cross folds. The table shows the percentage overlap of each ROI with the voxel 
weights matrix, the peak Z value within each region, the average Z value within each region, 
the number of voxels and the gross and fine anatomical description of the regions. FuG: 
Fussiform Gyrus, PhG: Parrahippocampal Gyrus, Amyg: Amygdala, Hipp: Hippocampus, 
L:Left,  R:Right 
Validating the PLS derived grey matter score  
Next, we derived the PLS derived grey matter score for a validation sample that did not include 
individuals that were used in the model development (Cross-modal associations validation 
sample I). This value represents the weighted linear sum of grey matter voxels that best 
described the ADNI-Mem score in the Development sample. We showed that this score 
accounts significantly for variance in ADNI-Mem for the Cross-modal associations validation 
sample I (n= 219) that was not previously used in the PLSr-RFE feature generation ([r2(217) = 
0.33, P < 0.0001]). This relationship remained significant when we controlled for (Age; r2(216) 
= 16%, P<0.0001, Gender; r2(216) = 24% P<0.0001, or Education; r2(216) =37% P<0.0001). 
It is likely that the higher variance explained by the PLS derived grey matter score for the 
validation sample I relative to the development sample is due to the significantly higher degree 
of atrophy (lower PLS grey matter score) in the validation sample I (Wilcoxon Signed Rank; 
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z=-3.42, p<0.0001). That is, a greater amount of variance in ADNI-Mem is likely explained by 
the greater amount of AD related atrophy in the validation sample.  
Further, we observed significant differences (independent sample t-tests) in the PLS derived 
grey matter score between three sub-groups (normal cognition, sMCI -retain diagnosis of MCI 
for 3+ years- and pMCI -progress to dementia within 3 years-) within the Development sample 
used in the PLSr-RFE analysis. In particular, the normal cognition group showed significantly 
higher scores than the pMCI group (t(170)=9.13, P<0.0001, Cohens D =1.5) and the sMCI 
showed significantly higher score than pMCI group (t(165)=5.7, P<0.0001, Cohens D =0.94). 
However, when comparing normal cognition vs. sMCI individuals we observed only a small 
effect [t(230)=3.7, P=0.00072 (FWE Corrected), Cohens D =0.48] (Figure 4.4).  
Taken together these results suggest that the PLS derived grey matter score captures variance 
that relates to memory dysfunction (i.e. poor ADNI-Mem scores) due to AD. 
 
Figure 4.4 distribution of PLS derived grey matter scores 
 
Figure 4.4. PLS derived grey matter scores for normal cognition, sMCI and pMCI groups: 
Boxplots of the PLS derived grey matter scores for cognitively normal, sMCI and pMCI 
groups. The centre line represents the median and the edges of the boxes represent the 25th 
and 75th percentiles of each sample. The medians of two samples are significantly different 
at the p<0.05 if the edge of the intervals around each notch do not overlap. Red points 
denote outliers 
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We next compared the variance explained in ADNI-Mem by the PLS derived grey matter 
score to the variance explained by the average grey matter density in medial temporal regions 
(i.e. amygdala, hippocampus) known to be related to ADNI-Mem (Nho et al., 2012). For each 
test set within the nested cross-validation framework, we extracted mean grey matter density 
from regions in the amygdala and hippocampus, as defined using the Brainnetome atlas (L. 
Fan et al., 2016). We then compared the variance explained in ADNI-Mem for these a-priori 
selected regions with the variance explained by the PLS derived grey matter feature.  
PLS derived grey matter score vs. A-Priori Regions 
We compared the variance explained in ADNI-Mem by the PLS derived grey matter score 
with the mean grey matter density from a set of corresponding regions known to be related to 
ADNI-Mem (Nho et al., 2012). For each of the test sets in our nested cross validation 
framework, we derived the PLS grey matter score and extracted the mean grey matter density 
from 8 anatomically defined ROIs (left/right medial Amygdala, left/right lateral Amygdala, 
left/right rostral hippocampus, left/right caudal hippocampus) taken from the Brainnetome 
Atlas (L. Fan et al., 2016). Further, we extracted the mean grey matter density across all 8 
medial temporal regions (Table 4.4). We found that the variance explained in the hold out 
test set for the PLSr-RFE framework (i.e. generalisation variance) was significantly higher 
than the variance explained by grey mater density from the a-priori selected regions. 
Table 4.4: Generalisation variance explained: A-priori regions vs. PLS derived grey 
matter score 
Region Anatomical Description L R 
p Cohen’s 
D 
R2 p Cohen’s 
D 
R2 
Amygdala mAmyg, medial amygdala <.0001 -1.14 0.15 0.01 -0.55 0.12 
Amygdala lAmyg, lateral amygdala <.0001 -1.06 0.07 <.0001 -1.05 0.1 
Hippocampus rHipp, rostral hippocampus <.0001 -1.31 0.13 <.0001 -1.21 0.11 
Hippocampus cHipp, caudal hippocampus <.0001 -2.02 0.05 <.0001 -1.09 0.06 
Aggregate 
Region 
Aggregate Description p Cohen’s D R2 
Mean Average Medial Temporal 
Regions 
<.0001 -1.12 0.11 
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Table 4.4 shows the statistics and effect sizes when comparing the amount of variance 
explained in the ADNI Mem score by the a-priori selected areas and the PLS derived grey 
matter score across all nested cross folds. 
 
This finding suggests that the multivariate relationship between grey matter voxels captured 
by the PLS accounts for higher variability in individual ADNI-Mem scores than the average 
grey matter density in brain regions defined by coarser parcellations.  
Finally, we tested whether the PLS derived grey matter score differs across individuals that 
vary in cortical tau pathology, as measured by FTP-PET (Table 4.5). Comparing individuals 
from an independent sample (Cross-modal associations validation sample) with tau positive 
vs. tau negative scores (independent samples t-test) showed the strongest effect within Braak 
stage 12 [t(444)=9.6 , P<0.0001 Cohens D =1.9]. Further, the PLS derived grey matter score 
correlated (Pearson’s correlation) significantly with cortical tau burden across all individuals, 
with the strongest effect for Braak stage 12 [r2(444) = 0.32, P< 0.0001]. These results are 
consistent with previous studies showing a strong relationship between memory, medial 
temporal lobe atrophy, and regional (or Braak 12 stage) deposition of tau (Cho et al., 2016; 
Harrison et al., 2019; Johnson et al., 2016; Knopman et al., 2019; Schöll et al., 2016)  
. 
Table 4.5 PLS derived grey matter score relationship with flortaucipir PET Tau 
Braak Stage Threshold Tau Positive vs Tau Negative GM Score vs Tau 
p t Cohen d Pos/Neg r2 
tau Braak 12 1.95 <.0001 9.7 1.9 27/419 0.32 
tau Braak 34 1.89 <.0001 8.3 1.5 33/413 0.15 
tau Braak 56 1.93 <.0001 5.7 1.3 21/425 0.08 
Table 4.5. (PLS derived grey matter score relationship with flortaucipir PET Tau) 
relationship of the PLS grey matter score with flortaucipir Tau measures. The table shows 
the threshold for tau positivity for each of the Braak stages, the statistical differences 
between the grey matter scores for tau positive vs. tau negative individuals, and the 
correlation of the PLS grey matter score with flortaucipir tau across all individuals. 
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Discussion 
Here, we develop a supervised feature generation method (PLSr-RFE) that allows us to 
derive predictive and interpretable biomarkers based on structural brain imaging data. We 
demonstrate that grey matter density in the medial temporal lobe predicts variability in 
memory scores (i.e. ADNI-Mem score). In particular, this grey matter score is shown to be 
predictive for the classification of sMCI vs. pMCI individuals, consistent with previous 
studies showing that grey matter density in the medial temporal lobe (MTL) is associated 
with AD (C. Davatzikos et al., 2009; Hedden & Gabrieli, 2004; Mak et al., 2017; Matsuda, 
2016; Rathore et al., 2017) and ADNI-Mem scores (Nho et al., 2012). Previous work using a 
comparable PLS methodology (sparse PLS) showed a similar spatial pattern of grey matter 
voxels that are predictive of MMSE scores (Monteiro, Rao, Shawe-Taylor, & Mourão-
Miranda, 2016). Extending beyond this work, we generate a biomarker based on a projection 
(PLS-derived grey matter score) that is shown to explain more variance in ADNI-Mem scores 
than the grey matter density estimated from the corresponding atlas-defined MTL region. 
Importantly, we show that this PLS-derived biomarker predicts cortical tau pathology as 
measured by PET, providing a strong link between regional brain atrophy, memory decline, 
and tau pathology (Maass et al., 2018). Thus, our PLSr-RFE methodology has the potential to 
enhance interoperability across cohorts that typically include grey matter measurements (i.e. 
structural MRI scans) but may vary in the inclusion of other variables (e.g. cognitive or tau 
measurements). Further, our results show that when structural MRI is un-modulated in the 
VBM process the ability to detect structural abnormalities due to AD is enhanced over 
modulated data. This largely supports the results of (Radua et al., 2014),  who suggest that 
grey matter density (un-modulated data) is better suited to reflect mesoscopic grey matter 
thinning that is evident in AD (W. Jagust, 2018). The analysis approach is in-line with 
previous studies which reduced structural neuroimaging data into AD indices (C. Davatzikos 
et al., 2009; Christos Davatzikos et al., 2019; Dong et al., 2017; Y. Fan et al., 2008; Young et 
al., 2018). Our approach extends these previous works as we have designed a method with 
the specific goal of interoperation. That is, the outcome of the PLSr-RFE methodology is a 
voxel weights matrix that can be applied to minimally pre-processed structural MRI to 
generate a single AD index that relates to cross modal AD biomarkers (i.e. cognition and tau 
accumulation). Future work using the same PLSr-RFE methodology can be extended to a 
wider range of measures derived from structural MRI scans (e.g. variation in cortical volume, 
shape and texture) that have been shown to be predictive of AD (for reviews: (Leandrou, 
 77 
Petroudi, Kyriacou, Reyes-Aldasoro, & Pattichis, 2018; Mateos-Pérez et al., 2018; Matsuda, 
2016)). In addition, the PLSr-RFE methodology can be used on alternative cognitive 
measures. For example, different imaging phenotypes related to online learning may also 
have predictive power in AD and offer a means to probe cognition without the use of lab 
based cognitive testing (J. Giorgio et al., 2018). A potential limitation of this work is that we 
did not extensively test and control for effects due to poor scan quality or scanner differences. 
All images were downloaded from the ADNI website following the standard pre-processing 
pipeline in an attempt to increase harmonisation across scanning sites. This included 
corrections due to gradient nonlinearity, non-uniform image intensity due to non-uniform 
receiver coil sensitivity and correction of non-uniformity due to wave effects (Jack et al., 
2008). However, no additional control analysis was performed to ensure that there was no 
carry over differences due to scanner site. In addition, no additional quality control was run to 
account for image artefacts due to subject movement. Using the novel methodology presented 
in (Methods: PLSr Recursive Feature Elimination (PLSr-RFE)) we have successfully 
generated a voxel scaling matrix that can easily be applied to generate a single index of 
Alzheimer’s related medial temporal atrophy. We show this grey matter score is predictive of 
memory dysfunction in an independent cohort. Further, the relationship between the grey 
matter score and cortical tau burden provides evidence the PLSr-RFE procedure is capable of 
transferring information from one cohort to another through a common medium (i.e. 
structural MRI). Finally, we introduce a single score of AD related medial temporal atrophy 
that can be used in subsequent classification models targeting AD patient populations.  
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5. Experimental Chapter 2: Modelling 
prognostic trajectories of cognitive decline 
due to Alzheimer’s disease 
Introduction 
Progression to dementia due to Alzheimer’s Disease (AD) involves multiple pathways of 
disease pathophysiology that impact cognition (Jack, Bennett, et al., 2018; Jack et al., 2013; 
Jack, Knopman, et al., 2010; W. Jagust, 2018). Individuals who develop dementia follow a 
trajectory from a stage of normal cognition to Mild Cognitive Impairment (MCI) and 
subsequent dementia (McKhann et al., 2011; Ronald C. Petersen et al., 2001; Sperling et al., 
2011). Predicting early onset of neurocognitive decline due to AD has major implications for 
timely clinical management and patient outcomes. Yet, diagnosis at early stages of disease is 
impeded by heterogeneity in patient populations due to comorbidities (e.g. affective or 
cerebrovascular disorders) that may lead to MCI diagnosis without further progression to AD 
(Ronald C Petersen, 2009). Determining disease trajectories for individuals diagnosed with 
MCI has major implications for prognosis and personalised interventions. 
Recent advances in machine learning allow us to develop predictive models of 
neurodegenerative disease by mining multimodal datasets that include measurements of 
cognition and neuropathology from large patient cohorts (Woo et al., 2017). In line with the 
2011 NIA-AA diagnostic framework for mild cognitive impairment or dementia stages in AD 
(Albert et al., 2011; McKhann et al., 2011), most machine learning models in AD have focused 
on binary classifications. For example, machine learning models have been shown to predict 
with high accuracy whether individuals diagnosed with MCI will decline (i.e. progressive MCI; 
pMCI) or remain stable (i.e. stable MCI; sMCI) (Rathore et al., 2017). Fewer models have 
achieved prediction of individual variability in disease progression (Tang et al., 2015; Woo et 
al., 2017) focusing primarily on probabilistic estimates of time to conversion to AD (Alsaedi 
et al., 2018; Casanova et al., 2013; Desikan et al., 2010; Jack, Jr, et al., 2010; K. Liu et al., 
2017; Michaud et al., 2017; Oulhaj et al., 2009; Young et al., 2014), with some models 
estimating exact time to conversion (Dukart et al., 2015; K. H. Thung et al., 2018; Vogel et al., 
2018).  
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Despite the high prediction accuracies achieved by machine learning algorithms, binary 
classification approaches are poorly constrained, as they are based on clinical labels rather than 
capturing information in longitudinal patient trajectories. As a result, individual patients at the 
class boundary that differ only slightly in their profile may be misclassified. Further, the 
validity and statistical power (Li et al., 2019) of these approaches is limited by the frequency 
of clinical follow-ups (i.e. the point of conversion may occur between clinical assessments) 
and inter-rater reliability (i.e. clinicians may differ in their assessment). Extending machine 
learning modelling to predict measures determined by diagnostic labelling (i.e. time to 
conversion) suffers from the same limitations, introducing bias and limiting the interpretability 
and interoperability of machine learning algorithms (Janssen, Mourão-Miranda, & Schnack, 
2018). Thus, novel modelling approaches that predict individualised trajectories of cognitive 
decline based on continuous measures need to be developed to enhance clinical validity and 
guide effective clinical interventions and drug discovery trials. 
 Here, we develop and implement a trajectory modelling approach that extends beyond binary 
classification. We use machine learning to stratify patients at early stages of impairment (i.e. 
MCI) based on baseline cognitive or biological data and determine individual prognostic 
trajectories based on continuous measures of cognitive decline (i.e. change in memory scores 
over time). Our trajectory modelling approach allows us to extract continuous information 
about progression to AD, in line with the current 2018 NIA-AA research framework that has 
transitioned to defining AD as a continuum (Jack, Bennett, et al., 2018). 
In particular, we used large-scale data from the Alzheimer’s disease Neuroimaging Initiative 
(ADNI) database. Cognitive data comprise composite scores across tasks; that is, summative 
measures of memory (i.e., ADNI- Mem (Crane et al., 2012)), executive function (i.e., ADNI –
EF (Gibbons et al., 2012)), and depression (Yesavage, 1988). Similar composite measures have 
been shown to be effective for diagnosing cognitive dysfunction (Ayutyanont et al., 2014; 
Donohue et al., 2014; Jutten et al., 2017, 2018; Langbaum et al., 2014). In addition, we used 
well-studied biomarkers of AD (W. Jagust, 2018; Resnick & Sojkova, 2011); that is, grey 
matter density derived from structural MRI scans, b-amyloid burden from PET scans and 
APOE 4 status.  
We adopted the metric learning framework (Generalised Metric Learning Vector Quantization, 
GMLVQ) and extended our approach beyond binary classification (i.e. sMCI vs. pMCI) to 
modelling of continuous measurements (i.e. change in ADNI-Mem scores). In particular, we 
first tested a low-parameter, interpretable model on a binary classification task (sMCI vs. 
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pMCI) and interrogated the key cognitive predictors that separate sMCI vs. pMCI individuals. 
We then trained our metric learning model on biological data– including the PLS-derived grey-
matter feature (Experimental Chapter 1: Deriving an interpretable and interoperable 
score of Alzheimer’s related atrophy), mean cortical b-amyloid burden, and APOE 4– and 
compared the classification accuracy across models trained with either cognitive or biological 
data.  
To extend our modelling approach beyond binary classification (i.e. sMCI vs. pMCI), we used 
the novel GMLVQ- scalar projection approach (Methods: GMLVQ-Scalar Projection) that 
generates a continuous metric of disease progression. We demonstrate that this metric relates 
to rate of future cognitive decline (i.e. change in ADNI-Mem scores following baseline), 
providing evidence that our methodology delivers a continuous prognostic score of individual 
cognitive decline due to AD. Further, our trajectory modelling approach determines predictive 
trajectories using only cognitive markers; yet, predicting disease trajectories improves when 
including non-invasively measured and interpretable biomarkers (i.e. grey matter density 
and/or APOE 4).  
Methods and materials 
ADNI Participants 
Data were obtained from the Alzheimer’s disease Neuroimaging Initiative (ADNI) database 
(adni.loni.usc.edu). ADNI was launched in 2003 as a public-private partnership, led by 
Principal Investigator Michael W. Weiner, MD. A major goal of ADNI has been to examine 
biomarkers including serial magnetic resonance imaging (MRI), and positron emission 
tomography (PET), with clinical and neuropsychological assessment to predict outcomes in 
mild cognitive impairment (MCI) and early Alzheimer’s disease (AD). Data samples are 
defined as: (1) Development data samples used for model formulation and within-sample 
validation, (2) independent validation data samples used for out-of-sample validation. Below 
we provide details for each data sample: 
1. Development Sample I:  
253 MCI individuals from ADNI-GO and ADNI-2 were used for model formulation and 
within-sample validation. These individuals had at least 3 longitudinal cognitive testing 
sessions where the baseline assessments (MRI and cognitive) were those closest to the time of 
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the first florbetapir (FBP) PET scan. All individuals had baseline cognitive measurements, 3T 
structural MRI, FBP-PET scan for measuring b-amyloid, and APOE genotyping.  
1. Development Sample II:  
167 MCI individuals (of the 253 MCI individuals in Development Sample I) have 3 years of 
clinical diagnostic assessments. Data from these individuals were used as dichotomous 
outcomes (stable vs. progressive MCI) for longitudinal predictions.  
2. Longitudinal prediction validation sample: 
 To out-of-sample-validate the model that generated longitudinal predictions, we drew an 
independent validation sample comprising 126 MCI individuals (ADNI-GO, ADNI-2). These 
individuals have baseline cognitive, 3T structural MRI, FBP-PET measurements and APOE 4 
genotyping. As for the data used for model formulation, baseline was defined as the assessment 
closest in time to an individual’s first FBP-PET scan acquired in ADNI. These individuals also 
have at least 3 longitudinal cognitive testing sessions that were used to validate the outcome 
measures for longitudinal predictions. 
 
Brain Imaging data 
MRI Acquisition 
Structural MRIs were acquired at ADNI-GO and ADNI-2 sites equipped with 3 T MRI 
scanners using a 3D MP-RAGE or IR-SPGR T1-weighted sequences, as described online 
(http://adni.loni.usc.edu/methods/documents/mri-protocols). 
PET Acquisition 
PET imaging was performed at each ADNI site according to standardised protocols. The FBP-
PET protocol entailed the injection of 10 mCi with acquisition of 20 min of emission data at 
50-70 min post injection.  
Image Analysis: FBP (Florbetapir PET) β-Amyloid 
FBP data were realigned, and the mean of all frames was used to co-register FBP data to each 
participant’s structural MRI. Cortical SUVRs were generated by averaging FBP retention in a 
standard group of ROIs (lateral and medial frontal, anterior and posterior cingulate, lateral 
parietal, and lateral temporal cortical grey matter) and dividing by the average uptake from a 
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composite reference region (including the whole cerebellum, pons/brainstem, and eroded 
subcortical white matter regions) to create an index of global cortical FBP burden for each 
subject (Susan M Landau et al., 2015).  
Imaging Analysis-MRI: Medial Temporal Grey Matter Atrophy 
Structural scans were segmented into grey matter, white matter and Cerebrospinal Fluid (CSF). 
The DARTEL toolbox (Ashburner, 2007) was then used to generate a study specific template 
to which all scans were normalised. Following this, individual grey matter segmentation 
volumes were normalised to MNI space without modulation. The unmodulated values for each 
voxel represent grey matter density at the voxel location.  
 All images were then smoothed using a 3mm3 isotropic kernel and resliced to MNI resolution 
1.5x1.5x1.5 mm voxel size. All structural MRI pre-processing was performed using Statistical 
Parametric Mapping 12 (http://www.fil.ion.ucl.ac.uk/spm/). 
To generate a single index of medial temporal atrophy we used a voxel weights matrix that 
was previously derived to generate an interpretable and interoperable disease-specific 
biomarker (Experimental Chapter 1: Deriving an interpretable and interoperable score 
of Alzheimer’s related atrophy). In brief, a feature generation methodology (partial least 
squares regression with recursive feature elimination (PLSr-RFE)) was used to apply a 
decomposition on a set of predictors (T1-weighted MRI voxels) to create orthogonal latent 
variables that show the maximum covariance with the response variable (memory score). 
Further, we performed recursive feature elimination by iteratively removing predictors 
(voxels) that have weak predictive value. The PLSr-RFE procedure results in a voxel weights 
matrix that is used to calculate a single score of AD related medial temporal atrophy. To 
generate an individual’s score of medial temporal atrophy we performed a matrix 
multiplication of the previously derived voxel weights matrix and each subject’s pre-
processed T1 weighted MRI scans.  
Cognitive Scores 
We used three baseline cognitive scores as predictors for longitudinal models: a) composite 
scores of memory function (ADNI-Mem) derived from the Rey Auditory Verbal Learning, AD 
Assessment Schedule-Cognition, Mini-Mental State Examination and Logical Memory tests 
(Crane et al., 2012).  b) composite scores of executive function (ADNI-EF) derived from the 
WAIS-R Digit Symbol Substitution, Digit Span Backwards, Trails A and B, Category Fluency 
and Clock Drawing tests (Gibbons et al., 2012). c) the sum of all elements from the geriatric 
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depression scale (GDS) (Yesavage, 1988). As individuals are excluded from ADNI with a GDS 
>5 we investigate affective disturbance at subthreshold levels of clinical depression. 
Generalised Metric Learning Vector Quantization (GMLVQ) 
We used the Generalised Metric Learning Vector Quantization (GMLVQ) framework 
(Schneider, Biehl, & Hammer, 2009) to generate and test binary classification models 
(Methods: GMLVQ-Scalar Projection) that classify sMCI vs. pMCI individuals 
(Development Sample II). Individuals were characterised as sMCI if they repeatedly received 
an MCI diagnosis for more than three years of clinical observation. Individuals who 
progressed from MCI to AD within a window of 3 years of clinical observation were 
characterised as pMCI. Individuals who progressed from MCI to AD after 3 years were 
excluded from the Development Sample II.  
GMLVQ belongs to the class of classifiers referred to as Learning Vector Quantization (LVQ). 
These classifiers operate in a supervised manner to iteratively modify class-specific prototypes 
and learn boundaries between classes. For each training example, the closest prototype of each 
class is determined, these prototypes are then updated so that the prototype defining the same 
class is moved towards the training example and other prototype(s) representing different 
class(es) are moved further away. The Generalised Metric LVQ (GMLVQ) extends the LVQ 
utilising a full metric-tensor for a more robust distance measure. By applying the metric-tensor, 
specific feature scaling can occur while also accounting for different feature scales and 
pairwise task-conditional dependencies in the input space. Interrogating the diagonal terms 
allow us to determine the key univariate predictors for separating sMCI vs. pMCI patients. 
Further, interrogating the off diagonal terms of the metric tensor allow us to investigate the 
multivariate predictors that contribute to this classification task. 
GMLVQ Cognitive model 
We used the (GMLVQ) framework to generate and test binary classification models that 
classify sMCI vs. pMCI individuals (Development Sample II) based on cognitive measures 
(GDS, ADNI-Mem and ADNI-EF).  
GMLVQ Biological model 
We followed the same methodology as for the GMLVQ Cognitive model (Development 
Sample II) to test the GMLVQ model on biological data. That is, we generated and tested 
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binary classification models based on metric learning that discriminate between the same sMCI 
vs. pMCI individuals based on biological data (PLS derived grey matter score, β-amyloid and 
APOE 4). Note that this sample includes 3 pMCI individuals who are β-amyloid negative (i.e. 
SUVR<1.11) at baseline. We did not restrict our measure of β-amyloid to a binary value but 
rather used continuous SUVR values to avoid model bias near the ADNI threshold of amyloid 
positivity.  
GMLVQ – Scalar Projection 
We next generated a continuous prediction using either baseline cognitive data (GDS, ADNI-
Mem, ADNI-EF) or baseline biological data (PLS Derived Grey matter score, β-amyloid, 
APOE 4) for MCI individuals (Development sample I). The GMLVQ- Scalar Projection 
method extends the GMLVQ framework to extract specific distance information from the 
sample vector 𝑥( and the learnt prototypes	𝑤(0/2.,31$100(#). Specifically, we determine the 
distance in the learnt space (i.e. after applying the learnt metric tensor) between an individual 
with sample vector 𝑥(	and the learnt prototype 𝑤0/2. along the vector separating 𝑤0/2. and 𝑤31$100(# (Methods: GMLVQ-Scalar Projection). 
A value of 1 indicates that a sample vector is incident to the pMCI prototype whereas a value 
of 0 indicates that a sample vector is incident to the sMCI prototype, and a value of 0.5 is the 
decision boundary separating the two classes within the binary classification framework. The 
scalar projection has a large positive value for pMCI individuals and zero or negative value for 
sMCI individuals. 
Relating the scalar projection to individual rates of future cognitive decline 
We used the GMLVQ-Scalar projection method for 253 MCI individuals (Development 
Sample I) to generate a cognitive scalar projection from baseline cognitive variables (GDS, 
ADNI-Mem, ADNI-EF), and a biological scalar projection from baseline biological variables 
(PLS Derived Grey matter score, β-amyloid, APOE 4). To test whether individual scalar 
projections relate to individual rates of future cognitive decline, we correlated (Pearson’s 
correlation) the scalar projection (generated using baseline predictors) with the rate of future 
change in ADNI-Mem scores. We computed the rate of future cognitive change by fitting a 
linear model to the ADNI-Mem scores across multiple measurements (Development Sample I: 
mean=5.7, std=1 time points; mean=4, std=1.7 years, Longitudinal prediction validation 
sample: mean=5, std=1.7 time points; mean=4.4, std=1.5 years). The slope of the linear model 
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represents the rate of change in ADNI-Mem score. Individual scores higher than 2 standard 
deviations from the sMCI mean score or less than 2 standard deviations from the pMCI mean 
score were determined as outliers and excluded from further analysis.  
Statistical Validation 
Within-sample validation: k-fold cross-validation (GMLVQ) 
Within-sample generalisation for the GMLVQ (Development Sample (b)) was assessed using 
k -fold cross validation (k=10). In brief, data was split into a series of training and test sets, 
whereby each sample point is present once in a test set. To select hyper-parameters for a given 
training sample, we used nested cross-validation. Within each fold, we used grid search in the 
parameter space; that is, we folded our training data into hyper parameter cross-validation test 
and training sets and searched across all possible combinations of hyper parameters. We 
selected the optimal set of hyper parameters for a given cross fold based on mean performance 
across hyper parameter cross-validation test sets. We then fixed the hyper parameters within 
each cross fold and train the models. To assess model generalisation performance, we averaged 
metrics (GMLVQ: Accuracy, Macro Averaged Error (MAE), True Positive (TP), True 
Negative (TN)) from the test set across all cross folds. 
Resampling GMLVQ 
We performed a resampling throughout the GMLVQ learning procedure to address class 
imbalance for the binary classification tasks. That is, within each cross fold, we down-sampled 
the majority class to the same number of samples as the minority class. We performed a random 
down-sampling of the data set 100 times respecting the class split defined, thus creating 100 
classifiers forming an ensemble. To determine the class of a given test point we performed 
majority voting among the 100 classifiers in the ensemble. Similarly, we interrogated the 
efficacy of our selected variables to perform the classification task via the average metric tensor 
across all resamples and cross folds.  
Within-sample validation: Random resampling (GMLVQ-Scalar Projection) 
Within-sample generalisation for the GMLVQ-scalar projection framework (Development 
Sample I) was assessed using random resampling. In brief, we tested the relationship between 
the scalar projection and rates of future cognitive decline by randomly splitting our sample into 
test and training data 1000 times. To avoid biasing the model in the training phase due to class 
 86 
imbalance in the data (majority class: sMCI= 113 vs. minority class: pMCI = 54), we resampled 
the data to generate balanced classes (i.e. number of sMCI equals number of pMCI 
individuals). This resampling process randomly selects half of the individuals in the minority 
class and the same number of individuals from the majority class as training data; with the 
remaining sample used as test data. The training data within a resampling was used in the 
GMLVQ framework to learn the metric tensor and prototype locations for each training set. 
We then calculated the GMLVQ-Scalar Projection for the corresponding test set and correlated 
these values (Pearson’s correlation) with the rate of future ADNI-Mem change for the same 
individuals. We assessed within-sample generalisation based on the median of the correlation 
coefficients generated from the test sets across resampling using 95% confidence intervals. 
Out-of-Sample validation: Longitudinal Predictions (GMLVQ-Scalar Projection) 
To test the out-of-sample generalisability of the GMLVQ-Scalar Projection in predicting 
individual rates of future cognitive decline, we drew a validation sample with longitudinal 
information (i.e. cognitive data from three or more measurements) (Longitudinal prediction 
validation sample). As described above, we derived the grey matter score for this validation 
sample from the voxel weight matrix generated from the PLSr-RFE (Experimental Chapter 
1. Deriving an interpretable and interoperable score of Alzheimer’s related atrophy). To 
generate the scalar projections for the longitudinal validation sample, we used the metric tensor 
and prototype locations generated from the trained model with the median test performance on 
Development sample II. Using the metric tensor and prototype locations from the cognitive 
and biological models, we then generated a cognitive scalar projection and a biological scalar 
projection for each individual in the longitudinal validation sample. We then correlated these 
scalar projections with the rate of change in future ADNI-Mem scores (i.e. following baseline). 
Correlation coefficients were computed using skipped Pearson Correlation (Robust Correlation 
Toolbox; (Pernet, Wilcox, & Rousselet, 2013). This method accounts for potential outliers and 
determines significance using bootstrapped confidence intervals (CI) from 1000 permutations. 
Comparing Correlations between samples: 
To test if the relationship between the GMLVQ-Scalar Projection and rate of future cognitive 
decline is significantly different between Development sample II and the Longitudinal 
prediction validation samples we used Fisher’s r to Z transformation. To compare if the 
relationship of the GMLVQ-Scalar Projection and rate of future cognitive decline is 
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significantly different between models using biological or cognitive data we generate a Steiger 
Z statistic (Steiger, 1980).  
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Results 
Cognitive Classification Models for predicting sMCI vs pMCI 
We tested whether a classification model that is based on the Generalised Metric Learning 
Vector Quantization (GMLVQ) framework and trained and tested on baseline cognitive data 
predicts progression from MCI to AD. In particular, we trained and tested both a linear and 
non-linear classifier to discriminate between sMCI and pMCI using cognitive data (Geriatric 
Depression Scale (GDS), ADNI Memory (ADNI-Mem) and ADNI Executive Function 
(ADNI-EF) from a sample of 167 MCI individuals (Development Sample II). We tuned the 
model with 2 hyper-parameters using nested cross validation and assessed its performance 
using 10-fold cross validation. The model successfully classified stable (sMCI; n=113) vs. 
progressive (pMCI; n=54) individuals [Accuracy: 81.4%, MAE: 17.6%, TP: 84.9%, TN 
79.8%]. We obtained identical performance by increasing model complexity to a non-linear 
classifier by increasing the number of prototypes per class to two [Accuracy:81.4%, 
MAE:17.6%, TP:84.9%, TN 79.8%], and therefore selected the linear model for further 
analysis. Interrogating the average metric tensor (Figure 5.1) showed that the most predictive 
feature was ADNI-Mem (mean:0.55, std:+-0.12), while ADNI-EF (mean:0.35, std:+-0.09) and 
GDS (mean:0.1, std:+-0.05) had moderate and minor contributions to the classification task, 
respectively. These results suggest that the baseline ADNI-Mem score is the most 
discriminative cognitive feature for classifying sMCI vs. pMCI, as indicated by the diagonal 
terms in the metric tensor that are scaled to sum to one. Further, learning a metric in the input 
space of the classifier enables us to extend beyond the weighting of individual input features 
(such as ADNI-Mem score) and study the higher-order interplay between pairs of features with 
respect to the classification task.  Interrogating the off diagonal terms of the metric tensor 
indicates that the interaction of GDS with ADNI-Mem or ADNI-EF is important for classifying 
sMCI vs. pMCI individuals. The positive off-diagonal terms indicate a positive interaction 
between the ADNI-Mem and ADNI-EF scores that group individuals from the same class. In 
contrast, the negative off diagonal terms indicate that the GDS score has a negative interaction 
with the ADNI-Mem and ADNI-EF scores and separate individuals into different classes. For 
example, individuals with similar baseline ADNI-Mem and ADNI-EF scores may be classified 
in different groups depending on their baseline GDS score, with higher scores likely reflecting 
affective disturbance and MCI comorbidity. 
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Figure 5.1 Cognitive model metric tensor 
 
Figure 5.1. Cognitive classification Model - Metric Tensor Metric tensor for the 
classification model (sMCI vs pMCI) generated using cognitive data (GDS, ADNI-Mem, 
ADNI-EF). The colour scale indicates the predictive value for each cell in the metric tensor, 
where diagonal terms sum to 1. The diagonal terms show strong contribution of the ADNI-
Mem score. The positive off diagonals terms indicate a positive interaction between the 
ADNI- Mem and ADNI-EF scores. The negative off diagonals terms indicate the negative 
interaction of the GDS score with the ADNI-Mem and ANDNI-EF scores. Refer to Methods: 
GMLVQ for examples of GMLVQ and possible interpretations. 
 
Comparing the Performance of Biological vs. Cognitive Models 
We next tested whether a classification model trained and tested on baseline biological data 
discriminates sMCI vs. pMCI. We developed a biological classification model of similar 
complexity to the cognitive model (i.e. linear classifier (1 prototype per class), 3 features, 2 
hyper parameters) based on the same data sample (Development Sample II, n=167) using as 
predictors: PLS derived grey matter score, β-amyloid burden (measured by FBP-PET) and 
APOE 4 status (positive: presence of 1 or 2 APOE4 alleles, negative: no APOE4 alleles). The 
model successfully discriminated between sMCI vs. pMCI individuals [Accuracy: 81.9%, 
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MAE: 18.3%, True Positive: 81.1%, True Negative 82.3%]. We observed comparable 
classification performance when we increased the complexity of the biological model to a non-
linear classifier (2 prototypes per class) [Accuracy: 80.7%, MAE: 19.2%, True Positive: 81.1%, 
True Negative: 80.5%]. The metric tensor of the model (Figure 5.2) indicates that the feature 
with the highest predictive value is baseline β-amyloid burden (mean:0.48, std:+-0.16), with 
similar contributions from baseline PLS derived grey matter (mean:0.28, std: +- 0.14) and 
APOE4 status (mean:0.24, std: +-0.10). Further, interrogating the off diagonal terms of the 
metric tensor indicated a positive interaction between baseline β-amyloid burden and APOE 4 
status; that is baseline β-amyloid burden and APOE 4 status groups individuals from the same 
class. In contrast, we observed a negative interaction between baseline β-amyloid burden and 
the baseline PLS derived grey matter score; that is, the combination of these features separates 
sMCI from pMCI individuals. For example, individuals with high baseline β-amyloid burden 
and low baseline PLS derived grey matter score (i.e. low grey matter density in medial temporal 
areas) are grouped in separate classes (sMCI vs. pMCI) from individuals with high baseline 
PLS derived grey matter score (i.e. high grey matter density) and low baseline β-amyloid 
burden. Finally, we observed no significant differences (t-tests across cross folds) in 
classification performance between the cognitive and biological models (Accuracy: [t(9)=-
0.13, P=0.90], MAE: [t(9)=0.17, P=0.87], True Positive: [t(9)=0.54, P=0.60], True Negative: 
[t(9)=-0.32, P=0.75]), suggesting that baseline cognitive and biological features contribute 
similarly to the binary classification of sMCI vs. pMCI individuals.  
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Figure 5.2 Biological model metric tensor 
 
Figure 5.2. Metric tensor for the classification model (sMCI vs pMCI) generated using 
biological data (PLS derived grey matter score, β-amyloid, APOE 4). The colour scale 
indicates the predictive value for each cell in the metric tensor, where diagonal terms sum to 
1. The diagonal terms show strong contribution of β- amyloid. The positive off diagonals 
terms indicate a positive interaction between β-amyloid and APOE 4. The negative off 
diagonals terms indicate the negative interaction of the PLS derived grey matter score with 
both β-amyloid and APOE 4. Refer to Methods: GMLVQ for examples of GMLVQ and 
possible interpretations. 
Trajectory modelling: Predicting Individual Variability in the Rate of Future 
Cognitive Decline  
Our analyses so far have focused on binary classifications (i.e. sMCI vs. pMCI). However, this 
approach is limited, as it assumes distinct patient classes and does not capture dynamic changes 
in disease progression over time. To extend beyond this binary framework, we developed a 
trajectory modelling approach by deriving a continuous metric based on a GMLVQ-scalar 
projection (i.e. distance of each MCI patient from the sMCI prototype) and using only baseline 
data. We then confirmed that this projection relates to individual variability in the rate of future 
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cognitive decline. In particular, we defined the rate of future cognitive decline as the rate of 
change in the ADNI-Mem scores across measurements following baseline, where baseline is 
defined as the date of the FBP-PET scan used as a predictor for deriving the GMLVQ-scalar 
projection. We focussed on change in memory performance as measured by ADNI-Mem, as a) 
memory decline has been shown to occur prior to decline in other cognitive domains in sporadic 
AD, b) our metric leaning model showed that ADNI-Mem was the most discriminative 
cognitive feature for the sMCI vs. pMCI classification compared to the other cognitive 
variables tested (GDS, ADNI-EF). For the same sample used in the binary classifications 
(Development Sample II) we observed that scalar projections derived from either the cognitive 
or the biological model account significantly for variance in the rate of future memory decline 
(Figure 5.3) (i.e. Cognitive: [r(165) = -0.41 (95% CI: [-0.51 -0.32]), P < 0.0001], Biological: 
[r(165) = -0.55 (95% CI: [-0.62 -0.47]), P < 0.0001]).   
 
Figure 5.3 Correlation of GMLVQ-Scalar projections with rate of memory change 
 
Figure 5.3. Correlation of the GMLVQ-scalar projections derived from the a) cognitive 
model, b) biological model with the rate of ADNI-Mem change for Development Sample I. 
Red dots indicate pMCI individuals, blue dots indicate sMCI individuals. The central black 
line is the regression line for the fit of the GMLVQ- scalar projection to the rate of ADNI-
Mem change; the dashed lines represent the 95% confidence intervals for this regression 
line. Data used to train the model (n = 52) were not used to test the relationship between the 
scalar projection and rates of future cognitive decline and are not shown here 
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Validation of scalar projection: Future rate of ADNI-Mem change with incomplete 
(missing) data.  
We next asked whether the GMLVQ-scalar projection approach could be implemented to 
predict future rate of cognitive decline for data with less than 3 years of clinical diagnosis. To 
incorporate these incomplete data from the model trained on Development Sample II, we chose 
the metric tensor and prototype positions from the model with the median test performance. 
We observed that scalar projections from both models (cognitive and biological) account for 
significant variance in the rate of future memory decline when the incomplete data was 
included in the test set (Note that data used to train the model with median test performance 
(n=52) were not used to test the relationship between the scalar projection and rates of future 
cognitive decline) (Figure 5.4). For the test sample used for the Cognitive model 
(Development Sample I) we observed a significant correlation between the cognitive scalar 
projection and the rate of future cognitive decline: [r(196) = -0.4 (95% CI: [-0.51 -0.29]), P < 
0.0001] that remained significant when including only incomplete data ([r(85) = -0.31 (95% 
CI: [-0.48 -0.13]), P < 0.0001]). For the test sample used for the Biological model 
(Development Sample I) we observed a significant correlation between the biological scalar 
projection and the rates of future cognitive decline [r(196) =-0.51 (95% CI:[-0.6 -0.4]), P < 
0.0001], that remained significant when including only incomplete data ([r(85) = (-0.45 (95% 
CI: [-0.59 -0.3]), P < 0.0001]). The observed r values for models incorporating incomplete data 
were comparable to the correlation values between the scalar projection and the rate of 
cognitive decline for individuals with complete clinical longitudinal information (Development 
Sample II: 3 years of clinical assessment) (Fisher’s r to Z, Cognitive: [Z=-0.86, P=0.39], 
Biological: [Z=-1, P=0.32]). These findings suggest that the GMLVQ-scalar projection 
approach allows us to make longitudinal predictions based on the rate of future cognitive 
decline from a limited number of longitudinal clinical assessments (i.e. less than 3 years).  
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Figure 5.4: Correlating GMLVQ-Scalar projections with rate of memory change with 
incomplete data 
 
Figure 5.4 shows the correlation of the GMLVQ-scalar projections derived from the a) 
cognitive model, b) biological model with the rate of ADNI-Mem change for Development 
Sample I. Red dots indicate pMCI individuals, blue dots indicate sMCI individuals and black 
dots indicate individuals with incomplete data. The central black line is the regression line 
for the fit of the GMLVQ-scalar projection to the rate of ADNI-Mem change; the dashed lines 
represent the 95% confidence intervals for this regression line. Data used to train the model 
(n=52) were not used to test the relationship between the scalar projection and rates of 
future cognitive decline and are not shown. Outliers identified by the Robust Correlation 
toolbox (cognitive: 11, biological=11) are not shown. 
 
Validation of scalar projection: Future rate of MMSE change.  
To further validate the clinical relevance of our scalar projection approach, we tested whether 
the scalar projections derived from either the cognitive or biological model relate to the rate of 
future MMSE change, as MMSE is typically used in clinical diagnosis. We observed that the 
scalar projections correlated significantly with the future rate of change in the MMSE score 
(Cognitive: [r(214) = -0.53,  P < 0.0001], Biological: [r(213) = -0.43, P <0.0001] (Figure 5.5). 
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Figure 5.5: Correlating the scalar projections from cognitive and biological models with 
rate of MMSE change 
 
Figure 5.5 shows the correlation of scalar projection derived from the  a) cognitive model, b) 
biological model with the rate of MMSE change for the original data sample. The central 
black line is the regression line for the fit of the GMLVQ-scalar projection to the rate of 
MMSE change; the dashed lines represent the 95% confidence intervals for this regression 
line. Red circles indicate pMCI individuals, blue circles sMCI individuals and black dots for 
the incomplete data (i.e. less than three years of clinical assessments). Note: 23 Individuals 
from the previous analysis had fewer than 3 MMSE tests from baseline. 
 
Validating the scalar projection: Out of sample.  
Next, we validated the relationship of the GMLVQ-scalar projection with cognitive decline 
for individuals with MCI against a new independent validation data sample (Longitudinal 
prediction validation sample). To calculate the scalar projections, we chose the metric tensor 
and prototype positions from the cognitive or biological models with the median test 
performance across resampling using the Development Sample II. To generate a baseline 
PLS derived grey matter score for the Longitudinal prediction validation sample, we 
multiplied the voxel weights matrix determined by PLSr-RFE on the Development sample 
(Experimental Chapter 1: Deriving an interpretable and interoperable score of 
Alzheimer’s related atrophy) with grey matter density from baseline structural scans for the 
longitudinal prediction validation sample (i.e. data not used for the PLSr-RFE feature 
generation). We observed a significant correlation of the scalar projection with the rate of 
future ADNI-Mem change for cognitive data [r(124) = -0.4, (95% CI: [-0.55 -0.25]), P < 
0.0001]. This relationship remained significant when we controlled for: Age; [r(123) = -0.32, 
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(95% CI: [-0.47 -0.14]), P= 0.0003], Gender; [r(123) = -0.4, (95% CI: [-0.55 -0.22]), P< 
0.0001], or Education; [r(123) = -0.4, (95% CI: [-0.54 -0.23]), P< 0.0001]). Further, we 
observed a significant correlation of the scalar projection with the rate of future ADNI-Mem 
change for biological data [r(124) = -0.68, (95% CI: [-0.76 -0.58]), P < 0.0001] (Figure 5.6). 
This relationship remained significant when we controlled for: Age; [r(123) = -0.57, (95% 
CI: [-0.67 -0.46]), P< 0.0001], Gender; [r(123) = -0.63, (95% CI: [-0.71 -0.53]), P< 0.0001], 
Education; [r(123) = -0.63, (95% CI: [-0.73 -0.53]), P< 0.0001]. This relationship was not 
significantly different between Development Sample I vs. Longitudinal prediction validation 
samples (Fisher’s r to Z, Cognitive model: [Z=-0.1, P=0.92], Biological model: [Z=-1.76, 
P=0.08]). Further, correlations between the scalar projection and the rate of future memory 
decline were significantly stronger for biological compared to cognitive models (Steiger’s Z, 
[Z=-3.86, P<0.0001]). This difference between models remained significant when we 
controlled for Age; (Steiger’s Z, [Z=-3.33, P=0.0004]), Gender; (Steiger’s Z, [Z=-3.57, 
P=0.0002]), or Education; (Steiger’s Z, [Z=-3.57, P=0.0002]). Taken together these findings 
suggest that the biological model explains significantly larger variance in the rate of future 
memory decline than the cognitive model.  
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Figure 5.6 Correlating scalar projections from cognitive and biological models with rate 
of memory change in an independent sample 
 
Figure 5.6. Out-of-sample Validation Correlation of scalar projection derived from the a) 
cognitive model, b) biological model with the rate of ADNI-Mem change for the longitudinal 
validation data set. Red dots indicate pMCI individuals, blue dots sMCI individuals. The 
central black line is the regression line for the fit of the GMLVQ-scalar pro- jection to the 
rate of ADNI-Mem change; the dashed lines represent the 95% confidence intervals for this 
regression line. Outliers identified by the Robust Correlation toolbox (cognitive n = 7, 
Biological n = 8) are not shown for illustrative purposes. Note that this validation sample 
includes data from 3 β- amyloid negative pMCI individuals who had a scalar projection of 
less than 0.25 (i.e. very close to the sMCI prototype). Investigating the relationship of the 
scalar projection to future cognitive decline for these individuals showed dissociable 
cognitive trajectories from most pMCI individuals. 
 
Finally, we tested whether our trajectory modelling approach delivers stronger predictions 
when including non-invasively measured data modalities to the basic baseline cognitive model. 
Adding the baseline PLS derived grey matter feature and APOE 4 status to the cognitive model 
showed a substantial increase in the variance in the rate of future memory change explained by 
the scalar projection (Table 5.1). These results suggest that predicting the rate of future 
cognitive decline is enhanced by adding non-invasively measured baseline biological features 
to baseline cognitive data.  
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Table 5.1 Correlations of scalar projections with the rate of ADNI-Mem change for 
models based on cognitive and / or biological data 
Data Type Pearson’s r [95% C.I] 
Cross Validation 
Pearson’s r 
Out-of-Sample 
Validation 
Biological: (GM+APOE4+ b-Amyloid) -0.55 [-0.66 -0.53] -0.68 [-0.76 -0.58] 
Cognitive: (GDS+ADNI-Mem+ADNI-EF) -0.41 [-0.5 -0.30] -0.4  [-0.55 -0.25] 
Cognitive+GM -0.46 [-0.52 -0.34] -0.49 [-0.61 -0.35] 
Cognitive+APOE 4 -0.47 [-0.55 -0.38] -0.48 [-0.61 -0.33] 
Cognitive+GM+APOE 4 -0.5 [-0.57 -0.42] -0.53 [-0.64 -0.4] 
ALL Variables: Cognitive + Biological -0.57 [-0.63 -0.49] -0.64 [-0.73 -0.52] 
Table 5.1. Correlations of scalar projections with the rate of ADNI-Mem change for models 
based on cognitive and / or biological data. Pearson's correlation coefficients are shown for 
Development Sample (b) based on cross-validation and the independent data used for out of 
sample validation (longitudinal validation sample). 
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Discussion 
Despite the importance of early diagnosis of AD for clinical practice and treatment, we still 
lack robust tools for predicting individual progression to dementia. The multimodal 
longitudinal measurements across large-scale samples available in ADNI provide a testbed for 
machine learning approaches that generate predictive features and discriminate between patient 
groups (Weiner et al., 2015, 2017). Here, we propose a novel trajectory modelling approach 
based on an integrated feature generation (PLSr-RFE) and classification (GMLVQ-scalar 
projection) methodology that predicts individual disease trajectories based on continuous 
measures of cognitive decline. Our modelling approach is in line with the current 2018 NIA-
AA research framework that defines AD as a continuum and advances the state-of-the-art and 
clinical validity of machine learning applications to the prediction of dementia due to AD in 
the following main respects. 
First, we successfully predict whether individuals will progress from MCI to dementia due to 
AD, employing a transparent machine learning approach (i.e. prototype based classifier with 
metric learning and linear decision boundary) trained on informative and interpretable 
baseline cognitive data. We show that baseline composite scores related to memory and 
executive function (ADNI-Mem, ADNI-EF composite score) are highly predictive of disease 
progression. The high cross-validated classification performance of our model is in line with 
previous studies showing that similar neuropsychological data are predictive of MCI 
progression to dementia due to AD (Belleville et al., 2017; Chapman et al., 2011; Pereira et 
al., 2018, 2017; Silva et al., 2013; Tabert et al., 2006). Further, we demonstrate a negative 
interaction between baseline cognitive (memory, executive function) and affective scores that 
separates individuals into different classes, with higher baseline affective scores potentially 
reflecting MCI comorbidity. Previous studies have shown that moderate to severe depressive 
symptoms (i.e. GDS> 15) are predictive of MCI conversion to AD (Defrancesco et al., 2017), 
while mild depressive symptoms do not increase conversion risk (Chen et al., 2008; 
Defrancesco et al., 2017). Here, we show that the interaction between scores that are 
indicative of mild depression (i.e. GDS<10) and memory dysfunction discriminates stable 
from progressive MCI individuals. Thus, our metric learning approach on multi domain data 
(i.e. cognitive and affective measurements) may provide a means of reducing MCI patient 
misclassification due to comorbidity (e.g. affective disturbance). 
Second, our trajectory modelling approach (GMLVQ-Scalar Projection) extends beyond 
binary patient classification approaches (Rathore et al., 2017) that are poorly constrained. 
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Recent methodological frameworks for mining neuroimaging data (Jollans et al., 2019) and 
predicting progression to AD (Samper-González et al., 2018) have focused on binary 
classifications that are based on discrete clinical labels (i.e. stable vs. progressive MCI), as 
determined by arbitrary criteria (e.g. within a 3 year period of clinical assessment). As a result, 
these approaches are limited by risk of patient misclassification. That is, patients at the class 
boundary with different disease trajectories may be classed in the same MCI group (e.g. a 
patient who progresses to AD within 1 day from clinical assessment and a patient who converts 
in 3 years will be classified as pMCI). Similarly, patients with similar disease trajectories may 
be classified in different MCI groups (e.g. a patient who converts in 3 years will be classified 
as pMCI, while a patient who remains stable for 3 years and progresses to dementia 1 day after 
the clinical assessment will be classified as sMCI). To overcome this limitation and make 
meaningful predictions in AD, modelling approaches need to capture continuous information 
in prognostic trajectories and consider target uncertainty (i.e. the future clinical diagnosis) (for 
review (Janssen et al., 2018)). Although recent time-to-event models (e.g. survival analysis 
models predicting time to conversion) (Alsaedi et al., 2018; Casanova et al., 2013; Desikan et 
al., 2010; Jack, Jr, et al., 2010; S. M. Landau et al., 2010; K. Liu et al., 2017; Michaud et al., 
2017; Oulhaj et al., 2009; Young et al., 2014) capture continuous information in patient 
trajectories they are limited by target uncertainty; that is, estimating the exact time to 
conversion is limited by the frequency of clinical follow-ups and poor inter-rater reliability (i.e. 
diagnoses may differ across clinicians).  
Our trajectory modelling approach predicts future ADNI-Mem scores based on baseline data, 
allowing us to capture individual disease trajectories and reducing the risk of patient 
misclassification. In particular, we derive continuous prognostic scores of individual cognitive 
decline (i.e. scalar projection) by training the model based on ‘noisy’ diagnostic labels (i.e. 
patient classes that are poorly defined e.g. sMCI vs pMCI). As our metric learning model has 
limited freedom (linear low-parameter model), separating continuous target values (i.e. 
individualised cognitive trajectories) into two broad classes (sMCI vs. pMCI) forces the model 
to extract key underlying structures in the data that distinguish between target values, ignoring 
subtle differences in target values. Further, employing separate feature generation (i.e. PLSr-
RFE) and classification (GMLVQ scalar projection) stages allows us to interrogate 
interpretable predictive features of progression to AD and derive predictions that generalise to 
patient data from independent samples from the model development sample. This is in contrast 
to deep learning methods that require large training samples and are shown to be difficult to 
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interpret and generalise (Christos Davatzikos, 2019), raising questions about the clinical utility 
of these approaches (for review (Topol, 2019)).  
Comparing our trajectory modelling methodology to binary classifications on the same data 
(i.e. cognitive vs. biological) shows dissociable results. A binary metric learning algorithm 
shows similar performance in the binary classification of MCI subgroups (sMCI vs. pMCI) 
when trained on baseline cognitive vs. biological data. In contrast, the scalar projection derived 
from biological data explains significantly higher individual variability in the rate of future 
cognitive decline than the scalar projection derived from cognitive data. Further, we 
demonstrate that the predictive power of our trajectory modelling methodology is enhanced 
when including non-invasively measured baseline biological data in addition to baseline 
cognitive data. Although our model shows high accuracy of cognitive decline when trained on 
cognitive data, there is a substantial gain in predictive efficacy when adding baseline data on 
APOE 4 status or grey matter density (PLS derived grey mater scores).  This is consistent with 
previous studies (Dukart et al., 2015; Vogel et al., 2018; Zhou et al., 2018) showing enhanced 
prediction of time to AD conversion when including biological compared to 
neuropsychological data alone. However, when investigating the additive effect of adding 
cognitive variables to the biological model of grey matter, APOE4 and b-Amyloid we did not 
see any improvement in modelling future cognitive change.   
Previous work on trajectory modelling has focused on discretising continuous values (i.e. 
future change in cognitive scores) into latent classes that are then used as outcome measures 
in classification models (Bhagwat et al., 2018; Hochstetler et al., 2015; Y. Wang et al., 2019; 
Wilkosz et al., 2010). For example, previous studies (Bhagwat et al., 2018) used machine 
learning (i.e. longitudinal Siamese neural-network) to fuse baseline and follow up imaging 
and clinical scores to predict whether individuals will decline fast or slow (based on MMSE 
scores) or fast, moderate or slow (based on ADAS-cog). Further studies (Hochstetler et al., 
2015) used classification and regression trees on baseline demographic, lifestyle, cognitive 
and biological data to classify individuals in three latent classes (fast, medium or slow 
decline) with similar growth patterns of cognitive and functional changes, while others 
(Wilkosz et al., 2010) used latent class trajectory models to derive six different trajectories 
for cognitive and behavioural decline due to AD. However, the generalisability and 
interoperability of these approaches have been recently questioned (Y. Wang et al., 2019). 
Our trajectory modelling approach differs from this previous work, as it avoids assumptions 
related to discretising continuous values. In particular, we derive a continuous metric (i.e. 
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scalar projection) from a discrete classification model (i.e. metric learning) that predicts 
individual rates of future cognitive change (i.e. change in ADNI-Mem).  Finally, our 
approach is in line with previous work predicting exact changes in MMSE or ADAS-Cog 
scores (Y. Fan et al., 2008; Zhang et al., 2012). In particular, previous studies used baseline 
and follow-up structural MRI and FDG-PET data to predict future scores on cognitive tests at 
different time intervals (Zhang et al., 2012), or structural MRI to predict the rate of change in 
MMSE scores (Y. Fan et al., 2008). Our modelling approach differs from this previous work 
in fusing baseline multimodal data into a single metric (i.e. scalar projection) to predict future 
rates of cognitive change (i.e. change in ADNI-Mem, or MMSE scores). In this work we 
derived the rate of cognitive change using the linear least squares fit of ADNI-Mem over 
time. However, as the proposed AD cascade suggests that cognitive change associated with 
AD follows a sigmoidal shape over time, the hypothesised rate of change will follow an 
inverted U shape (Jack, Knopman, et al., 2010). In this work we only investigated the 
relationship of the scalar projection with rate of cognitive change for individuals who are 
MCI and therefore cognitive change over time is more likely to be linear than sigmoidal (Jack 
et al., 2013; Jack, Knopman, et al., 2010). However, a more complex fit may be preferred 
when attempting to predict cognitive change for a population including cognitively normal 
and demented individuals. Further, although we show no difference between the sample with 
incomplete (i.e less than three years of follow-up) and complete (i.e. three or more years of 
follow up) longitudinal follow-up, we did not control for the variability due to different 
duration of follow-ups. In future work we can account for this variability in follow-up length 
in a more principled way using linear mixed effects models.  
In sum, we propose a robust methodology based on modelling multimodal data that determines 
predictive and interpretable markers of individual variability in progression to dementia due to 
AD. Although our investigations have focused on amnestic MCI, our methodology has the 
potential to be extended to predict individual disease trajectories specific to AD subtypes, 
following recent work modelling neuroimaging data (Dong et al., 2016; Young et al., 2018). 
Further, previous work on preclinical populations has investigated the role of grey matter 
atrophy and cortical amyloid burden in future cognitive decline (Bilgel et al., 2018; Burnham, 
Bourgeat, Doré, Savage, Brown, Laws, Maruff, Salvado, Ames, Martins, Masters, Rowe, & 
Villemagne, 2016; Dumurgier et al., 2017; Insel et al., 2015). Extending our trajectory 
modelling approach to preclinical populations using multimodal data has high clinical 
relevance, especially as clinical trials are moving towards less severely affected individuals 
who are unlikely to progress over the short time scales of clinical trials (Bilgel et al., 2014, 
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2017; Grober et al., 2008; Mormino et al., 2014). Thus, our approach has strong potential to 
deliver tools of high clinical relevance that reduce patient misclassification and facilitate 
effective stratification of individuals to prognostic or treatment pathways and clinical trials 
based on individualised rates of cognitive decline.  
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6. Experimental Chapter 3: Predicting future 
regional tau accumulation in early 
Alzheimer’s disease 
Introduction 
Preclinical Alzheimer’s Disease (AD) is a protracted process with multiple pathophysiological 
events occurring well before clinical manifestations (Dubois et al., 2016). Early phases involve 
molecular interactions between the b-amyloid and tau proteins, providing an opportunity to 
establish a more mechanistic and precise understanding of events that lead to the development 
of AD over the long term. One approach to tracking these events is the utilisation of machine 
learning to build predictive models of pathophysiological change in the earliest stages of AD.  
With the availability of PET scanning to image both b-amyloid and tau pathology in the brain, 
associations between AD related biomarkers can be examined in-vivo  (for reviews: (B. Hall 
et al., 2017; W. Jagust, 2018; Schöll et al., 2019). These studies have shown that AD related 
cognitive impairment is dependent on cortical b-amyloid accumulation that facilitates the  
spread of tau into the neocortex resulting in neurodegeneration (L. Wang et al., 2016). In the 
absence of b-amyloid the presence of tau in the medial temporal lobe is insufficient to initiate 
widespread pathological neurodegeneration (Hanseeuw et al., 2019; L. Wang et al., 2016). In 
addition, recent evidence linking  the apolipoprotein E gene and tau suggests that the presence 
of the APOE4 allele worsens tau related neurodegeneration independent of b-amyloid (Shi & 
Holtzman, 2018; Shi et al., 2017; van der Kant, Goldstein, & Ossenkoppele, 2020). Given this 
model of the AD pathological cascade (Jack et al., 2013; Jack, Knopman, et al., 2010), the 
staging of AD has shifted from a clinical syndromic diagnosis (Albert et al., 2011; McKhann 
et al., 2011) to a continuum of biomarker characteristics (Jack, Bennett, et al., 2018). In this 
framework, cognitively unimpaired individuals with evidence of b-amyloid and pathological 
tau accumulation are defined as having preclinical AD, and those with mild cognitive 
impairment (MCI) and similar biomarkers have AD. As a result, there is now a greater need 
for models that predict longitudinal change in pathological biomarkers rather than simply a 
change in clinical labels based on syndromic diagnosis.  
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Here, we utilised machine learning to quantify the multivariate relationships between the 
major factors underlying the pathogenesis of AD: APOE 4 genotype, b-amyloid, tau and 
neurodegeneration. Recently we developed a machine learning approach that derives a single 
prognostic index from APOE 4 genotype with measures of b-amyloid derived from either 
[18F]-florbetapir (FBP) or [11C]-PiB PET scans and a continuous measure of medial temporal 
atrophy derived from structural MRI (Methods: GMLVQ-Scalar projection). Previously 
we used this approach to show that the model derived prognostic index (scalar projection) is 
predictive of individualised rates of future memory change in MCI patients (Experimental 
Chapter 2: Modelling prognostic trajectories of cognitive decline due to Alzheimer’s 
disease). Here, we extended this to preclinical AD samples by using our machine learning 
framework to test whether the scalar projection derived from baseline data can classify and 
stage such individuals based on future pathological tau accumulation.  
Recent converging evidence highlights that patterns of tau spread (measured in-situ by 
longitudinal FTP-PET) are robust across preclinical AD cohorts (Jack, Wiste, et al., 2018; 
Pontecorvo et al., 2019; Schultz et al., 2018). This stereotypical spreading pattern for 
preclinical AD (i.e. b-amyloid positive individuals who are cognitively unimpaired) shows that 
tau initially accumulates within the temporal cortex then spreads to the superior and medial 
regions of the parietal cortex prior to cognitive impairment (Jack, Wiste, et al., 2018; Schultz 
et al., 2018).  
We hypothesised that individuals classified as early AD using our machine learning approach 
would have the characteristic pattern tau accumulation (measured by longitudinal FTP-PET) 
(Jack, Wiste, et al., 2018; Pontecorvo et al., 2019; Schultz et al., 2018). Further, we anticipated 
that our modelling approach using multimodal biomarkers (i.e. APOE4, b-amyloid PET and 
MRI) will require fewer patients than b-amyloid alone to detect a clinically meaningful change 
in future tau accumulation. Finally, based on our previous work we believed that individual 
variability in the scalar projection relates to individual variability in regional future tau 
accumulation.  
Our results show that the characteristic spreading pattern of tau in preclinical AD is predictable 
using baseline non-tau biomarkers, particularly when stratifying groups using multimodal data. 
Further, we show in an independent sample of cognitively unimpaired community dwelling 
individuals that the scalar projection predicts individualised rates of future tau accumulation 
with striking accuracy and regional specificity.   
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Materials and Methods 
Study Design and Participants: 
Three separate cohorts were used to generate and test predictive models of regional future tau 
accumulation. Two cohorts were drawn from the ADNI database: ADNI2/GO and ADNI 3 
(adni.loni.usc.edu). ADNI was launched in 2003 as a public-private partnership, led by 
Principal Investigator Michael W. Weiner, MD. A major goal of ADNI has been to examine 
biomarkers including serial magnetic resonance imaging (MRI), and positron emission 
tomography (PET), with clinical and neuropsychological assessment to predict outcomes in 
mild cognitive impairment (MCI) and early Alzheimer’s disease (AD). 
A third validation cohort was taken from the Berkeley Aging Cohort Study (BACS). This 
cohort is comprised of community-dwelling cognitively intact elderly individuals with a 
Geriatric depression scale (GDS) (Yesavage, 1988) score ≤10, Mini mental status examination 
(MMSE) (Folstein, Folstein, & McHugh, 1975) score ≥25, no current neurological and 
psychiatric illness, normal functions on verbal and visual memory tests (all scores ≥−1.5 SD 
of age-adjusted, gender-adjusted, and education-adjusted norms) and age of 60–90 (inclusive) 
years. All subjects underwent a detailed standardised neuropsychological test session and 
neuroimaging measurements, all of which were obtained in close temporal proximity with 
follow up every 1 to 2 years. 
Data from 488 individuals from ADNI 2/GO were used to train the machine learning model. 
Individuals were placed into three categories based on their baseline and longitudinal clinical 
diagnosis, with baseline defined as the evaluation closest to the first florbetapir (FBP) PET 
scan acquired in ADNI: Demented (n=181, 158 amyloid positive at baseline): individuals have 
a baseline diagnosis of demented; Stable Condition (SC) (n=145, 34 amyloid positive at 
baseline): individuals have a baseline diagnosis of cognitively normal and retain this diagnosis 
at follow up for 3 or more years; Early Alzheimer’s Disease (EAD) (n=162, 135 amyloid 
positive at baseline): individuals have un unstable diagnosis of cognitively normal (n=18) or 
MCI (n=144) and have either reverted from or progressed to dementia throughout their 
enrolment in ADNI (i.e. either reverted (n=81) or progressed to dementia (n=81)). We included 
individuals in the EAD group who were MCI at baseline but have received a diagnosis of 
demented prior to baseline in this group as we anticipate they are likely affected by AD 
pathology but are at an earlier stage of AD than the Demented group. Further, as our machine 
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learning model is designed with limited freedom (only a few parameters) when training using 
noisy diagnostic labels it is optimised to account for target uncertainty without leading to over-
fitting.  
Data from 115 individuals from ADNI 3 were used to test the relationship between the scalar 
projection and regional future tau accumulation. These individuals were either cognitively 
normal (n=72) or MCI (n=43) at baseline (defined as the diagnosis closest to the first 
flortaucipir (FTP) PET scan acquired in ADNI 3) and have at least one follow-up FTP PET 
scan. 
Data from 56 community dwelling individuals from BACS were used to test the accuracy of 
predictions of regional future tau accumulation. These individuals were cognitively normal 
(n=56) at baseline (defined as the diagnosis closest to the first FTP PET scan acquired in 
BACS) and have at least one follow-up FTP PET scan. 
Brain Imaging data  
MRI Acquisition 
Structural MRIs for the ADNI samples were acquired at ADNI-GO, ADNI-2 and ADNI-3 sites 
equipped with 3 T MRI scanners using a 3D MP-RAGE or IR-SPGR T1-weighted sequences, 
as described online (http://adni.loni.usc.edu/methods/documents/mri-protocols). Structural 
MRIs for the BACS sample were collected on either a 1.5T or 3T MRI scanner at the Lawrence 
Berkeley National Laboratory (LBNL) or UC Berkeley using 3D MP-RAGE T1- weighted 
sequences. All ADNI and BACS scans were acquired with voxel sizes of approximately 1mm 
X 1mm X 1mm. MRI data were used for quantitation of the PET data. 
PET Acquisition  
PET imaging was performed at each ADNI site according to standardised protocols. The FBP-
PET protocol entailed the injection of 10 mCi with acquisition of 20 min of emission data at 
50-70 min post injection. The FTP-PET protocol entailed the injection of 10 mCi of tracer 
followed by acquisition of 30 min of emission data from 75-105 min post injection. 
For the BACS, PIB PET scans were collected at LBNL. After ∼15 mCi tracer injection into an 
antecubital vein, dynamic acquisition frames were obtained in 3D acquisition mode over a 90 
min measurement interval (4 × 15 s frames, 8 × 30 s frames, 9 × 60 s frames, 2 × 180 s frames, 
8 × 300 s frames, and 3 × 600 s frames) after x-ray CT. FTP PET scans were collected following 
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an injection of ~10 mCi of tracer in a protocol identical to that used for ADNI. All BACS 
participants were studied on a Siemens Biograph PET/CT. 
Imaging Analysis-MRI: Medial Temporal Grey Matter Atrophy 
Structural scans were segmented into grey matter, white matter and Cerebrospinal Fluid (CSF). 
The DARTEL toolbox (Ashburner, 2007) was then used to generate a study specific template 
to which all scans were normalised. Following this, individual grey matter segmentation 
volumes were normalised to MNI space without modulation. The unmodulated values for each 
voxel represent grey matter density at the voxel location.  All images were then smoothed using 
a 3mm3 isotropic kernel and resliced to MNI resolution 1.5x1.5x1.5 mm voxel size. All 
structural MRI pre-processing was performed using Statistical Parametric Mapping 12 
(http://www.fil.ion.ucl.ac.uk/spm/). 
To generate a single index of medial temporal atrophy we used a voxel weights matrix that 
was previously derived to generate an interpretable and interoperable disease-specific 
biomarker (Experimental Chapter 1: Deriving an interpretable and interoperable score 
of Alzheimer’s related atrophy). In brief, a feature generation methodology (partial least 
squares regression with recursive feature elimination (Methods: PLSr Recursive Feature 
Elimination (PLSr-RFE)) was used to apply a decomposition on a set of predictors (T1-
weighted MRI voxels) to create orthogonal latent variables that show the maximum 
covariance with the response variable (memory score). Further, we performed recursive 
feature elimination by iteratively removing predictors (voxels) that have weak predictive 
value. The PLSr-RFE procedure results in a voxel weights matrix that is used to calculate a 
single score of AD related medial temporal atrophy. This index of medial temporal atrophy 
has been shown to predict memory deficits, relate to individual tau burden and discriminates 
stable MCI and progressive MCI individuals. To generate an individual’s score of medial 
temporal atrophy we performed a matrix multiplication of the previously derived voxel 
weights matrix and each subject’s pre-processed T1 weighted MRI scans.  
Imaging Analysis (ADNI)-PET: FBP (Florbetapir PET) β-Amyloid 
FBP data were realigned, and the mean of all frames was used to co-register FBP data to each 
participant’s structural MRI. Cortical Standardised Uptake Value Ratios (SUVR)s were 
generated by averaging FBP retention in a standard group of ROIs generated using FreeSurfer 
(v5.1) parcellations (lateral and medial frontal, anterior and posterior cingulate, lateral parietal, 
and lateral temporal cortical grey matter) and dividing by the average uptake from a composite 
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reference region (including the whole cerebellum, pons/brainstem, and eroded subcortical 
white matter regions) to create an index of global cortical FBP burden (b-amyloid) for each 
subject (Susan M Landau et al., 2015). 
Imaging Analysis (BACS)-PET: PiB (Pittsburgh Compound B) β-Amyloid 
Distribution volume ratios (DVRs) were generated with Logan graphical analysis on the 
aligned PIB frames using the native-space grey matter cerebellum as a reference region, fitting 
35–90 min after injection. 
For each subject, a global cortical PIB index was derived from the native-space DVR image 
coregistered to the MRI using FreeSurfer (5.1) parcellations using the Desikan-Killiany atlas 
(Desikan et al., 2006) to define frontal (cortical regions anterior to the precentral sulcus), 
temporal (middle and superior temporal regions), parietal (supramarginal gyrus, 
inferior/superior parietal lobules, and precuneus), and anterior/posterior cingulate regions- 
ROIs combined as a weighted average. There was no partial volume correction performed. 
Image analysis-PET: FTP (Flortaucipir PET) tau:  
FTP data were realigned and the mean of all frames used to coregister FTP to each participant’s 
MRI acquired closest to the time of the FTP-PET. FTP SUVR images were generated by  
dividing voxel wise FTP uptake values by the average value within a mask of eroded 
subcortical white matter regions (Harrison et al., 2019). MR images were segmented and 
parcellated into 72 ROIs taken from the Desikan-Killany atlas using Freesurfer (V5.3). These 
ROIs were then used to extract from the normalised FTP-PET images regional SUVR data. 
Left and right hemisphere ROIs were averaged to generate 36 ROIs for further analysis. We 
calculated the future annualised rate of tau accumulation for each of the 36 ROIs either by 
taking the difference between the follow-up and baseline FTP-PET scans divided by the time 
interval in years from baseline (when only 2 FTP scans were taken), or fitting a linear least 
squares fit to 3 or more FTP-PET scans and extracting the parameter estimate for the slope of 
the ROI SUVR vs. time in years from baseline (when 3 or more FTP scans were taken). In the 
ADNI 3 sample the average time between FTP-PET scans is 1.22 +- std: 0.38 years with the 
number of follow-up FTP-PET scans n (2 FTP-PET scans) =93, n (3 FTP-PET scans) =17, n 
(4 FTP-PET scans) =5. In the BACS cohort the average time between FTP-PET scans is 1.8 +- 
std:0.65 years with the number of follow-up FTP-PET scans n (2 FTP-PET scans) =37, n (3 
FTP-PET scans) =19. 
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Model Predictors and outcomes 
Three baseline biological markers related to AD were used as predictors to generate the scalar 
projection from the machine learning model: a) Cortical amyloid burden (b-amyloid) measured 
using either FBP (ADNI) or PiB (BACS) PET, b) medial temporal atrophy derived from the 
T1 weighted structural MRI and c) APOE 4 genotype.  Previously, we have shown when 
trained on these baseline data our machine learning approach can predict future changes in 
cognition for individuals diagnosed as MCI (Experimental Chapter 2: Modelling prognostic 
trajectories of cognitive decline due to Alzheimer’s disease). Here, we use the same baseline 
variables to generate predictions for early AD populations (i.e. individuals who are cognitively 
normal or MCI at baseline). 
The primary outcome measure for the predictive models is regional future annualised rate of 
tau accumulation (SUVR/year). A secondary outcome measure is changes in future cognition 
over the same time scale as the longitudinal FTP scans, as measured by the Preclinical 
Alzheimer’s Cognitive Composite (PACC). 
To test changes in future cognition for individuals from ADNI 3 we used the previously derived 
ADNI-PACC measure (adni.loni.usc.edu) (Donohue et al., 2014). Of the 115 ADNI 3 
individuals with multiple FTP-PET scans 102 individuals had multiple measures of the PACC 
over a similar time period (within 6 months of the baseline FTP-PET and the final FTP-PET 
scan). Future annualised change in PACC is calculated by either taking the difference between 
the follow-up and baseline PACC scores divided by the time interval in years from baseline 
(when only 2 PACC scores are available), or fitting a linear least squares fit to 3 or more PACC 
scores and extracting the parameter estimate for the slope of the PACC vs time in years from 
baseline (when 3 or more PACC scores are available). The average time between PACC testing 
sessions scans is 1.04 +- std: 0.44 years with the number of follow-up PACC testing sessions 
n (2 PACC sessions) =82, n (3 PACC sessions) =18, n (4 PACC sessions) =2.        
Prediction Models: 
Generalised Metric Learning Vector Quantization (GMLVQ)-Scalar Projection: We 
previously developed a machine learning approach based on the GMLVQ classification 
framework: GMLVQ-Scalar Projection (Methods: GMLVQ-Scalar Projection). This 
approach allows us to derive a continuous prognostic metric by training a model based on 
diagnostic labels. In brief, we trained a metric learning model (GMLVQ) with baseline 
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multimodal data (medial temporal grey matter atrophy, β-amyloid, APOE 4 genotype). 
GMLVQ operates in a supervised manner to iteratively modify class-specific prototypes and 
learn boundaries between classes. For each training example, the closest prototype of each 
class is determined, these prototypes are then updated so that the prototype defining the same 
class is moved towards the training example and other prototype(s) representing different 
class(es) are moved further away. We have previously shown that this GMLVQ modelling 
approach classifies MCI patients into subgroups (progressive vs. stable) with high specificity 
and sensitivity. Extending the binary model, we derived a single prognostic distance measure 
(scalar projection) that separates individuals based on their future diagnosis. Previously we 
calculated the scalar projection to separate individuals who are stable MCI from progressive 
MCI showing that the continuous value predicts individualised future cognitive decline 
(Experimental Chapter 2: Modelling prognostic trajectories of cognitive decline due to 
Alzheimer’s disease). Here, we apply the same framework on a new sample, deriving the 
scalar projection and making individualised predictions of future regional tau accumulation in 
early AD populations.  
GMLVQ- scalar projection implementation:  
From the training sample the model learns the multivariate relationship between b-amyloid, 
medial temporal atrophy and APOE 4 (metric tensor 𝛬) and the location in multidimensional 
space that best classifies SC vs EAD individuals (prototype locations: 𝑤(,L)). For any new 
subject with b-amyloid, medial temporal atrophy and APOE 4 (sample vector: 𝑥() the scalar 
projection can be calculated by a series of simple linear equations.  
1. Transform the sample vector 𝑥( and prototypes 𝑤(,L)	into the learnt space via the 
metric tensor	𝛬. Note as the metric tensor is learnt in the squared Euclidean space we 
transform using the square root of the metric tensor (i.e. 𝛬N/) 
1.a 𝑋( = 𝛬N/	𝑥( 
1.b 𝑊(,L) = 𝛬N/𝑤(,L) 
2. Centre the coordinate system on 𝑊() and calculate the orthogonal projection of each 
vector 𝑋( onto the vector 𝑊(L), in this co-ordinate system. 
2.a 𝑃𝑟𝑜𝑗𝑒𝑐𝑡𝑖𝑜𝑛 =  ¡¢£¤⃑ .¢¥¦§¢£¤⃑K¢¥¦§¢£¤⃑ K  
3. To normalise the projections with respect to the position of the prototype 𝑊(), the we 
divided the projection by the norm of 𝑊L𝑊⃑ : 
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4. a 𝑆𝑐𝑎𝑙𝑎𝑟	𝑃𝑟𝑜𝑗𝑒𝑐𝑡𝑖𝑜𝑛 =  ¡¢£¤⃑ .¢¥¦§¢£¤⃑K¢¥¦§¢£¤⃑ K¨      
 
To determine a meaningful threshold of the scalar projection for separating individuals who 
are SC from EAD individuals we use logistic regression for the ADNI 2/GO sample labelled 
as SC, EAD, and Demented. This results in a probabilistic boundary based on scalar projection. 
Determining Regions of significant AD related tau accumulation:  
We first classified individuals from ADNI 3 as either SC or EAD based on each individual’s 
scalar projection. For the individuals who are classified as EAD (based on the probabilistic 
threshold value) we performed a subsequent first level analysis to determine which of the 36 
selected ROIs will accumulate tau in the future (i.e. regions with a future annualised rate of 
accumulation statistically greater than 0).  
Predicting individual variability in Regional Tau Accumulation:  
Finally, for regions that pass first level significance (i.e. within regions that significantly 
accumulating tau) we trained a series of regression models using ADNI 3 individuals classified 
as EAD to test if the scalar projection relates to individual variability in regional future rate of 
tau accumulation (dependent variable: regional future tau accumulation, independent variable: 
scalar projection).  We then tested these models by making individualised predictions –out of 
sample- for individuals classified as EAD from the BACS sample. To test the accuracy of the 
regional predictions we calculated the shared variance between the observed future 
accumulation of tau and the model generated prediction using baseline biological data (i.e. 
scalar projection). 
Statistical Analysis: 
We used logistic regression to define a probabilistic boundary that separates individuals who 
are SC from EAD. Using the ADNI 2/GO sample we fit a three class (SC, EAD, Demented) 
logistic regression to determine the threshold value of the scalar projection. We set the 
threshold as the probability an individual is less than 50% likely to be SC.  To determine the 
regions that will significantly accumulate tau for individuals classified as EAD we used one 
tailed one sample t-tests. As we are testing if regions are accumulating tau we use right tail t-
tests to determine if the future rate of tau accumulation is significantly greater than 0 per ROI 
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for individuals classified as EAD. To compare required sample sizes for different models 
derived using ADNI 3 data we calculated the sample size needed for an arm of a hypothetical 
clinical trial designed to detect a 25% reduction in annual change (rate of tau accumulation, 
rate of PACC decline) with a significance of 0.05 and a power of a=0.8. For each comparison, 
we defined the null hypothesis as the mean and standard deviation of the rate of change 
calculated from the observed sample, where the alternate hypothesis is a 25% reduction of the 
mean of the observed sample. For each of the regions that showed significant tau accumulation 
we fit a robust linear regression (robustfit MATLAB) to predict future tau accumulation using 
the scalar projection. Setting the dependent variable as future regional tau accumulation and 
the independent variable as scalar projection we learnt a series of ROI regression equations. 
 
Finally, using the fits derived from ADNI 3 data we generated predictions of tau accumulation 
for individuals classified as EAD in BACS.  
 
We tested the accuracy of these predictions in the BACS sample by calculating the shared 
variance between the predicted future rate of tau accumulation and the observed future rate of 
tau accumulation after treating for outliers (robust correlation (Pernet et al., 2013)). 
  
𝑅𝑎𝑡𝑒	𝑜𝑓	𝑇𝑎𝑢	𝐴𝑐𝑐𝑢𝑚𝑢𝑙𝑎𝑡𝑖𝑜𝑛	(𝐴𝐷𝑁𝐼	3)	°±² = 𝛽(𝐴𝐷𝑁𝐼	3)°±² ∗ 𝐸𝐴𝐷	𝑆𝑐𝑎𝑙𝑎𝑟	𝑃𝑟𝑜𝑗𝑒𝑐𝑡𝑖𝑜𝑛(𝐴𝐷𝑁𝐼	3) 
𝑃𝑟𝑒𝑑𝑖𝑐𝑡𝑒𝑑	𝑅𝑎𝑡𝑒	𝑜𝑓	𝑇𝑎𝑢	𝐴𝑐𝑐𝑢𝑚𝑢𝑙𝑎𝑡𝑖𝑜𝑛	(𝐵𝐴𝐶𝑆)	°±² = 𝛽(𝐴𝐷𝑁𝐼	3)°±² ∗ 𝐸𝐴𝐷	𝑆𝑐𝑎𝑙𝑎𝑟	𝑃𝑟𝑜𝑗𝑒𝑐𝑡𝑖𝑜𝑛(𝐵𝐴𝐶𝑆) 
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Results  
Biological classification model for predicting stable condition vs early AD 
We used a recent adaptation to the Generalised Metric Learning Vector Quantisation 
(GMLVQ) machine learning framework (Methods: GMLVQ-scalar projection) to generate 
a prognostic index (scalar projection) from three biological markers measured at baseline: 
cortical β-amyloid measured using PET, medial temporal atrophy measured using T1 weighted 
MRI and APOE 4 genotype.  
The scalar projection is derived to discriminate stable cognitively normal individuals (SC) vs. 
early AD individuals with an unstable diagnosis (EAD). After the model was trained to 
discriminate SC vs. EAD we then determined the distance an individual is from the prototypical 
position of a SC. This distance is calculated along the learned axis that is predictive of future 
diagnosis (i.e. SC towards EAD) (i.e. scalar projection). We applied this approach training the 
model to discriminate SC vs EAD on data from the Alzheimer’s Disease Neuroimaging 
Initiative (ADNI) 2/GO cohort. 
First, the model classifies SC (n=145) vs. EAD (n=162) individuals with cross-validated class-
balanced accuracy of 86.4% (Figure 6.1a). Further, using logistic regression we show that an 
individual is more than 50% likely to be classified EAD if they have a scalar projection greater 
than 0.4. Next, using the model trained on ADNI2/GO data we derived the scalar projection 
for individuals from two independent cohorts: a) ADNI 3 (CN=72, MCI=43) b) Berkeley 
Aging Cohort Study (BACS) (CN=56). The scalar projection classified 61 ADNI3 participants 
and 33 BACS participants as SC, with 54 ADNI3 and 23 BACS participants classified as EAD.  
(i.e. scalar projection greater than 0.4) (Figure 6.1b). We next tested if the scalar projection 
was significantly correlated with potential confounds using Pearson correlations. We observed 
that the scalar projection was weakly related to baseline age in ADNI 3 (r(113)=0.28, p=0.003) 
but not in BACS (r(54)=0.187, p=0.168) and it was unrelated to education (BACS: r(54)=-
0.011, p=0.94, ADNI 3: r(113)=-0.014, p=0.88) or gender (BACS: t(54)=-1.52, p=0.136, 
ADNI 3: t(113)=-0.582, p=0.56). 
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Figure 6.1: Deriving the scalar projection in three cohorts 
 
Figure 6.1a. The distribution of scalar projection for individuals from ADNI2/GO who are 
SC (Stable Condition), EAD (Early AD) and Demented. Figure 6.1b. The distribution of 
scalar projection for BACS and ADNI 3 individuals. The dashed black line represents the 
probabilistic boundary used to classify SC vs EAD, all individuals to the right of the line are 
classified as EAD. 
 
Comparing rate of tau accumulation for stable condition vs early AD  
For individuals from ADNI 3, we used longitudinal FTP-PET to compare regional future tau 
accumulation for individuals classified as SC vs. EAD. We extracted regional SUVR values 
from 36 Desikan-Kilany ROIs and calculated annualised rate of change per ROI. ROIs were 
grouped together in order to approximate the topographical distribution of tau in the Braak 
Staging scheme, as previously described. For individuals with 2 FTP-PET scans we used the 
difference between the follow-up and baseline FTP-PET scans divided by the time interval in 
years from baseline. For individuals with 3 or more FTP-PET scans we used the least squares 
fit of time from baseline vs. ROI SUVR.  
 We observed that EAD individuals accumulated global cortical tau (mean rate of tau 
accumulation within the 36 Desikan-Kilany ROIs) 2.8 times faster than SC individuals (Table 
6.1). Further, testing which regions significantly accumulated tau (i.e. rate of accumulation 
significantly greater than 0 by one tail t-tests within each ROI) showed that EAD individuals 
accumulate tau primarily in Braak stages 4 and 5 ROIs (Table 6.1, Figure 6.2). In contrast, 
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those classified as SC did not show clear tau accumulation across cortical regions, with only a 
weak but significant effect in the middle temporal ROI t(60) =1.71, p=0.047) Figure 6.2d. 
There was no difference in cognitive change in (as measured by future annualised change in 
PACC) over the same time period between individuals classified as SC(mean=-0.161/year) vs. 
EAD(mean=-0.6/year) (t(100)=-1.04, p=0.30). However, individuals classified as EAD 
showed significant worsening (i.e. rate of PACC change significantly less than 0) in future 
cognitive ability (one tail t-test t(47)=-1.87, p=0.034).    
 
Figure 6.2 Regional future rate of tau accumulation 
 
 
Figure 6.2. The future annualised rate of tau accumulation for ADNI 3 individuals across the 
36 Desikan Kilany ROIs. Figure 6.2a. Mean future annualised rate of tau accumulation for 
individuals classified as the Early AD (EAD). Figure 6.2b. Mean future annualised rate of 
tau accumulation for individuals classified as Stable Condition (SC). Figure 6.2c The 
regions in red are significantly accumulating tau for individuals classified as Early AD 
(EAD). Figure 6.2d The regions in red are significantly accumulating tau for individuals 
classified as Stable Condition (SC). 
 
 
Table 6.1. Regional future annualised rate of tau accumulation (over page) 
Table 6.1. Shows measures of future regional annualised rate of tau accumulation taken from 
the Desikan Killany atlas for ADNI 3 individuals within the 6 Braak stages. The mean future 
annualised rate of tau accumulation and test statistics describing whether a region is 
significantly accumulating tau for individuals classified as Stable Condition (SC) (Left block) 
and for individuals classified as Early AD (EAD) (Right block) 
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Braak Stage Region 
Stable Condition (n=61) Early AD (n=54) 
 
Significantly 
Accumulating Tau 
 
Significantly 
Accumulating Tau 
mean 
accumulation 
(SUVR/Year) t-stat p-val 
mean 
accumulation 
(SUVR/Year) t-stat p-val 
1 ENTORHINAL 0.0006 0.130 0.448 0.0120 2.259 0.014 
2 HIPPOCAMPUS 0.0009 0.233 0.408 -0.0011 -0.285 0.612 
3 
PARAHIPPOCAMPAL 0.0021 0.574 0.284 0.0049 1.149 0.128 
FUSIFORM 0.0032 0.941 0.175 0.0135 2.920 0.003 
LINGUAL 0.0018 0.507 0.307 0.0033 0.899 0.186 
AMYGDALA -0.0001 -0.025 0.510 0.0099 2.235 0.015 
4 
MIDDLETEMPORAL 0.0066 1.713 0.046 0.0164 3.332 <0.001 
CAUDALANTERIORCINGULATE 0.0005 0.129 0.449 -0.0012 -0.541 0.705 
ROSTRALANTERIORCINGULATE 0.0009 0.270 0.394 -0.0070 -2.842 0.997 
POSTERIORCINGULATE 0.0025 0.796 0.215 0.0056 1.741 0.044 
ISTHMUSCINGULATE 0.0022 0.697 0.244 0.0070 2.331 0.012 
INSULA -0.0003 -0.103 0.541 0.0022 0.809 0.211 
INFERIORTEMPORAL 0.0059 1.484 0.072 0.0171 3.477 <0.001 
TEMPORALPOLE -0.0073 -1.302 0.901 -0.0001 -0.041 0.516 
5 
SUPERIORFRONTAL 0.0020 0.652 0.259 0.0021 0.852 0.199 
LATERALORBITOFRONTAL 0.0032 1.032 0.153 -0.0023 -0.870 0.806 
MEDIALORBITOFRONTAL -0.0011 -0.309 0.621 -0.0041 -1.439 0.922 
FRONTALPOLE 0.0038 0.818 0.208 0.0008 0.167 0.434 
CAUDALMIDDLEFRONTAL 0.0033 1.096 0.139 0.0069 1.967 0.027 
ROSTRALMIDDLEFRONTAL 0.0022 0.641 0.262 0.0026 0.836 0.203 
PARSOPERCULARIS 0.0032 1.010 0.158 0.0037 1.476 0.073 
PARSORBITALIS 0.0067 1.348 0.091 -0.0021 -0.418 0.661 
PARSTRIANGULARIS 0.0035 0.920 0.181 0.0018 0.549 0.293 
LATERALOCCIPITAL 0.0045 1.007 0.159 0.0180 2.887 0.003 
SUPRAMARGINAL 0.0000 0.010 0.496 0.0103 2.654 0.005 
INFERIORPARIETAL 0.0024 0.721 0.237 0.0184 3.725 <0.001 
SUPERIORTEMPORAL 0.0016 0.464 0.322 0.0033 0.973 0.168 
SUPERIORPARIETAL 0.0023 0.589 0.279 0.0150 3.213 0.001 
PRECUNEUS 0.0016 0.587 0.280 0.0088 2.694 0.005 
BANKSSTS 0.0039 1.200 0.117 0.0108 2.358 0.011 
TRANSVERSETEMPORAL -0.0042 -1.259 0.893 -0.0034 -0.964 0.830 
6 
PERICALCARINE 0.0025 0.793 0.216 0.0021 0.549 0.293 
POSTCENTRAL 0.0013 0.400 0.345 0.0029 0.856 0.198 
CUNEUS 0.0006 0.187 0.426 0.0082 1.890 0.032 
PRECENTRAL 0.0017 0.570 0.285 0.0025 0.910 0.184 
PARACENTRAL 0.0027 0.816 0.209 0.0051 1.499 0.070 
 
Mean 0.0019 
  
0.0054 
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Comparing required sample size to detect change in tau accumulation vs 
cognitive decline 
To examine the clinical utility of regional future rate of tau accumulation as an outcome 
measure we contrasted the sample size (at the same power) required to observe cognitive 
decline vs regional future tau accumulation for individuals classified as EAD. We defined a 
clinically meaningful change as a 25% reduction in rate of change of either regional tau 
accumulation or PACC change.  
For individuals classified as EAD we calculated that the required sample size (for a significance 
level of p=0.05 at a power of a=0.8) to detect a 25% reduction in rate of PACC change is 
n=1730. However, to detect a 25% reduction in regional future tau accumulation in the selected 
areas (Figure 6.2c) at the same power level an average sample size of n=1127 is required. 
Thus, using future rate of tau accumulation as a clinical outcome measure instead of future rate 
of cognitive decline delivers a reduction in required sample size of 35%.  
Comparing required sample size to detect change in tau accumulation for 
multimodal vs unimodal classification  
Next we compared prediction of regional future tau accumulation for individuals classified as 
EAD (n=54) based on the scalar projection vs. those classified based only on being β-amyloid 
positive (n=61). We observed that individuals classified as EAD using multimodal data (i.e. 
scalar projection) accumulated global cortical tau 1.5 times faster than individuals who are 
defined only by β-amyloid positivity (Table 6.2).  
We next compared required sample sizes to detect a 25% decrease in rate of future tau 
accumulation (given significance level of p=0.05 at power of a=0.8) for EAD vs β-amyloid 
only individuals within regions significantly accumulating tau for individuals classified as 
EAD (Figure 6.2c). We observe on average a 47% reduction in sample size when stratifying 
based on a classification of EAD (n=1127) vs β-amyloid positive only (n=2146). By using the 
tau-accumulating regions from the EAD subjects we may have biased the estimates, so we 
repeated the calculations using regions in which β-amyloid positive individuals are 
significantly accumulating tau. This showed an average a 30% reduction in sample size when 
stratifying based on a classification of EAD (n=831) vs β-amyloid positive only (n=1190) 
(Figure 6.3).  
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These results support the clinical utility of performing group stratification using a classification 
of EAD based on multimodal data in contrast to β-amyloid status alone.  
 
Figure 6.3 reduction in sample size to observe change when stratifying using 
multimodal data vs. β-amyloid positive only 
 
Figure 6.3 shows the percentage reduction of sample size to observe a 25% reduction in tau 
accumulation per region for groups defined my multimodal data (EAD) or β-amyloid status 
only. 
Table 6.2. Regional future annualised rate of tau accumulation early AD vs b-amyloid 
positive (over page) 
Table 6.2. Shows measures of future annualised rate of tau accumulation for regions taken 
from the Desikan Killany atlas within the 6 Braak stages. The mean future annualised rate of 
tau accumulation and test statistics describing whether a region is significantly accumulating 
tau for individuals classified as Early AD (EAD) (Left block) and for individuals who are b-
amyloid positive only (Right block). The Sample size reported is for a hypothetical clinical 
trial looking to observe a 25% reduction in rate of tau accumulation per region. The right 
most column compares the required sample size to observe the same effect for groups defined 
my multimodal data (EAD) or amyloid status only. 
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Braak 
Stage Region 
Early AD (EAD) b-amyloid Positive EAD vs 
b-amyloid 
Positive 
 
Significantly 
Accumulating Tau 
 
Significantly 
Accumulating Tau 
mean 
accumulation 
(SUVR/Year) t-stat p-val 
sample 
size 
mean 
accumulation 
(SUVR/Year) t-stat p-val 
sample 
size 
relative 
difference in 
sample size 
1 ENTORHINAL 0.0120 2.259 0.014 1332 0.007 1.386 0.085 3990 0.33 
2 HIPPOCAMPUS -0.0011 -0.285 0.611 NaN -0.002 -0.437 0.668 NaN NaN 
3 
PARAHIPPOCAMPAL 0.0049 1.149 0.127 5141 0.004 0.845 0.201 10719 0.48 
FUSIFORM 0.0135 2.920 0.002 798 0.013 2.899 0.003 914 0.87 
LINGUAL 0.0033 0.899 0.186 8384 0.005 1.374 0.087 4060 2.07 
AMYGDALA 0.0099 2.235 0.014 1360 0.007 1.630 0.054 2886 0.47 
4 
MIDDLETEMPORAL 0.0164 3.332 <0.001 613 0.014 3.284 0.001 713 0.86 
CAUDALANTERIORCINGULATE -0.0012 -0.541 0.704 NaN -0.004 -1.278 0.897 NaN NaN 
ROSTRALANTERIORCINGULATE -0.0070 -2.842 0.996 NaN -0.007 -2.950 0.998 NaN NaN 
POSTERIORCINGULATE 0.0056 1.741 0.043 2240 0.005 1.480 0.072 3501 0.64 
ISTHMUSCINGULATE 0.0070 2.331 0.011 1250 0.006 1.852 0.034 2236 0.56 
INSULA 0.0022 0.809 0.211 10366 0.001 0.505 0.308 30012 0.35 
INFERIORTEMPORAL 0.0171 3.477 <0.001 563 0.017 3.728 <0.001 553 1.02 
TEMPORALPOLE -0.0001 -0.041 0.516 NaN -0.004 -0.936 0.823 NaN NaN 
5 
SUPERIORFRONTAL 0.0021 0.852 0.199 9354 0.000 0.163 0.435 286961 0.03 
LATERALORBITOFRONTAL -0.0023 -0.870 0.805 NaN -0.002 -0.834 0.796 NaN NaN 
MEDIALORBITOFRONTAL -0.0041 -1.439 0.922 NaN -0.005 -1.874 0.967 NaN NaN 
FRONTALPOLE 0.0008 0.167 0.434 242813 -0.002 -0.404 0.656 NaN NaN 
CAUDALMIDDLEFRONTAL 0.0069 1.967 0.027 1755 0.004 1.142 0.129 5879 0.30 
ROSTRALMIDDLEFRONTAL 0.0026 0.836 0.203 9701 0.000 0.090 0.464 940607 0.01 
PARSOPERCULARIS 0.0037 1.476 0.073 3117 0.003 0.965 0.169 8226 0.38 
PARSORBITALIS -0.0021 -0.418 0.661 NaN -0.003 -0.613 0.729 NaN NaN 
PARSTRIANGULARIS 0.0018 0.549 0.292 22520 0.000 0.040 0.484 4761379 0.00 
LATERALOCCIPITAL 0.0180 2.887 0.002 816 0.016 2.887 0.003 921 0.89 
SUPRAMARGINAL 0.0103 2.654 0.005 965 0.007 1.972 0.027 1972 0.49 
INFERIORPARIETAL 0.0184 3.725 <0.001 491 0.015 3.322 0.001 697 0.70 
SUPERIORTEMPORAL 0.0033 0.973 0.167 7172 0.001 0.435 0.333 40574 0.18 
SUPERIORPARIETAL 0.0150 3.213 0.001 659 0.012 2.784 0.004 990 0.67 
PRECUNEUS 0.0088 2.694 0.004 937 0.008 2.454 0.009 1274 0.74 
BANKSSTS 0.0108 2.358 0.011 1222 0.009 2.173 0.017 1625 0.75 
TRANSVERSETEMPORAL -0.0034 -0.964 0.830 NaN -0.004 -0.993 0.838 NaN NaN 
6 
PERICALCARINE 0.0021 0.549 0.292 22521 0.003 0.703 0.242 15505 1.45 
POSTCENTRAL 0.0029 0.856 0.197 9250 0.001 0.326 0.373 71983 0.13 
CUNEUS 0.0082 1.890 0.032 1900 0.005 1.378 0.087 4035 0.47 
PRECENTRAL 0.0025 0.910 0.183 8200 0.001 0.210 0.417 174022 0.05 
PARACENTRAL 0.0051 1.499 0.070 3022 0.004 1.311 0.097 4456 0.68 
 
Mean 0.0054 
   
0.0037 
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Predicting individual variability in tau accumulation 
Using the ADNI 3 sample we fit linear regression equations to test whether the scalar projection 
(derived from the model trained on ADNI2/GO) predicts individual variability in future tau 
accumulation (Table 6.3). Of the 15 regions that were significantly accumulating tau (Figure 
6.2c) 13 showed a significant relationship of the scalar projection and individual rates of future 
tau accumulation (Figure 6.4a), explaining up to 30% of variance in the temporal cortex and 
20% in superior and medial regions of the posterior parietal cortex (Figure 6.4b). 
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Figure 6.4 predicting individual variability in future tau accumulation in ADNI 3 early 
AD 
 
 
Figure 6.4a. The significant (p<0.05) regional parameter estimates from linear regressions 
to predict future rate of tau accumulation for individuals classified as Early AD (EAD). The 
colour scale indicates the parameter estimate for the slope of the regression fit (i.e. relative 
annualised rate of future change of regional tau accumulation measured in SUVR/Year). 
Figure 6.4b. Shows the percentage of variance explained when using scalar projection to 
predict future rate of tau accumulation for individuals classified as Early AD (EAD) from the 
ADNI 3 cohort. 
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Table 6.3. Fitting individual variability in regional future annualised rate of tau 
accumulation 
Braak Stage Region 
Beta Estimate 
(SUVR/Year) t-stat p-val 
%Variance 
Explained 
1 ENTORHINAL -0.019 -1.327 0.190 0.69 
3 
FUSIFORM 0.053 3.526 <0.001 30.0 
AMYGDALA 0.015 0.919 0.362 2.04 
4 
MIDDLETEMPORAL 0.040 2.069 0.044 7.94 
POSTERIORCINGULATE 0.027 2.460 0.017 9.27 
ISTHMUSCINGULATE 0.028 2.762 0.008 24.18 
INFERIORTEMPORAL 0.040 2.098 0.041 13.62 
5 
CAUDALMIDDLEFRONTAL 0.034 2.826 0.007 12.25 
LATERALOCCIPITAL 0.046 2.207 0.032 14.89 
SUPRAMARGINAL 0.032 3.041 0.004 3.89 
INFERIORPARIETAL 0.046 2.853 0.006 8.67 
SUPERIORPARIETAL 0.049 3.522 <0.001 8.67 
PRECUNEUS 0.034 3.034 0.004 19.5 
BANKSSTS 0.041 2.687 0.010 9.35 
6 CUNEUS 0.030 2.129 0.038 7.84 
Table 6.3. Shows the parameter estimates and associated statistics for the robust regression 
equations using the scalar projection to predict regional future tau accumulation for 
individuals from ADNI 3 classified as Early AD (EAD). 
 
Predicting individual variability in tau accumulation for an independent 
cognitively normal sample 
To test the robustness of these regional fits we generated individualised predictions of future 
tau accumulation for CN individuals classified as EAD from the BACS sample. Using the 
model trained on ADNI2/GO individuals we derived the scalar projection from baseline 
multimodal biological data in BACS participants (figure 6.1b). We used the linear equations 
relating the scalar projection to rate of future tau accumulation derived from the 13 regions 
with significant correlations in the ADNI 3 sample to predict the future rate of tau accumulation 
in these ROIs in the BACS participants. Individualised predictions of future tau accumulation 
explain up to 39% of the observed variance in the temporal cortex and 32% in superior and 
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medial regions of the posterior parietal cortex (Table 6.4, Figure 6.5). Finally, we showed that 
for individuals who are classified as SC from the BACS sample no regional future tau 
accumulation can be predicted (Table 6.4). Therefore, our predictions are robust and specific 
for staging individuals who are transitioning from non-pathological aging to Alzheimer’s 
Disease.  
 
Table 6.4. Predicting regional future annualised tau accumulation in BACS 
Braak Stage Region 
ADNI 3 Beta 
Estimate 
(SUVR/Year) 
SC (n=33) EAD (n=23) 
Predicted 
Variance 
Explained % 
Predicted 
Variance 
Explained % 
3 FUSIFORM 0.053 3.02 26.11 
4 
MIDDLETEMPORAL 0.040 0.48 21.82 
POSTERIORCINGULATE 0.027 0.09 12.18 
ISTHMUSCINGULATE 0.028 0.00 2.79 
INFERIORTEMPORAL 0.040 1.45 22.47 
5 
CAUDALMIDDLEFRONTAL 0.034 0.89 0.89 
LATERALOCCIPITAL 0.046 2.38 6.79 
SUPRAMARGINAL 0.032 0.28 32.19 
INFERIORPARIETAL 0.046 0.02 2.31 
SUPERIORPARIETAL 0.049 0.59 20.95 
PRECUNEUS 0.034 2.47 26.74 
BANKSSTS 0.041 0.51 38.46 
6 CUNEUS 0.030 2.51 0.01 
Table 6.4. Shows the shared variance of the predicted regional future tau accumulation and 
the observed future tau accumulation for individuals from the BACS cohort. The right most 
column shows the shared variance for individuals classified as Early AD (EAD). The column 
second from the right shows the shared variance for individuals classified as Stable 
Condition (SC) 
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Figure 6.5 prediction accuracy of future tau accumulation in BACS early AD 
 
Figure 6.5. The percentage of shared variance of the predicted regional future tau 
accumulation and the observed future tau accumulation for individuals classified as Early 
AD (EAD) from the BACS cohort. 
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Discussion  
These results describe the use of machine learning to combine continuous information from 
AD biomarkers to predict pathological changes in tau accumulation in early and asymptomatic 
stages of AD. We use well characterised AD biomarkers (β-amyloid, medial temporal atrophy, 
APOE 4) to generate a prognostic index for stratification. Using this multimodal index derived 
from baseline data, we predict future tau accumulation, a known pathological driver of AD 
progression. Further, we highlight that when stratifying by multimodal measures future tau 
accumulation is more sensitive to change than the gold standard cognitive instrument. Finally, 
we are able to predict spatially specific individualised changes in tau accumulation in an out-
of-sample group of cognitively normal people, highlighting the strong predictive ability of this 
metric in preclinical AD populations.  
Utilising a recently developed machine learning approach (Methods: GMLVQ-Scalar 
Projection) we derived a prognostic index (scalar projection) from baseline biomarkers that 
accurately classified individuals in the early stages of AD. Using this model derived index we 
showed that individuals classified as early AD will accumulate tau in a topography 
stereotypical of preclinical AD (Jack, Wiste, et al., 2018; Pontecorvo et al., 2019; Schultz et 
al., 2018). We established the clinical relevance of our approach showing that, for individuals 
classified as early AD, the rate of tau accumulation provides a 35% reduction in sample size 
to detect a clinically meaningful change relative to the gold standard cognitive instrument 
(PACC (Donohue et al., 2014)). Similar to previous work we have been able to successfully 
stratify individuals based on the pattern of tau accumulation in early AD and accurately 
reproduce the topography seen in several independent cohorts. The regions which we 
predicted would show tau accumulation are biologically plausible, corresponding strongly to 
regions of tau deposition demonstrated by numerous other laboratories and largely 
corresponding to a proposed “meta-ROI” for tau quantitation  (Jack, Wiste, et al., 2018; 
Pontecorvo et al., 2019; Schultz et al., 2018). Use of this ROI similarly demonstrates a 
smaller sample size to detect clinically meaningful change than using a cognitive measure  
(Jack, Wiste, et al., 2018).  
Extending previous work, we show that a multimodal measure is superior to a unimodal (i.e. 
b-amyloid positive only) classification for determining if an individual will accumulate 
pathological tau.  Individuals who are classified as early AD using multimodal data are 
accumulating tau at 1.5 times the rate as b-amyloid positive only individuals. Further, when 
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using multimodal data vs. b-amyloid status only to stratify populations there is a greater than 
30% reduction in the sample size required to observe a clinically meaningful change in the 
stereotypical pattern of pathological tau accumulation. The benefit of combining multimodal 
data for stratification in preclinical AD has been discussed in the context of future changes in 
cognition (Allison et al., 2019; Bilgel et al., 2018; Burnham, Bourgeat, Doré, Savage, Brown, 
Laws, Maruff, Salvado, Ames, Martins, Masters, Rowe, Villemagne, et al., 2016; Dumurgier 
et al., 2017; Insel et al., 2015; Jansen et al., 2018). These studies show that grey matter atrophy 
and cortical b-amyloid burden relate to separable patterns of future cognitive decline (Bilgel et 
al., 2018; Burnham, Bourgeat, Doré, Savage, Brown, Laws, Maruff, Salvado, Ames, Martins, 
Masters, Rowe, Villemagne, et al., 2016; Dumurgier et al., 2017; Insel et al., 2015). Given the 
association between longitudinal changes in tau and cognitive decline  in the early AD phase 
(Hanseeuw et al., 2019), our results reiterate the benefit of combining continuous values of b-
amyloid and grey matter atrophy for prognostication in early AD. Taking these findings into 
consideration, as well as the anticipated benefit in using tau accumulation as a primary 
endpoint, we show that our multimodal prognostic index can support clinical trial design, 
particularly in the early AD stage. 
Moving beyond binary classifications we showed that the scalar projection predicts individual 
variability in future regional tau accumulation within regions known to be affected in early 
AD. We show that these individualised predictions generalise to an independent sample of 
cognitively normal community dwelling individuals. Further, we show within this community 
dwelling population these predictions are specific to individuals who are classified as early 
AD. Several studies have investigated individual variability in future tau accumulation, 
focussing primarily on associations between simultaneous changes in pathophysiology 
(Franzmeier et al., 2020; Hanseeuw et al., 2019; Harrison et al., 2019). Unlike these previous 
approaches we have used a multimodal approach to make explicit individualised predictions 
specific to early AD, validating these predictions in a community dwelling population.    
There are several limitations of the current framework. First, our model is trained on grey 
matter atrophy in the medial temporal lobe. Previously we established this grey matter value 
relates to memory deficits, baseline tau and separates individuals who are stable MCI from 
progressive MCI (Experimental Chapter 1: Deriving an interpretable and interoperable 
score of Alzheimer’s related atrophy). However, as our previous research only focussed on 
ADNI participants this measure of atrophy likely captures information specific to typical 
amnestic AD populations. Given that dissociable patterns of tau spreading have been 
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observed for atypical AD variants (i.e. posterior cortical atrophy and logopenic progressive 
aphasia) (Sintini et al., 2019) additional measures of atrophy might be necessary for a larger 
scale predictive model. In addition, while FTP PET measures largely correspond to 
pathological spreading of AD related tau (Schöll et al., 2016), the off target binding of FTP 
limits it’s sensitivity to classify other tauopathies. Specifically, a model attempting to predict 
tauopathies affecting the midbrain and frontotriatal regions (i.e. progressive supranuclear 
palsy, corticobasal syndrome) may not be possible using FTP (Lowe et al., 2016). However, 
by applying a similar framework using a different tracer differential diagnosis of tauopathies 
may be possible.   
A potential limitation of this work is that we did not extensively test and control for effects 
due to poor scan quality or scanner differences. Images downloaded from the ADNI website 
following the standard pre-processing pipeline in an attempt to increase harmonisation across 
scanning sites. This included corrections due to gradient nonlinearity, non-uniform image 
intensity due to non-uniform receiver coil sensitivity and correction of non-uniformity due to 
wave effects (Jack et al., 2008). However, no additional control analysis was performed to 
ensure that there was no carry over differences due to scanner site. Further, there was no 
additional investigation into the potential scanner effects between data from ADNI and data 
from either the 1.5T or 3T scans from BACS. In addition, no additional quality control was 
run to account for image artefacts due to subject movement. 
In this work we derived the rate of future tau accumulation using the linear least squares fit of 
regional FTP-PET over time. However, as the proposed AD cascade suggests that tau 
accumulation follows a sigmoidal shape over time, the hypothesised rate of change will 
follow an inverted U shape (Jack, Knopman, et al., 2010). In this work we only investigated 
the relationship of the scalar projection with rate of tau accumulation for individuals who are 
cognitively normal or MCI and therefore tau accumulation over time (i.e. rate of tau 
accumulation) is more likely to be linear than sigmoidal (Jack et al., 2013; Jack, Knopman, et 
al., 2010). However, a more complex fit may be preferred when attempting to predict future 
tau accumulation for a population including cognitively normal, MCI and demented 
individuals. Further, we did not control for the variability due to different duration of follow-
ups. In future work we can account for this variability in follow-up length in a more 
principled way using linear mixed effects models.  
In sum, we have shown that the pathological spreading pattern of tau in early AD is predictable 
using baseline biomarkers. We highlighted that when designing clinical trials not only is 
pathological tau accumulation an optimal outcome measure, but a stratification based on 
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multimodal data is more specific to early AD. Further, we showed that a prognostic index 
derived from baseline multimodal biomarkers predicts individualised rates of future 
pathological tau accumulation in early AD. Here, we successfully translated rich AD specific 
information from a large research cohort to make individualised predictions of 
pathophysiological change in a cognitively normal community sample.  
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7. Discussion 
 
 
 
Undeniably, the proliferation of machine learning approaches in AD research is an exciting 
integration of computer science with neuroscience and has real-world potential. However, a 
fine balance must be struck in computational neuroscience ensuring the field does not favour 
computational innovations that lack neuroscientific insights. This deviation away from 
biologically constrained models and the acceptance of ‘black box’ approaches has 
questionable clinical utility and is evident with the paucity of these tools in clinical decision 
making (Topol, 2019). In light of this, the motivation of this thesis was to introduce a 
predictive framework that is easily interpretable but also not heavily constrained. That is, the 
driving force in the methodology presented is not one of improve accuracy at all costs by 
increasing model complexity or number of predictors. Rather, it is to generate and combine 
robust features that are widely accepted into a single framework. In doing so we limit the 
constraints that our model places on the data to make predictions reducing the chance of 
overfitting. More importantly we can make predictions that are related to AD as a clinical 
category, which are not specifically constrained to the task used to generate them (i.e. 
interoperation).   
Our integrated framework (Figure 7.1) relies on three key components: 
1. Selecting neuroimaging and cognitive data that will be linked due to disease 
pathology. 
2. Using the PLSr-RFE framework to generate a feature optimised for generalisation 
performance. 
3. Using the GMLVQ-scalar projection approach to model prognostic trajectories.  
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Figure 7.1 Integrated framework 
 
Figure 7.1 shows the integrated framework presented in this thesis. Stage 1. Involves the 
selection of associated cognitive and neuroimaging markers. Stage 2. Is the feature 
generation process using the PLSr-RFE framework. Stage 3. Is the modelling of prognostic 
trajectories. 
 
At each stage of our modelling framework we can investigate the interactions between 
predictors and outcomes and gain key neuroscientific insights. 
Our approach offers several specific advantages over previous modelling: 
1. Our novel integrated feature generation (PLSr-RFE) method allows us to reduce high 
dimensional collinear data (structural MRI) into a single robust and interpretable feature (PLS-
derived grey matter score). 
2. Interrogating the metric tensor within the GMLVQ framework allows us to interpret the 
weights of univariate (diagonal) and multivariate (off diagonal) features that are predictive of 
progression to AD. 
3. Extending the binary GMLVQ classification task to our trajectory modelling approach 
(GMLVQ-Scalar Projection) allows us to generate highly informative individualised disease 
trajectories. This approach is in line with the 2018 NIA-AA research framework that has 
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transitioned to defining AD as a continuum based on continuous measures rather than discrete 
clinical labelling.  
4.  The GMLVQ-Scalar Projection approach uses broad classes based on ‘noisy’ diagnostic 
labels to derive a highly sensitive continuous prognostic score. This allows us to capitalise on 
data that was collected and labelled based on the 2011 NIA-AA syndromic classification 
scheme. 
5. The prognostic index that is derived from the GMLVQ-Scalar Projection approach is not 
constrained to a single predictive task. That is, the relationship between the scalar projection 
and pathological changes used to validate is clinical utility are implicitly learnt and therefore 
capable of interoperation.  
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Feature Generation: PLSr-RFE 
Highlighting the utility of the approach, several studies have demonstrated methods for 
reducing structural neuroimaging data into AD indices (C. Davatzikos et al., 2009; Christos 
Davatzikos et al., 2019; Y. Fan et al., 2008; Young et al., 2018). Our approach is a significant 
extension to this work, as we have designed a method with the specific goal of interoperation. 
That is, the outcome of the PLSr-RFE methodology is a voxel weights matrix that can be 
applied to minimally pre-processed structural MRI to generate a single AD index that relates 
to cross modal AD biomarkers (i.e. cognition and tau accumulation). 
One increasingly prevalent problem in the field has been the failure of models to generalise to 
new populations. There are several potential reasons that models do not generalise. The first 
is that approaches using the same training data to generate features and perform classification 
tasks are prone to overfitting. The second, is that approaches to generate indices based on a 
neural state or clinical symptoms may be too heavily constrained to the feature generation 
task and may not transfer well to the subsequent classification task.  
An example of overfitting data can occur when researchers favour a feature generation 
approach that is specific to the subsequent classification task performed (i.e. the feature is 
built to maximise the classification accuracy of separating sMCI vs pMCI). Applied to the 
problem of AD prediction, we would require longitudinal data to  
1. Generate our feature, 2. Train our classifier, 3 cross-validate our model. In our case this 
would limit our sample to 167 people (sMCI=113, pMCI=54). Although we could achieve 
high discriminability between groups, with a relatively small sample there is no guarantee 
that the same feature will work equally as well with a new group of patients.  
Therefore, to increase the sample size available to generate our feature we favour a transfer 
learning approach. We reasoned that as ADNI Mem is discriminative of sMCI vs pMCI and 
atrophy is linked to poor memory performance, a score of atrophy that is predictive of ADNI 
Mem should also discriminate sMCI vs pMCI. In taking this approach we no longer require 
longitudinal data to generate our feature, utilising a much larger cross-sectional sample of 
589 people. In using this transfer learning approach, we increased our feature generation 
sample by 352% greatly reducing our chance of overfitting our model development sample. 
A second advantage of our approach is that we obtain greater specificity to clinical sub-
groups than the outcome measure used to generate the feature (i.e. ADNI Mem). Specifically, 
we derive a score of atrophy that is predictive of ADNI Mem and is also sensitive to the 
heterogeneity of MCI pathologies. As we show in our second experimental chapter ADNI 
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Mem is a sensitive measure to discriminate sMCI vs pMCI. However, poor ADNI Mem 
scores are not specific to underlying AD pathology. That is, sMCI (false positives for AD) 
have a lower ADNI Mem score than healthy controls (normal cognition: NC). The 
heterogeneity in the underlying pathology of amnestic MCI and it’s lack of specificity to AD 
was one of the driving motivations of the 2018 research framework transitioning from 
syndromic to a biological definition of AD (Jack, Bennett, et al., 2018). Using our approach, 
we can outperform the predictive value of raw ADNI Mem scores by capturing the variance 
in ADNI Mem that is both sensitive and specific to pMCI (Figure 7.2).  
 
Figure 7.2 Sensitivity and specificity of ADNI Mem and PLS derived grey matter score 
to AD 
 
Figure 7.2 shows that while ADNI Mem is sensitive to pMCI it is not specific (i.e. sMCI is 
lower than NC), however the atrophy biomarker is both sensitive and specific to pMCI. Note: 
Amyloid positive sMCI were removed from sample to account for potential slow converters. 
 
We achieved this by constraining our model to learn the association between two coupled 
process (atrophy and memory dysfunction). Given the sampling criteria of the MCI cohort in 
ADNI (multi-domain amnestic MCI), we reasoned that the most common cause of memory 
deficits in ADNI will likely be due to AD pathology. Thus, our biomarker of medial temporal 
atrophy has high face validity. Here, we leveraged the sample characteristics of ADNI to 
unveil a multivariate score of medial temporal atrophy as a predictor of cognitive 
dysfunction. However, the lack of heterogeneity in ADNI limited our ability to extract 
biomarkers related to atypical AD variants. Future work will apply a similar approach to a 
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more heterogeneous sample looking to uncover atrophic patterns that relate to non-amnestic 
related cognitive decline.  
The outcome of the PLSr-RFE process is an easily deployable grey matter mask that can be 
used for quick and effective appraisal of MRI taken from the clinic. This is evident when we 
use the grey matter mask derived in experimental chapter 1 on a sample of patients scanned 
from the Cambridge Memory Clinic. We show a similar relationship for this sample, with 
lower grey matter atrophy scores related to lower ACEr Memory score R2 = 20% (Figure 
7.3). 
 
Figure 7.3 generalisation performance of PLS derived grey matter score in independent 
sample 
 
Figure 7.3 shows the relationship of pls grey matter score derived on ADNI data in 
experimental chapter 1 and ACEr-Memory score from a sample recruited from the 
Cambridge memory clinic (r(101)=0.45, p<0.0001). Red dots are patients diagnosed as AD, 
blue dots are patients diagnosed as MCI and black dots are diagnosed as non-
neurodegenerative disease. 
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Using our approach, we observe the same relationship between the grey matter score and 
memory dysfunction in a heterogeneous sample taken from routine clinical patients. Further, 
we see that the atrophy biomarker captures memory dysfunction that can be validated to any 
sensitive memory score not just specific to ADNI Mem. Therefore, we have demonstrated 
that our method is both more sensitive and produces outputs that generalise to new patient 
groups. 
We designed the PLSr-RFE model to handle structural MRI, however the approach can easily 
be deployed on other neuroimaging data (i.e. functional MRI, PET, DTI) to combine 
multimodal neuroimaging predictors to make predictions (Karlaftis et al., 2019). Looking 
beyond neuroimaging predictors, an interesting avenue of future research would utilise the 
PLSr-RFE approach to generate polygenic risk scores. There have been several attempts at 
deriving a robust polygenic risk score for late onset AD, however these have had limited 
success (Chasioti, Yan, Nho, & Saykin, 2019). To date the most common approaches to 
combine genetic information from Single Nucleotide Polymorphisms (SNPs) have been 
based on approximations of multivariate relationships. That is, mass univariate tests have 
been used to determine frequent SNPs in a sample and these prevalent SNPs are then 
summed to form a single score. Prior to performing this sum (either linear or weighted) SNPs 
are pre-processed to try and remove linkage disequilibrium (i.e. nearby SNPs have similar 
associations) in an attempt to remove redundancies in SNP information. This is achieved by 
pruning similar SNPs resulting in a set of largely uncorrelated SNPs. Both the summing of 
mass univariate statistics and the exclusion of correlated information are distinct weaknesses 
when trying to derive an AD genetic composite score. The PLSr-RFE is well suited to 
alleviate these issues as the PLSr model is well equipped to handle correlated predictors. 
Further, the PLSr-RFE approach will remove redundant information in a principled way, to 
optimise generalisation performance. Taken together the PLSr-RFE approach has strong 
potential to uncover highly predictive genetic features in AD.   
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Unveiling interactive predictors of AD progression: 
GMLVQ 
Here, we used the GMLVQ classification framework to extract interactive cognitive factors 
that separate stable MCI from progressive MCI. Using this transparent machine learning 
approach, trained on informative and interpretable baseline cognitive data, we can extract key 
insights into cognitive data that is prognostic of cognitive decline. Our model could 
discriminate the two broad classes (sMCI vs pMCI) with accuracy above 80% giving us 
confidence that the univariate and multivariate relationships uncovered by the metric tensor 
are meaningful. We show that baseline composite scores related to memory and executive 
function (ADNI-Mem, ADNI-EF composite score) are highly predictive of disease 
progression. Further, we demonstrate a negative interaction between baseline cognitive 
(memory, executive function) and affective scores that separates individuals into different 
classes. Previous studies have shown that moderate to severe depressive symptoms (i.e. 
GDS> 15) are predictive of MCI conversion to AD (Defrancesco et al., 2017), while mild 
depressive symptoms do not increase conversion risk (Chen et al., 2008; Defrancesco et al., 
2017). Here, similar to previous work  (Chen et al., 2008; Defrancesco et al., 2017) we do not 
show a univariate relationship with mild depressive symptoms on MCI conversion (i.e. 
diagonal term of metric tensor). However, when interrogating the multivariate relationships 
between predictors (i.e. off diagonal term of metric tensor) we discover that the interaction 
between scores that are indicative of mild depression (i.e. GDS<10) and cognitive 
dysfunction is predictive of MCI progression. Thus, our metric learning approach on multi 
domain data (i.e. cognitive and affective measurements) has unveiled subtle interactions 
between baseline cognition and affective disturbance related to AD. Looking beyond the 
work presented here we can investigate this multivariate association further, elucidating 
neural mechanisms that underpin this relationship, potentially reducing MCI patient 
misclassification due to comorbidity (e.g. affective disturbance). 
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Modelling trajectories: GMLVQ-Scalar Projection.  
Our trajectory modelling approach (GMLVQ-Scalar Projection) extends beyond binary 
patient classification frameworks that are poorly constrained. Here, we aimed to make 
meaningful predictions in AD by deriving an approach that captures continuous prognostic 
trajectories. Our machine learning approach is particularly well suited to tasks when training 
labels have a high degree of target uncertainty (e.g. future clinical diagnosis). In particular, 
we derived continuous prognostic scores (i.e. scalar projection) by training the model based 
on ‘noisy’ diagnostic labels. As our metric learning model has limited freedom (linear low-
parameter model), separating continuous target values (i.e. individualised trajectories) into 
two broad classes (stable vs. progress) forces the model to extract key multivariate 
relationships in the data that distinguish between target populations, ignoring subtle 
differences in target values which can lead to overfitting. Using the GMLVQ-scalar 
projection model we learn the multivariate relationship between predictors (metric tensor) 
and the location in multidimensional space that best discriminates between stable and 
progressive individuals (prototype locations). Within this learnt space we then determine the 
distance an individual is from the prototypical position of stable individuals along the learned 
axis that is predictive of future diagnosis (i.e. stable towards progressive). That is, we derive 
a scalar value from the projection of any sample point along the prognostic axis.  
Modelling trajectories of Cognitive Decline  
Despite the importance of early diagnosis of Alzheimer’s disease for clinical practice and 
treatment, we still lack robust tools for predicting individual progression to dementia. The 
multimodal longitudinal measurements across large-scale samples available in ADNI provide 
a testbed for machine learning approaches that generate predictive features and discriminate 
between patient groups (Weiner et al., 2015, 2017). Here, we tested whether prognostic 
trajectories generated from baseline cognitive data are predictive of future memory decline 
for MCI patients. We found that a prognostic measure derived from cognitive data is 
reasonably predictive of future decline (R2 =16%), and with the inclusion of non-invasive 
biological predictors predictive performance improves (R2 =23%). However, when deriving 
trajectories to predict cognitive decline the best performing model is built from well validated 
AD biomarkers (R2 =46%).   
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Modelling trajectories from validated biomarkers 
Numerous studies throughout the last decade have provided evidence for the hypothetical 
model of the AD pathological cascade (Jack et al., 2013; Jack, Knopman, et al., 2010). This 
widely accepted model has shifted the staging of AD from a clinical syndromic diagnosis 
(Albert et al., 2011; McKhann et al., 2011) to a continuum of biomarker characteristics (Jack, 
Bennett, et al., 2018). We show that our multimodal prognostic index (scalar projection) is 
successful at predicting cognitive decline in MCI individuals. Our approach has strong 
potential to deliver fine stratification of patients for personalised treatment plans and enrolment 
into clinical trials. We decided to train on available biomarkers from ADNI 2/GO cohort (i.e. 
structural MRI, amyloid PET, APOE 4). However, our machine learning approach can be 
deployed readily if different biological data is available. For example, if in a different cohort a 
predictor is not available (i.e. genetic markers) we can readily retrain the model on ADNI data 
omitting the missing feature. This lends a robustness to our models that is critical in dealing 
with the variability in clinical approach or available diagnostic tests between individuals. 
Further, as the relationship between the scalar projection and cognitive decline is implicitly 
learnt (i.e. change in ADNI Mem is not used in model formulation) we can validate our model 
using different cognitive measures (i.e. change in ACEr). 
Using grey matter atrophy and β-amyloid as predictors we retrained the GMLVQ-scalar 
projection model to differentiate sMCI vs pMCI patients in ADNI. Below we show that we can 
use this model to predict cognitive decline in an independent sample of MCI patients recruited 
from the Cambridge Memory Clinic (Figure 7.4) (R2(16)=28.1%, p=0.02).  
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Figure 7.4 generalisation performance of GMLVQ-scalar projection in an independent 
cohort 
 
Figure 7.4 shows the generalisation of the model trained on ADNI data to predict in an 
independent UK sample. 
 
This good generalisation performance highlights that our approach is robust and malleable to 
use different predictors to generate prognostic trajectories for MCI patients. However, β-
amyloid PET is not routinely collected in the clinical setting. Looking forward we aim to use 
this approach to generate predictions on more readily available neuroimaging and cognitive 
data. 
Modelling trajectories of biomarker change  
Given the transition to defining AD in terms of biomarkers (i.e. ATN framework), machine 
learning models must now be designed to predict pathological biomarker changes or face 
becoming clinically irrelevant. Here, we use machine learning to combine continuous 
information from AD biomarkers to predict pathological changes in tau accumulation in the 
preclinical stages of AD. Our approach directly addresses the 2018 FDA framework for 
designing clinical trials in the stage 1 (preclinical) phase of AD (Rafii & Aisen, 2019). We use 
well characterised AD biomarkers (β-amyloid, medial temporal atrophy, APOE 4) to generate 
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a prognostic index for stratification. Using this multimodal index derived from baseline data, 
we predict future tau accumulation, a known pathological driver of AD progression.  
Deploying our machine learning approach, we were able to accurately predict which 
individuals will accumulate pathological tau. In both the ADNI and BACS samples we 
uncovered regions that largely replicates findings from several other studies. Using baseline 
FTP as a proxy for disease severity, Pontecorvo et al.  show that in earlier stages of AD 
increases in FTP were seen predominantly in the inferior lateral temporal cortex and in the 
posterior cingulate (Pontecorvo et al., 2019). In addition, Schultz et al. show that preclinical 
AD individuals (b-amyloid positive cognitively unimpaired) accumulate tau in regions 
extending from the amygdala, banks of the superior temporal sulcus, entorhinal, fusiform, 
inferior parietal, inferior temporal cortex parahippocampal gyrus and precuneus (Schultz et al., 
2018). This largely supports the definition comprising the ‘meta regions’ of tau accumulation 
described in Jack et al (Jack, Wiste, et al., 2018) (Figure 7.5). 
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Figure 7.5 correspondence of predication accuracy within tau susceptible regions 
reported in independent cohorts 
 
 
Figure 7.5 shows the regions that are significantly accumulating tau in early AD across 
different cohorts. Figure 7.5a. shows the accuracy of predictions from the work presented in 
experimental chapter 3. Figure 7.5b shows the meta regions defined by Jack et al 2018, The 
regions comprising the early Alzheimer’s disease change and temporal meta-region of 
interest are indicated in red, blue, aqua, magenta; regions in green are the late AD change 
meta regions. Figure 7.5c. shows longitudinal tau accumulation patterns from Pontecorvo et 
al. 2019, the heat map is the mean voxel-wise change from baseline to 18 months for β-
amyloid+ subjects with intermediate tau deposition at baseline. Figure 7.5d taken from 
Schultz et al. 2018, shows the difference in tauopathy in cognitively unimpaired β-amyloid+ 
cohort compared to β-amyloid-. 
 
Extending previous work, we show that a multimodal measure is superior to a unimodal (i.e. 
b-amyloid positive only) classification for determining if an individual will accumulate 
pathological tau. We show that using multimodal data vs. b-amyloid status only to stratify 
populations results in a 46% reduction in the sample size required to observe a clinically 
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meaningful change in pathological tau accumulation. Here, we have shown that we can 
robustly predict the pathological spreading pattern of tau in the earliest stages of AD. Further, 
we have been able to empirically assess the predictive quality of different data types; a key 
finding being that a stratification based on multimodal data is more sensitive than amyloid 
status alone. Using our approach, we successfully translated rich AD information from the 
ADNI research cohort to make individualised predictions of pathophysiological change in an 
independent community-based population.  
In sum, our GMLVQ-scalar projection methodology is a robust approach to combine baseline 
multimodal biomarkers into a prognostic metric across the AD continuum. Looking beyond 
the work presented in this thesis we aim to incorporate newly derived biomarkers from 
neuroimaging, genetic and cognitive composite scores to refine predictions of pathological 
change in AD.  
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Final Remarks 
This thesis describes several key developments in the application of machine learning 
algorithms to clinically relevant questions of diagnosis, prognosis and disease mechanisms.  
Our key insight is that algorithms should not be optimised for highly specific prediction 
tasks, but rather attempt to make predictions that capture a disease state. That is, predictions 
should capture dynamic changes in multiple associated pathological processes of the same 
disease and not be too heavily constrained to any given task. In achieving this goal, we can 
capitalise on readily available data to 1) predict disease state 2) identify meaningful sub-
groups 3) generate individualised predictions of disease trajectory. The developed 
methodology has potential to be deployed in a wide range of clinical domains. To date the 
success of machine learning in this field has been limited by its reliance on often hard to 
acquire predictors and a view of between-group discriminability as the measure to be 
optimised. Here, we present an alternative view and highlight a multitude of potential new 
research avenues with direct clinical applications. 
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8. Conclusions and Future Directions: 
 
Benchmarks of Machine learning in AD research  
Throughout the last decade machine learning has become a favoured approach to model 
multivariate interactions to diagnose and prognosticate in AD. Machine learning has been 
applied using a wide range of data from neuroimaging and cognitive scores, to biosensors and 
blood markers. To derive a benchmark of model performance in AD prediction we summarised 
accuracies of published papers diagnosing AD from cognitively normal and prognosticating at 
the MCI stage (i.e. sMCI vs pMCI) (Figure 8.1). These accuracies are derived from papers 
listed in three separate reviews (Ebrahimighahnavieh et al., 2020; Rathore et al., 2017; Tanveer 
et al., 2020). From the papers presented within these reviews we have separated the machine 
learning accuracies into either basic machine learning or deep and ensemble prediction 
methods.  
In Figure 8.1a we show the averages of published accuracies in separating cognitively normal 
vs AD. We present an on average view of benchmark classification performances using a range 
of data modalities and how these accuracies have evolved over time. We see using this meta-
analysis approach that classification performance of cognitively normal vs AD has remained 
fairly consistent over the last decade on average exceeding 90% accuracy. Further, when we 
separate published results into basic machine learning approaches (i.e. support vector 
machines, linear discriminate analysis or logistic regression) and more complex deep and 
ensemble approaches there doesn’t appear to be any systematic benefit of one approach over 
the other. Taken together this shows that a classification accuracy of over 90% is required to 
be at benchmarked performance when classifying cognitively normal vs AD. Further, we see 
that although there has been methodological innovation over the past decade this benchmark 
accuracy has remained fairly constant. 
Figure 8.1b shows the accuracies of classifiers separating sMCI from pMCI over the last 6 
years. Similar to the classification of cognitively normal vs AD Figure 8.1b gives an average 
view of classification performance and encompasses predictors from different data modalities. 
Here, we see over the last 6 years that benchmark performances are between 70 and 80% 
accuracy. Unlike the classifiers built to discriminate between cognitively normal and AD there 
does appear to be a gradual increase in classification performance over the last 6 years. 
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However, as with the CN and AD classification there does not appear to be a systematic benefit 
of one learning approach over another.  
 
Figure 8.1 Machine learning benchmark accuracies 
 
 
Figure 8.1a shows the average classification accuracy in diagnosing cognitive normal (CN) 
vs AD each year from 2008 to 2019. Figure 8.1b shows the average classification accuracies 
in classifying individuals who are stable MCI (sMCI) vs individuals who are progressive MCI 
(pMCI) for each year from 2011 to 2019. Blue dots are the average classification accuracy per 
year for papers using basic machine learning approaches presented in [1] (Tanveer et al., 
2020) (CN vs AD no. publications=47 2008:2019; sMCI vs pMCI no. publications =8 
2015:2018). Blue squares are the average classification accuracies each year for papers using 
basic machine learning approaches presented in [2] (Rathore et al., 2017) (CN vs AD no. 
publications =43 2008:2016; sMCI vs pMCI no. publications =25 2011:2016 ). Red circles 
are the average classification accuracy per year for papers using deep or ensemble machine 
learning approaches presented in [1] (Tanveer et al., 2020) (CN vs AD no. publications =42 
2008:2019; sMCI vs pMCI no. publications =21 2011:2019). Red squares are the average 
classification accuracy per year for papers using deep or ensemble machine learning 
approaches presented in [3] (Ebrahimighahnavieh et al., 2020) (CN vs AD no. publications 
=83 2012:2019; sMCI vs pMCI no. publications =27 2013:2019). Black diamonds are the 
meta averages across all machine learning approaches presented in the three reviews. 
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Comparison of current results with benchmarks  
Based on the meta-analysis shown on figure 8.1b the most recent benchmark performance in 
the sMCI vs pMCI classification is an accuracy of 78.4%. This meta average is derived from 
only deep learning and ensemble approaches and therefore may not represent the current 
benchmark accuracies across all classifier types (i.e. basic machine learning and more 
computationally complex approaches). In the work presented in this thesis using the GMLVQ 
machine learning approach we achieved a classification accuracy of 81.5% for the model built 
using cognitive data only and an accuracy of 81.9% for the model built using biological data. 
Therefore, our interpretable linear approach performs better than the average deep learning 
application to this problem. We are currently unable to compare the performance of the scalar 
projection machine learning approach to other models to predict individualised trajectories as 
consistent outcome measures are not as common (i.e. variability in cognitive outcome 
measures). However, in the future data prediction challenges offer an objective way to compare 
machine learning approaches that aim to capture individualised trajectories. For example, the 
TADPOLE challenge is designed to use standardised ADNI data sets to test predictions across 
three different tasks. 1.) prediction of diagnosis, 2.) change in ventricle volume and 3.) change 
in ADAS-cog scores (Marinescu et al., 2018). In the future we will apply our machine learning 
approach to make predictions in this data and compare the prediction performance of the scalar 
projection in modelling individualised trajectories from other methodologies submitted to the 
challenge.  
 
Limitations to current benchmarks 
Figure 8.1 gives an overview of how well machine learning has performed over the last decade, 
however this does not represent a systematic review of the literature. Rather, we provide an 
overall picture of how the field is evolving and whether there appears to be any perceived 
benefit in using more complex deep methods over basic machine learning approaches. The 
combined accuracies cover a wide range of data modalities, feature extraction and cross 
validation approaches and these are discussed in more detail in the original review articles. 
However, across each of these reviews it is apparent that a lack of sample heterogeneity is a 
major limitation of these modelling papers. For example, 90% of the papers reviewed 
by Ebrahimighahnavieh et.al use ADNI data to build their models (Ebrahimighahnavieh et al., 
 148 
2020). The use of ADNI in most machine learning papers poses a major concern for future 
developments and clinical utility. Given the exclusion criterion and sampling characteristics of 
ADNI, models are built on highly homogeneous and likely non representative samples. That 
is, the exclusion criterions of ADNI remove individuals with co-morbid conditions, including 
those with existing vascular conditions. Given that mixed dementia phenotypes of vascular 
dementia and AD are common, this limits the generalisability of models built in ADNI to a 
clinical setting. Further, the samples within ADNI are generally highly educated and Caucasian 
dominant. These two factors therefore skew samples to higher socioeconomic brackets. Given 
that socioeconomic factors have a considerable effect on general health (Adler & Ostrove, 
1999) as well as cognitive health (Greenfield & Moorman, 2019) this greatly limits any models 
ability to be deployable in a real world setting.  
Looking into the future, considerable work needs to be done to a.) combine data from many 
different cohorts to generate a more heterogeneous sample and to b.) harmonise these data so 
that predictions are not limited by nuances in the data (i.e. scanner differences or cognitive 
outcome measures). Given the diverse disease aetiologies of patients who present to a memory 
clinic this harmonisation is a critical interstitial step for developing machine learning tools with 
real world impact.  
 
 
Future directions  
Title of Project and Brief Description  
Title: Predicting cognitive trajectories in a harmonised global cohort. 
 
Harmonising cognitive data to generate robust trajectories: The primary goal of large global 
studies investigating Alzheimer’s Disease (AD) is to make meaningful and robust conclusions 
on cognitive outcomes. However, this is challenging due to heterogeneous cognitive test 
batteries used across studies and non-representative sampling characteristics. Despite these 
limitations cognitive composites have become the favoured method for tracking and predicting 
cognitive trajectories. Given the variability in cognitive test batteries and sampling 
characteristics between studies these cognitive composites suffer from poor interoperability, 
that is they are study specific and cannot be generalised to the wider population or be built 
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leveraging multiple large data sets. The proposed project will address this issue by aggregating 
cognitive data across a wide range of studies and generating a cross study cognitive composite. 
 
Mathematical Approaches to harmonise data: There is significant variability across tests used 
in cognitive test batteries in large longitudinal data sets. However, between these studies there 
are many overlapping cognitive tests (i.e. shared tests across cognitive batteries). Specifically, 
this project will involve the aggregation of these data into an incomplete matrix and utilise data 
imputation to solve for missing values (i.e. the predicted score on a test that was not 
administered within a study). Using the imputed matrix, we will then generate a set of cross 
study cognitive composites leveraging modern psychometric modelling techniques. We will 
then test to see if the resultant cognitive composite is both sensitive to AD pathology (i.e. 
amyloid positivity) and robust across cohorts.  
 
Neuroimaging biomarkers: Using ADNI we have developed and validated the PLSr-RFE 
biomarker generation methodology. Previously we used this methodology to capture latent 
structures in T1 structural MRI that relate to AD symptomology from the ADNI data base, 
which is a typical amnestic AD research sample. This method has generated robust, reliable 
and interpretable biomarkers in structural MRI. However, due to the sampling characteristics 
of ADNI we were able to extract only the typical medial temporal atrophy phenotype. Using 
the harmonised heterogeneous sample from several global cohorts we hope to uncover different 
neuroimaging phenotypes related to cognitive dysfunction. Specifically, by combining ADNI 
with samples that have different inclusion criteria (i.e. including co-morbid vascular 
conditions) we hope to find neuroimaging markers related to cognitive dysfunction in AD, 
vascular dementia and mixed AD and vascular dementia. Further, we will use the PLSr-RFE 
procedure to derive predictive features in different neuroimaging modalities (e.g. DTI, fMRI). 
Given that we will be using several imaging modalities taken from many different sites data 
reliability will be investigated thoroughly. To achieve this, we will generate a series of artificial 
neuroimaging markers (e.g. cortical thinning and white matter legions) prior to pre-processing 
and compare the ability to detect these artificial markers across the different scanner sites.  
 
Prognostic modelling validation: Using the derived neuroimaging markers we will then use 
the GMLVQ-scalar projection approach to generate predictions of cognitive trajectories. Using 
the harmonised cross cohort composite we will look to determine how sensitive this measure 
is to AD related change (i.e. amyloid positivity) and how robust predictions of cognitive 
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trajectories are using the scalar projection approach. Using samples that are recruited in a 
memory clinic setting we will then test our predictions out of sample. Finally, we will run a 
cost benefit analysis of using different neuroimaging markers so we can determine the most 
effective and least expensive measures to accurately model individual disease trajectories.  
 
 
 
Machine learning in clinical practice 
Within the field of clinical medicine there has been a rapid expansion of data generation, 
curation and storage. Not only have the total numbers of data available increased but also the 
digitisation of large data, such as; medical imaging, genome sequencing, real time biosensors 
and health records. Naturally with such large quantities of data becoming available; high 
throughput, rapid, and autonomous analysis is an exciting prospect. This desire for an all in 
one kind of approach lends itself to deep learning. Accordingly, deep learning is one of the 
most heavily publicised routes to achieving rapid and precise diagnosis in clinical medicine.  
Deep learning vs. traditional machine learning 
Traditional machine learning is a two-stage process that relies on machine intelligence as well 
as specific expertise from a human operator to select or construct informative representations 
(i.e. features) of raw data. In contrast, deep learning is the desired all in one package as the 
learning algorithm is fed raw or minimally pre-processed data and autonomously learns a set 
of lower dimensional representations allowing samples to be distinguishable from one another 
(i.e. cognitively normal or AD). The deep learning architecture is a series of layers of basic 
non-linear functions, as the raw data is passed from layer to layer the input space becomes 
iteratively transformed so that in the final layers of the model a judgement can be made. Deep 
learning is not a recent concept but until recently neither the digitised data nor computational 
resources were available for deep learning to truly be effective. Recently, however, thanks to 
Moore’s law and the internet, deep learning is now one of the most favoured types of learning 
algorithm in big data. The field in which deep learning has come into its own is computer 
vision, where it has excelled at image recognition (Krizhevsky et al., 2012).  Given the success 
in computer vision deep learning is well suited to analysis of medical imaging. Accordingly, 
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deep learning has shown encouraging results when applied to detect abnormalities across 
several medical disciplines such as dermatology, radiology, ophthalmology, and pathology (for 
reviews (Esteva et al., 2019; Topol, 2019) . Within the field of clinical medicine deep learning 
models are now approaching clinician level accuracy in a variety of diagnostic tasks that use 
medical imaging (for review (X. Liu et al., 2019)). 
Specifically, within the field of radiology deep learning is now entering the clinical pathway, 
with a deep learning model deployed in Indian hospitals producing interpretations of chest X-
rays with accuracies that that are of equal or better than radiologists (R. Singh et al., 2018). 
This applied appraisal of radiography by deep learning is also helping with rapid diagnosis of 
fractures in difficult regions and can improve sensitivity to small fractures over trained ER 
clinicians while drastically reducing to make an accurate diagnosis (Lindsey et al., 2018). 
Clearly deep learning is capable of performing the high throughput, rapid and precise appraisal 
of imaging data particularly in tasks that are time sensitive. However, although there is 
substantial research in deep learning for AD prediction (Ebrahimighahnavieh et al., 2020) there 
are no currently available clinical AD deep learning tools.   
Why deep learning is not found in clinical practice in AD? 
The most common applications of deep learning in AD research are for a.) Diagnosis of 
cognitively normal vs AD and b.) prognostication of sMCI vs pMCI. There are two 
fundamental barriers to these types of predictive algorithms ever becoming clinically 
deployable. The first regards the utility -or lack thereof- of an algorithm that separates 
cognitively individuals from individuals with dementia. Given that there are clearly observable 
cognitive differences between a cognitively normal and demented individual and that generally 
clear and distinctive markers can be seen on neuroimaging (i.e. large ventricles, medial 
temporal and global atrophy), rapid inspection by a radiographer and clinician is already 
feasible. With this in mind a more useful deployment in clinic is the use of deep learning to 
separate individuals with dementia but different disease aetiologies (i.e. AD vs PD). These 
types of deep learning algorithms have been developed and are successful at discerning 
underlying disease (Joshi et al., 2010).  
In the case of deep learning approaches that have been developed for prognostication (i.e. sMCI 
vs pMCI) the issue is less of practicality but more of fundamental design. As discussed at 
multiple points in this thesis there are several inherent issues with designing an algorithm to 
separate sMCI vs pMCI. For example, these models define class labels based on arbitrary 
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follow up duration (i.e. stable MCI for how long? Progress within what time frame?) and 
heavily biased clinical diagnosis. Previous work interrogating the sensitivity and specificity of 
a diagnosis of probable AD ante mortem, and, the presence of pathological biomarkers post 
mortem shows that diagnoses of probable AD have a sensitivity to pathology between 70.9% 
and 87.3% and a specificity between 44.3% and 70.8% (Beach, Monsell, Phillips, & Kukull, 
2012). 
When defining the ground truth (i.e. the clinician’s diagnosis) for model formulation on a 
diagnosis that in its own right has poor sensitivity and specificity to AD the model will always 
be limited by the reliability of the clinical diagnosis. Given that a deep learning algorithm is 
heavily parameterised to minimise error in training, the model will use variability in the 
neuroimaging in an attempt to describe the variance within the clinician’s appraisal. Thus, the 
model will overfit the data to replicate a clinician and not diagnose a disease. In doing so there 
is a lower chance of this model generalising to a new sample, because although the variance of 
the clinical diagnosis is not random (i.e. patient independence and carer appraisal) it is unlikely 
that there will be markers within the neuroimaging that can explain this variation.  
With this in mind, any deep learning that is built with the sole purpose of prognostication of 
sMCI vs pMCI seems invalid. Therefore, future mathematical development of deep learning 
models to increase performance on the heavily researched classification of sMCI vs pMCI has 
almost no clinical utility. However, that is not to say that all deep learning does not serve a 
purpose in AD prediction.  
Taking Deep learning into the clinic 
Previous successes of applied deep learning within a clinical setting centre around the rapid 
and sensitive appraisal of diagnostic imaging. Within AD research a potential application could 
be the rapid count and grading of cerebral micro bleeds. For example, using deep learning to 
combine information from a set of MRI sequences (e.g. multiparametric mapping) a rapid 
account of the underlying vasculature for a given subject could be made available to the 
clinician. Armed with this snapshot of the cerebral vascular health the unique or additive effect 
of vascular dementia on AD could be elucidated in a clinical setting, resulting in more targeted 
treatment and care plans.  
Given the success of deep learning in segmentation, another potential application in AD 
research is the rapid and accurate segmentation of fine anatomical structures. This would allow 
several different contrasts (i.e. T1 T2*) to be applied simultaneously for a given subject and 
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fine scale volumetrics of medial temporal structures be performed. Performed longitudinally, 
these assessments not only give the clinician a fine scale physiological assessment of the 
neurodegeneration process in AD but could also provide a sensitive diagnostic tool to isolate 
non typical (i.e. non amnestic dominant) AD variants.  
Looking into the future, deep learning offers an interesting and clinically relevant route of 
innovation by generating synthetic data. As the current diagnostic framework of AD can 
require up to three separate imaging modalities, the ability to synthesise some imaging markers 
(i.e. generate PET from MRI) is of critical significance both from a safety and economic 
perspective. A subtype of deep learning Generative Adversarial Networks (GANs) provides 
the perfect framework for synthesising these data. GANs are two neural networks that aim to 
fool each other, where the generator network aims to build a representation of the data (i.e. 
neuroimaging scan) that confuses the discriminator as to the real of synthetic data. This type 
of modelling approach has already seen success in synthesising PiB PET data to determine 
demyelination in multiple sclerosis, where a GAN was successfully able to combine imaging 
data from MRI (structural and DTI) to generate synthetic PiB PET data (Wei et al., 2020). 
Bridging the gap to clinic with traditional machine 
learning 
As discussed previously the most common classification tasks in AD research have either 
limited clinical utility (i.e. cognitively normal vs AD) or have questionable validity (i.e. sMCI 
vs pMCI), therefore the use of poorly interpretable and heavily constrained models (i.e. deep 
learning) may not bridge the gap from research to the clinic. Machine learning however offers 
a different route. As features need to be carefully constructed with expertise knowledge, a 
predictive tool may have more clinical utility to operate a two-stage process. First, following 
expert research, highly predictive features are extracted from the raw patient data. Following 
this these features should then be conferred to the clinician along with relevant parametric 
statistics (e.g. 80% of amyloid positive individuals have a value of X or greater). Following 
this, a multivariate prediction using the presented features is made (i.e. machine learning) and 
similarly this multivariate prediction is conferred to the clinician using a meaningful metric. 
For example, survival statistics are commonplace in clinical medicine and therefore may 
provide a smoother adoption into clinic.  
There are several motivations behind this type of entry to the clinic. First, by presenting the 
clinician with the features used to make the prediction the initial stage of the model operates 
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as a rapid data aggregator and consolidator, allowing for near immediate interpretation of high 
dimensional data (i.e. neuroimaging). Second, by displaying how the algorithm makes 
predictions including the physiological origin of the predictors a greater transparency is 
achieved and will likely confer greater trust in the resultant prediction. Finally, by having an 
open and transparent system the machine learning researcher and the clinician can work 
synergistically to determine the most effective and meaningful predictions to make.  
 
Going forward, machine learning approaches need to be looked at with healthy scepticism as 
models will always be limited by a.) the test-retest reliability of the outcome measure and b.) 
the resolution of the outcome measure. In light of this, it may be of more use to try and predict 
real world outcomes rather than changes in proprietary lab administered tests. For example, it 
is likely more useful for clinician and patient alike to accurately predict a time when the patient 
is no longer able to remain independent, rather than a decrease in the MMSE. This disconnect 
between predicted outcomes and clinically useful prognosis represents a significant barrier to 
machine learning entering the clinical treatment pathway for AD. Therefore, the road to 
implementing these highly useful and powerful tools into clinic requires a constant interaction 
between clinicians, patients and researchers into what is a meaningful prediction.  
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9. Summary 
 
Since the first presentation on Auguste D in 1906 the scientific inquiry regarding the driving 
forces in AD have been well documented. Diligent work across the biological and clinical 
sciences has elucidated genetic, cellular and system level interactions that lead to AD. 
However, a treatment, and reliable prognosis of AD still eludes clinical neuroscience. 
Recently, the global AD research community has united to coordinate the collection, curation 
and sharing of expanses of predictive data. In doing so they have encouraged researchers to 
use data intensive computational approaches to try and integrate multi domain data into a 
holistic picture of AD. However, the computationally minded researcher must carefully 
approach this task, ensuring that due diligence is taken to respect the years of fastidious 
collection and collation of data by biologists. Therefore, it is imperative that computational 
approaches be readily distilled to biologists. Further, it is clear, for a computational approach 
to truly impact clinical practice the underlying decision made by the machine must be 
interpretable and tractable by the clinical practitioner.  
Here we have endeavoured to achieve these goals. We have introduced a series of 
computational approaches that derive and utilise interpretable predictors to model prognostic 
trajectories in AD. In keeping with the state-of-the-art biological definitions of AD we have 
also made our models approachable to biologists; incorporating interpretable, reliable and 
well-defined measures of the biomarkers that define AD. In doing so we have introduced a 
computational approach that makes accessible but clinically meaningful predictions.  
  
 156 
References 
 
Adler, N., & Ostrove, J. (1999). Socioeconomic Status and Health: What We Know and 
What We Don’t. https://doi.org/10.1111/j.1749-6632.1999.tb08101.x 
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., … 
Phelps, C. H. (2011). The diagnosis of mild cognitive impairment due to Alzheimer’s 
disease: Recommendations from the National Institute on Aging-Alzheimer’s 
Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s 
& Dementia, 7(3), 270–279. https://doi.org/10.1016/J.JALZ.2011.03.008 
Allison, S. L., Koscik, R. L., Cary, R. P., Jonaitis, E. M., Rowley, H. A., Chin, N. A., … 
Johnson, S. C. (2019). Comparison of different MRI-based morphometric estimates for 
defining neurodegeneration across the Alzheimer’s disease continuum. NeuroImage: 
Clinical, 23, 101895. https://doi.org/10.1016/j.nicl.2019.101895 
Alsaedi, A., Abdel-Qader, I., Mohammad, N., & Fong, A. C. (2018). Extended cox 
proportional hazard model to analyze and predict conversion from mild cognitive 
impairment to alzheimer’s disease. In 2018 IEEE 8th Annual Computing and 
Communication Workshop and Conference (CCWC) (pp. 131–136). IEEE. 
https://doi.org/10.1109/CCWC.2018.8301669 
Alzheimer’s Association. (2018). 2018 Alzheimer’s disease facts and figures. Alzheimer’s 
and Dementia, 14(3), 367–429. https://doi.org/10.1016/j.jalz.2018.02.001 
Alzheimer, A. (1907). Uber eine eigenartige Erkrankung der Hirnrinde. Zentralbl. Nervenh. 
Psych., 18, 177–179. 
Arbabshirani, M. R., Plis, S., Sui, J., & Calhoun, V. D. (2017). Single subject prediction of 
brain disorders in neuroimaging: Promises and pitfalls. NeuroImage, 145, 137–165. 
https://doi.org/10.1016/j.neuroimage.2016.02.079 
Ashburner, J. (2007). A fast diffeomorphic image registration algorithm. NeuroImage, 38(1), 
95–113. https://doi.org/10.1016/j.neuroimage.2007.07.007 
Ayutyanont, N., Langbaum, J. B. S., Hendrix, S. B., Chen, K., Fleisher, A. S., Friesenhahn, 
M., … Reiman, E. M. (2014). The Alzheimer’s prevention initiative composite cognitive 
test score: sample size estimates for the evaluation of preclinical Alzheimer’s disease 
treatments in presenilin 1 E280A mutation carriers. The Journal of Clinical Psychiatry, 
75(6), 652–660. https://doi.org/10.4088/JCP.13m08927 
Baker, S. L., Maass, A., & Jagust, W. J. (2017). Considerations and code for partial volume 
 157 
correcting [18F]-AV-1451 tau PET data. Data in Brief, 15, 648–657. 
https://doi.org/10.1016/J.DIB.2017.10.024 
Bakkour, A., Morris, J. C., Wolk, D. A., & Dickerson, B. C. (2013). The effects of aging and 
Alzheimer’s disease on cerebral cortical anatomy: Specificity and differential 
relationships with cognition. NeuroImage, 76, 332–344. 
https://doi.org/10.1016/j.neuroimage.2013.02.059 
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., … 
Morris, J. C. (2012). Clinical and biomarker changes in dominantly inherited 
Alzheimer’s disease. New England Journal of Medicine, 367(9), 795–804. 
https://doi.org/10.1056/NEJMoa1202753 
Beach, T. G., Monsell, S. E., Phillips, L. E., & Kukull, W. (2012). Accuracy of the clinical 
diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease 
Centers, 2005-2010. Journal of Neuropathology and Experimental Neurology, 71(4), 
266–273. https://doi.org/10.1097/NEN.0b013e31824b211b 
Belleville, S., Fouquet, C., Hudon, C., Zomahoun, H. T. V., & Croteau, J. (2017). 
Neuropsychological Measures that Predict Progression from Mild Cognitive Impairment 
to Alzheimer’s type dementia in Older Adults: a Systematic Review and Meta-Analysis. 
Neuropsychology Review, 27(4), 328–353. https://doi.org/10.1007/s11065-017-9361-5 
Bhagwat, N., Viviano, J. D., Voineskos, A. N., Chakravarty, M. M., & Initiative, A. D. N. 
(2018). Modeling and prediction of clinical symptom trajectories in Alzheimer’s disease 
using longitudinal data. PLOS Computational Biology, 14(9), e1006376. 
https://doi.org/10.1371/journal.pcbi.1006376 
Bilgel, M., An, Y., Helphrey, J., Elkins, W., Gomez, G., Wong, D. F., … Resnick, S. M. 
(2018). Effects of amyloid pathology and neurodegeneration on cognitive change in 
cognitively normal adults. Brain, 141(8), 2475–2485. 
https://doi.org/10.1093/brain/awy150 
Bilgel, M., An, Y., Lang, A., Prince, J., Ferrucci, L., Jedynak, B., & Resnick, S. M. (2014). 
Trajectories of Alzheimer disease-related cognitive measures in a longitudinal sample. 
Alzheimer’s & Dementia, 10(6), 735-742.e4. 
https://doi.org/10.1016/J.JALZ.2014.04.520 
Bilgel, M., Koscik, R. L., An, Y., Prince, J. L., Resnick, S. M., Johnson, S. C., & Jedynak, B. 
M. (2017). Temporal order of Alzheimer’s disease-related cognitive marker changes in 
BLSA and WRAP longitudinal studies. Journal of Alzheimer’s Disease, 59(4), 1335–
1347. https://doi.org/10.3233/JAD-170448 
 158 
Bischof, G. N., Jessen, F., Fliessbach, K., Dronse, J., Hammes, J., Neumaier, B., … van 
Eimeren, T. (2016). Impact of tau and amyloid burden on glucose metabolism in 
Alzheimer’s disease. Annals of Clinical and Translational Neurology, 3(12), 934–939. 
https://doi.org/10.1002/acn3.339 
Blennow, K., Wallin, A., Ågren, H., Spenger, C., Siegfried, J., & Vanmechelen, E. (1995). 
tau protein in cerebrospinal fluid - A biochemical marker for axonal degeneration in 
Alzheimer disease? Molecular and Chemical Neuropathology, 26(3), 231–245. 
https://doi.org/10.1007/BF02815140 
Blennow, Kaj, & Hampel, H. (2003, October 1). CSF markers for incipient Alzheimer’s 
disease. Lancet Neurology. Lancet Publishing Group. https://doi.org/10.1016/S1474-
4422(03)00530-1 
Blumer, A., Ehrenfeucht, A., Haussler, D., & Warmuth, M. K. (1987). Occam’s Razor. 
Information Processing Letters, 24(6), 377–380. https://doi.org/10.1016/0020-
0190(87)90114-1 
Braak, H., & Braak, E. (1991, September). Neuropathological stageing of Alzheimer-related 
changes. Acta Neuropathologica. Springer-Verlag. https://doi.org/10.1007/BF00308809 
Braak, Heiko, & Del Tredici, K. (2011). The pathological process underlying Alzheimer’s 
disease in individuals under thirty. Acta Neuropathologica, 121(2), 171–181. 
https://doi.org/10.1007/s00401-010-0789-4 
Braak, Heiko, & Del Tredici, K. (2012, December). Where, when, and in what form does 
sporadic Alzheimer’s disease begin? Current Opinion in Neurology. 
https://doi.org/10.1097/WCO.0b013e32835a3432 
Brier, M. R., Gordon, B., Friedrichsen, K., McCarthy, J., Stern, A., Christensen, J., … Ances, 
B. M. (2016). Tau and Ab imaging, CSF measures, and cognition in Alzheimer’s 
disease. Science Translational Medicine, 8(338), 338ra66. 
https://doi.org/10.1126/scitranslmed.aaf2362 
Brion, J.-P. (1998). Neurofibrillary Tangles and Alzheimer’s Disease. European Neurology, 
40(3), 130–140. https://doi.org/10.1159/000007969 
Burnham, S. C., Bourgeat, P., Doré, V., Savage, G., Brown, B., Laws, S., … AIBL Research 
Group. (2016). Clinical and cognitive trajectories in cognitively healthy elderly 
individuals with suspected non-Alzheimer’s disease pathophysiology (SNAP) or 
Alzheimer’s disease pathology: a longitudinal study. The Lancet Neurology, 15(10), 
1044–1053. https://doi.org/10.1016/S1474-4422(16)30125-9 
Burnham, S. C., Bourgeat, P., Doré, V., Savage, G., Brown, B., Laws, S., … Villemagne, V. 
 159 
L. (2016). Clinical and cognitive trajectories in cognitively healthy elderly individuals 
with suspected non-Alzheimer’s disease pathophysiology (SNAP) or Alzheimer’s 
disease pathology: a longitudinal study. The Lancet Neurology, 15(10), 1044–1053. 
https://doi.org/10.1016/S1474-4422(16)30125-9 
Casanova, R., Hsu, F.-C., Sink, K. M., Rapp, S. R., Williamson, J. D., Resnick, S. M., … 
Initiative,  for the A. D. N. (2013). Alzheimer’s Disease Risk Assessment Using Large-
Scale Machine Learning Methods. PLoS ONE, 8(11), e77949. 
https://doi.org/10.1371/journal.pone.0077949 
Castellani, R. J., Plascencia-Villa, G., & Perry, G. (2019, July 1). The amyloid cascade and 
Alzheimer’s disease therapeutics: theory versus observation. Laboratory Investigation. 
Nature Publishing Group. https://doi.org/10.1038/s41374-019-0231-z 
Castellano, J. M., Kim, J., Stewart, F. R., Jiang, H., DeMattos, R. B., Patterson, B. W., … 
Holtzman, D. M. (2011). Human apoE isoforms differentially regulate brain amyloid-β 
peptide clearance. Science Translational Medicine, 3(89). 
https://doi.org/10.1126/scitranslmed.3002156 
Chapman, R. M., Mapstone, M., McCrary, J. W., Gardner, M. N., Porsteinsson, A., Sandoval, 
T. C., … Reilly, L. A. (2011). Predicting conversion from mild cognitive impairment to 
Alzheimer’s disease using neuropsychological tests and multivariate methods. Journal 
of Clinical and Experimental Neuropsychology, 33(2), 187–199. 
https://doi.org/10.1080/13803395.2010.499356 
Chasioti, D., Yan, J., Nho, K., & Saykin, A. J. (2019, May 1). Progress in Polygenic 
Composite Scores in Alzheimer’s and Other Complex Diseases. Trends in Genetics. 
Elsevier Ltd. https://doi.org/10.1016/j.tig.2019.02.005 
Chen, R., Hu, Z., Wei, L., Qin, X., McCracken, C., & Copeland, J. R. (2008). Severity of 
depression and risk for subsequent dementia: cohort studies in China and the UK. 
British Journal of Psychiatry, 193(05), 373–377. 
https://doi.org/10.1192/bjp.bp.107.044974 
Cho, H., Choi, J. Y., Hwang, M. S., Kim, Y. J., Lee, H. M., Lee, H. S., … Lyoo, C. H. 
(2016). In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease 
spectrum. Annals of Neurology, 80(2), 247–258. https://doi.org/10.1002/ana.24711 
Chu, C., Hsu, A. L., Chou, K. H., Bandettini, P., & Lin, C. P. (2012). Does feature selection 
improve classification accuracy? Impact of sample size and feature selection on 
classification using anatomical magnetic resonance images. NeuroImage, 60(1), 59–70. 
https://doi.org/10.1016/j.neuroimage.2011.11.066 
 160 
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, 
G. W., … Pericak-Vance, M. A. (1993). Gene dose of apolipoprotein E type 4 allele and 
the risk of Alzheimer’s disease in late onset families. Science, 261(5123), 921–923. 
https://doi.org/10.1126/science.8346443 
Crane, P. K., Carle, A., Gibbons, L. E., Insel, P., Mackin, R. S., Gross, A., … Initiative,  for 
the A. D. N. (2012). Development and assessment of a composite score for memory in 
the Alzheimer’s Disease Neuroimaging Initiative (ADNI). Brain Imaging and Behavior, 
6(4), 502–516. https://doi.org/10.1007/s11682-012-9186-z 
Crary, J. F., Trojanowski, J. Q., Schneider, J. A., Abisambra, J. F., Abner, E. L., Alafuzoff, I., 
… Nelson, P. T. (2014). Primary age-related tauopathy (PART): a common pathology 
associated with human aging. Acta Neuropathologica, 128(6), 755–766. 
https://doi.org/10.1007/s00401-014-1349-0 
Cui, Y., Liu, B., Luo, S., Zhen, X., Fan, M., Liu, T., … Initiative,  the A. D. N. (2011). 
Identification of Conversion from Mild Cognitive Impairment to Alzheimer’s Disease 
Using Multivariate Predictors. PLoS ONE, 6(7), e21896. 
https://doi.org/10.1371/journal.pone.0021896 
Cummings, J., Reiber, C., & Kumar, P. (2018). The price of progress: Funding and financing 
Alzheimer’s disease drug development. Alzheimer’s and Dementia: Translational 
Research and Clinical Interventions, 4, 330–343. 
https://doi.org/10.1016/j.trci.2018.04.008 
Davatzikos, C., Xu, F., An, Y., Fan, Y., & Resnick, S. M. (2009). Longitudinal progression 
of Alzheimer’s-like patterns of atrophy in normal older adults: the SPARE-AD index. 
Brain, 132(8), 2026–2035. https://doi.org/10.1093/brain/awp091 
Davatzikos, Christos. (2019, August 15). Machine learning in neuroimaging: Progress and 
challenges. NeuroImage. Academic Press Inc. 
https://doi.org/10.1016/j.neuroimage.2018.10.003 
Davatzikos, Christos, Sotiras, A., Fan, Y., Habes, M., Erus, G., Rathore, S., … Kontos, D. 
(2019). Precision diagnostics based on machine learning-derived imaging signatures. 
Magnetic Resonance Imaging, 64, 49–61. https://doi.org/10.1016/j.mri.2019.04.012 
De Leon, M. J., Convit, A., Wolf, O. T., Tarshish, C. Y., DeSanti, S., Rusinek, H., … Fowler, 
J. (2001). Prediction of cognitive decline in normal elderly subjects with 2-[18F]fluoro-
2-deoxy-D-glucose/positron-emission tomography (FDG/PET). Proceedings of the 
National Academy of Sciences of the United States of America, 98(19), 10966–10971. 
https://doi.org/10.1073/pnas.191044198 
 161 
Defrancesco, M., Marksteiner, J., Kemmler, G., Fleischhacker, W. W., Blasko, I., & 
Deisenhammer, E. A. (2017). Severity of Depression Impacts Imminent Conversion 
from Mild Cognitive Impairment to Alzheimer’s Disease. Journal of Alzheimer’s 
Disease, 59(4), 1439–1448. https://doi.org/10.3233/JAD-161135 
Desikan, R. S., Fischl, B., Cabral, H. J., Dillon, W. P., Salat, D. H., Settecase, F., … 
Glastonbury, C. M. (2010). Automated MRI measures predict progression to 
Alzheimer’s disease. Neurobiology of Aging, 31(8), 1364–1374. 
https://doi.org/10.1016/j.neurobiolaging.2010.04.023 
Desikan, R. S., Ségonne, F., Fischl, B., Quinn, B. T., Dickerson, B. C., Blacker, D., … 
Killiany, R. J. (2006). An automated labeling system for subdividing the human cerebral 
cortex on MRI scans into gyral based regions of interest. NeuroImage, 31(3), 968–980. 
https://doi.org/10.1016/j.neuroimage.2006.01.021 
Devanand, D. P., Pradhaban, G., Liu, X., Khandji, A., De Santi, S., Segal, S., … De Leon, M. 
J. (2007). Hippocampal and entorhinal atrophy in mild cognitive impairment: Prediction 
of Alzheimer disease. Neurology, 68(11), 828–836. 
https://doi.org/10.1212/01.wnl.0000256697.20968.d7 
Dickerson, B. C., Stoub, T. R., Shah, R. C., Sperling, R. A., Killiany, R. J., Albert, M. S., … 
Detoledo-Morrell, L. (2011). Alzheimer-signature MRI biomarker predicts AD dementia 
in cognitively normal adults. Neurology, 76(16), 1395–1402. 
https://doi.org/10.1212/WNL.0b013e3182166e96 
Dickerson, Bradford C., Bakkour, A., Salat, D. H., Feczko, E., Pacheco, J., Greve, D. N., … 
Buckner, R. L. (2009). The cortical signature of Alzheimer’s disease: Regionally 
specific cortical thinning relates to symptom severity in very mild to mild AD dementia 
and is detectable in asymptomatic amyloid-positive individuals. Cerebral Cortex, 19(3), 
497–510. https://doi.org/10.1093/cercor/bhn113 
Dong, A., Toledo, J. B., Honnorat, N., Doshi, J., Varol, E., Sotiras, A., … Davatzikos, C. 
(2016). Heterogeneity of neuroanatomical patterns in prodromal Alzheimer’s disease: 
links to cognition, progression and biomarkers. Brain, 140(3), aww319. 
https://doi.org/10.1093/brain/aww319 
Dong, A., Toledo, J. B., Honnorat, N., Doshi, J., Varol, E., Sotiras, A., … Davatzikos, C. 
(2017). Heterogeneity of neuroanatomical patterns in prodromal Alzheimer’s disease: 
links to cognition, progression and biomarkers. Brain, 140(3), 735–747. 
https://doi.org/10.1093/brain/aww319 
Donohue, M. C., Sperling, R. A., Salmon, D. P., Rentz, D. M., Raman, R., Thomas, R. G., … 
 162 
Aisen, P. S. (2014). The Preclinical Alzheimer Cognitive Composite. JAMA Neurology, 
71(8), 961. https://doi.org/10.1001/jamaneurol.2014.803 
Donovan, N. J., Amariglio, R. E., Zoller, A. S., Rudel, R. K., Gomez-Isla, T., Blacker, D., … 
Rentz, D. M. (2014). Subjective cognitive concerns and neuropsychiatric predictors of 
progression to the early clinical stages of Alzheimer disease. American Journal of 
Geriatric Psychiatry, 22(12), 1642–1651. https://doi.org/10.1016/j.jagp.2014.02.007 
Dubois, B., Hampel, H., Feldman, H. H., Scheltens, P., Aisen, P., Andrieu, S., … Jack, C. R. 
(2016). Preclinical Alzheimer’s disease: Definition, natural history, and diagnostic 
criteria. Alzheimer’s & Dementia, 12(3), 292–323. 
https://doi.org/10.1016/j.jalz.2016.02.002 
Dukart, J., Sambataro, F., & Bertolino, A. (2015). Accurate prediction of conversion to 
Alzheimer’s disease using imaging, genetic, and neuropsychological biomarkers. 
Journal of Alzheimer’s Disease, 49(4), 1143–1159. https://doi.org/10.3233/JAD-150570 
Dumurgier, J., Hanseeuw, B. J., Hatling, F. B., Judge, K. A., Schultz, A. P., Chhatwal, J. P., 
… Gómez-Isla, T. (2017). Alzheimer’s Disease Biomarkers and Future Decline in 
Cognitive Normal Older Adults. Journal of Alzheimer’s Disease, 60(4), 1451–1459. 
https://doi.org/10.3233/JAD-170511 
Ebrahimighahnavieh, M. A., Luo, S., & Chiong, R. (2020). Deep learning to detect 
Alzheimer’s disease from neuroimaging: A systematic literature review. Computer 
Methods and Programs in Biomedicine, 187, 105242. 
https://doi.org/10.1016/j.cmpb.2019.105242 
Esteva, A., Robicquet, A., Ramsundar, B., Kuleshov, V., DePristo, M., Chou, K., … Dean, J. 
(2019, January 1). A guide to deep learning in healthcare. Nature Medicine. Nature 
Publishing Group. https://doi.org/10.1038/s41591-018-0316-z 
Fan, L., Li, H., Zhuo, J., Zhang, Y., Wang, J., Chen, L., … Jiang, T. (2016). The Human 
Brainnetome Atlas: A New Brain Atlas Based on Connectional Architecture. Cerebral 
Cortex, 26(8), 3508–3526. https://doi.org/10.1093/cercor/bhw157 
Fan, Y., Batmanghelich, N., Clark, C. M., & Davatzikos, C. (2008). Spatial patterns of brain 
atrophy in MCI patients, identified via high-dimensional pattern classification, predict 
subsequent cognitive decline. NeuroImage, 39(4), 1731–1743. 
https://doi.org/10.1016/j.neuroimage.2007.10.031 
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975). “Mini-mental state”. A practical 
method for grading the cognitive state of patients for the clinician. Journal of 
Psychiatric Research, 12(3), 189–198. https://doi.org/10.1016/0022-3956(75)90026-6 
 163 
Franzmeier, N., Neitzel, J., Rubinski, A., Smith, R., Strandberg, O., Ossenkoppele, R., … 
Raj, B. A. (2020). Functional brain architecture is associated with the rate of tau 
accumulation in Alzheimer’s disease. Nature Communications, 11(1), 1–17. 
https://doi.org/10.1038/s41467-019-14159-1 
Frölich, L., Peters, O., Lewczuk, P., Gruber, O., Teipel, S. J., Gertz, H. J., … Kornhuber, J. 
(2017). Incremental value of biomarker combinations to predict progression of mild 
cognitive impairment to Alzheimer’s dementia. Alzheimer’s Research and Therapy, 
9(1), 84. https://doi.org/10.1186/s13195-017-0301-7 
Furst, A. J., Rabinovici, G. D., Rostomian, A. H., Steed, T., Alkalay, A., Racine, C., … 
Jagust, W. J. (2012). Cognition, glucose metabolism and amyloid burden in Alzheimer’s 
disease. Neurobiology of Aging, 33(2), 215–225. 
https://doi.org/10.1016/j.neurobiolaging.2010.03.011 
Gallucci, M., Di Battista, M. E., Battistella, G., Falcone, C., Bisiacchi, P. S., & Di Giorgi, E. 
(2018). Neuropsychological tools to predict conversion from amnestic mild cognitive 
impairment to dementia. The TREDEM Registry. Aging, Neuropsychology, and 
Cognition, 25(4), 550–560. https://doi.org/10.1080/13825585.2017.1349869 
Gibbons, L. E., Carle, A. C., Mackin, R. S., Harvey, D., Mukherjee, S., Insel, P., … 
Alzheimer’s Disease Neuroimaging Initiative. (2012). A composite score for executive 
functioning, validated in Alzheimer’s Disease Neuroimaging Initiative (ADNI) 
participants with baseline mild cognitive impairment. Brain Imaging and Behavior, 6(4), 
517–527. https://doi.org/10.1007/s11682-012-9176-1 
Giorgio, J., Karlaftis, V. M., Wang, R., Shen, Y., Tino, P., Welchman, A., & Kourtzi, Z. 
(2018). Functional brain networks for learning predictive statistics. Cortex, 107. 
https://doi.org/10.1016/j.cortex.2017.08.014 
Giorgio, Joseph, Jagust, W. J., Baker, S., Landau, S. M., Tino, P., & Kourtzi, Z. (2020). Title: 
Predicting future regional tau accumulation in asymptomatic and early Alzheimer’s 
disease. BioRxiv, 2020.08.15.252601. https://doi.org/10.1101/2020.08.15.252601 
Giorgio, Joseph, Landau, S., Jagust, W., Tino, P., & Kourtzi, Z. (2020). Modelling prognostic 
trajectories of cognitive decline due to Alzheimer’s disease. NeuroImage: Clinical, 
102199. https://doi.org/10.1016/j.nicl.2020.102199 
Glenner, G. G., & Wong, C. W. (1984). Alzheimer’s disease: Initial report of the purification 
and characterization of a novel cerebrovascular amyloid protein. Biochemical and 
Biophysical Research Communications, 120(3), 885–890. 
https://doi.org/10.1016/S0006-291X(84)80190-4 
 164 
Goate, A., Chartier-Harlin, M. C., Mullan, M., Brown, J., Crawford, F., Fidani, L., … Hardy, 
J. (1991). Segregation of a missense mutation in the amyloid precursor protein gene with 
familial Alzheimer’s disease. Nature, 349(6311), 704–706. 
https://doi.org/10.1038/349704a0 
Goldgaber, D., Lerman, M. I., McBride, O. W., Saffiotti, U., & Gajdusek, D. C. (1987). 
Characterization and chromosomal localization of a cDNA encoding brain amyloid of 
Alzheimer’s disease. Science, 235(4791), 877–880. 
https://doi.org/10.1126/science.3810169 
Gordon, B. A., Blazey, T. M., Su, Y., Hari-Raj, A., Dincer, A., Flores, S., … Benzinger, T. L. 
S. (2018). Spatial patterns of neuroimaging biomarker change in individuals from 
families with autosomal dominant Alzheimer’s disease: a longitudinal study. The Lancet 
Neurology, 17(3), 241–250. https://doi.org/10.1016/S1474-4422(18)30028-0 
Greenfield, E. A., & Moorman, S. M. (2019). Childhood Socioeconomic Status and Later 
Life Cognition: Evidence From the Wisconsin Longitudinal Study. Journal of Aging and 
Health, 31(9), 1589–1615. https://doi.org/10.1177/0898264318783489 
Grober, E., Hall, C. B., Lipton, R. B., Zonderman, A. B., Resnick, S. M., & Kawas, C. 
(2008). Memory impairment, executive dysfunction, and intellectual decline in 
preclinical Alzheimer’s disease. Journal of the International Neuropsychological 
Society, 14(2), 266–278. 
Grundke-Iqbal, I., Iqbal, K., Tung, Y. C., Quinlan, M., Wisniewski, H. M., & Binder, L. I. 
(1986). Abnormal phosphorylation of the microtubule-associated protein tau (tau) in 
Alzheimer cytoskeletal pathology. Proceedings of the National Academy of Sciences of 
the United States of America, 83(13), 4913–4917. 
https://doi.org/10.1073/pnas.83.13.4913 
Hall, B., Mak, E., Cervenka, S., Aigbirhio, F. I., Rowe, J. B., & O’Brien, J. T. (2017, July 1). 
In vivo tau PET imaging in dementia: Pathophysiology, radiotracer quantification, and a 
systematic review of clinical findings. Ageing Research Reviews. Elsevier Ireland Ltd. 
https://doi.org/10.1016/j.arr.2017.03.002 
Hall, S., Öhrfelt, A., Constantinescu, R., Andreasson, U., Surova, Y., Bostrom, F., … 
Hansson, O. (2012). Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the 
differential diagnosis of patients with dementia and/or Parkinsonian disorders. Archives 
of Neurology, 69(11), 1445–1452. https://doi.org/10.1001/archneurol.2012.1654 
Hanseeuw, B. J., Betensky, R. A., Jacobs, H. I. L., Schultz, A. P., Sepulcre, J., Becker, J. A., 
… Johnson, K. (2019). Association of Amyloid and Tau with Cognition in Preclinical 
 165 
Alzheimer Disease: A Longitudinal Study. JAMA Neurology, 76(8), 915–924. 
https://doi.org/10.1001/jamaneurol.2019.1424 
Hardy, J. A., & Higgins, G. A. (1992). Alzheimer’s disease: The amyloid cascade hypothesis. 
Science. https://doi.org/10.1126/science.1566067 
Harrison, T. M., La Joie, R., Maass, A., Baker, S. L., Swinnerton, K., Fenton, L., … Jagust, 
W. J. (2019). Longitudinal tau accumulation and atrophy in aging and alzheimer disease. 
Annals of Neurology, 85(2), 229–240. https://doi.org/10.1002/ana.25406 
Hedden, T., & Gabrieli, J. D. E. (2004). Insights into the ageing mind: a view from cognitive 
neuroscience. Nature Reviews Neuroscience, 5(2), 87–96. 
https://doi.org/10.1038/nrn1323 
Hinrichs, C., Singh, V., Xu, G., & Johnson, S. C. (2011). Predictive markers for AD in a 
multi-modality framework: An analysis of MCI progression in the ADNI population. 
NeuroImage, 55(2), 574–589. https://doi.org/10.1016/J.NEUROIMAGE.2010.10.081 
Hochstetler, H., Trzepacz, P. T., Wang, S., Yu, P., Case, M., Henley, D. B., … Lyketsos, C. 
G. (2015). Empirically Defining Trajectories of Late-Life Cognitive and Functional 
Decline. Journal of Alzheimer’s Disease, 50(1), 271–282. https://doi.org/10.3233/JAD-
150563 
Holmberg, B., Johnels, B., Blennow, K., & Rosengren, L. (2003, February 1). Cerebrospinal 
fluid Aβ42 is reduced in multiple system atrophy but normal in Parkinson’s disease and 
progressive supranuclear palsy. Movement Disorders. 
https://doi.org/10.1002/mds.10321 
Hong, Y. T., Veenith, T., Dewar, D., Outtrim, J. G., Mani, V., Williams, C., … Menon, D. K. 
(2014). Amyloid imaging with carbon 11 - Labeled pittsburgh compound B for 
traumatic brain injury. JAMA Neurology, 71(1), 23–31. 
https://doi.org/10.1001/jamaneurol.2013.4847 
Hutton, M., Lendon, C. L., Rizzu, P., Baker, M., Froelich, S., Houlden, H. H., … Heutink, P. 
(1998). Association of missense and 5’-splice-site mutations in tau with the inherited 
dementia FTDP-17. Nature, 393(6686), 702–704. https://doi.org/10.1038/31508 
Ikonomovic, M. D., Klunk, W. E., Abrahamson, E. E., Mathis, C. A., Price, J. C., Tsopelas, 
N. D., … DeKosky, S. T. (2008). Post-mortem correlates of in vivo PiB-PET amyloid 
imaging in a typical case of Alzheimer’s disease. Brain : A Journal of Neurology, 131(Pt 
6), 1630–1645. https://doi.org/10.1093/brain/awn016 
Insel, P. S., Mattsson, N., Mackin, R. S., Kornak, J., Nosheny, R., Tosun-Turgut, D., … 
Alzheimer’s Disease Neuroimaging Initiative, A. D. N. (2015). Biomarkers and 
 166 
cognitive endpoints to optimize trials in Alzheimer’s disease. Annals of Clinical and 
Translational Neurology, 2(5), 534–547. https://doi.org/10.1002/acn3.192 
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., … 
Contributors, R. (2018). NIA-AA Research Framework: Toward a biological definition 
of Alzheimer’s disease. Alzheimer’s & Dementia : The Journal of the Alzheimer’s 
Association, 14(4), 535–562. https://doi.org/10.1016/j.jalz.2018.02.018 
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Feldman, H. H., Frisoni, G. B., … 
Dubois, B. (2016, August 2). A/T/N: An unbiased descriptive classification scheme for 
Alzheimer disease biomarkers. Neurology. Lippincott Williams and Wilkins. 
https://doi.org/10.1212/WNL.0000000000002923 
Jack, C. R., Bernstein, M. A., Fox, N. C., Thompson, P., Alexander, G., Harvey, D., … 
Weiner, M. W. (2008, April). The Alzheimer’s Disease Neuroimaging Initiative 
(ADNI): MRI methods. Journal of Magnetic Resonance Imaging. NIH Public Access. 
https://doi.org/10.1002/jmri.21049 
Jack, C. R., & Holtzman, D. M. (2013, December 18). Biomarker modeling of alzheimer’s 
disease. Neuron. Cell Press. https://doi.org/10.1016/j.neuron.2013.12.003 
Jack, C. R., Jr, Wiste, H. J., Vemuri, P., Weigand, S. D., Senjem, M. L., … Initiative,  the A. 
D. N. (2010). Brain beta-amyloid measures and magnetic resonance imaging atrophy 
both predict time-to-progression from mild cognitive impairment to Alzheimer’s 
disease. Brain, 133(11), 3336. https://doi.org/10.1093/BRAIN/AWQ277 
Jack, C. R., Knopman, D. S., Chételat, G., Dickson, D., Fagan, A. M., Frisoni, G. B., … Vos, 
S. J. B. (2016, February 1). Suspected non-Alzheimer disease pathophysiology-concept 
and controversy. Nature Reviews Neurology. Nature Publishing Group. 
https://doi.org/10.1038/nrneurol.2015.251 
Jack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., … 
Trojanowski, J. Q. (2013). Tracking pathophysiological processes in Alzheimer’s 
disease: an updated hypothetical model of dynamic biomarkers. The Lancet. Neurology, 
12(2), 207–216. https://doi.org/10.1016/S1474-4422(12)70291-0 
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., … 
Trojanowski, J. Q. (2010). Hypothetical model of dynamic biomarkers of the 
Alzheimer’s pathological cascade. The Lancet. Neurology, 9(1), 119–128. 
https://doi.org/10.1016/S1474-4422(09)70299-6 
Jack, C. R., Knopman, D. S., Weigand, S. D., Wiste, H. J., Vemuri, P., Lowe, V., … 
Petersen, R. C. (2012). An operational approach to National Institute on Aging-
 167 
Alzheimer’s Association criteria for preclinical Alzheimer disease. Annals of Neurology, 
71(6), 765–775. https://doi.org/10.1002/ana.22628 
Jack, C. R., Wiste, H. J., Schwarz, C. G., Lowe, V. J., Senjem, M. L., Vemuri, P., … 
Petersen, R. C. (2018). Longitudinal tau PET in ageing and Alzheimer’s disease. Brain, 
141(5), 1517–1528. https://doi.org/10.1093/brain/awy059 
Jack, C. R., Wiste, H. J., Weigand, S. D., Therneau, T. M., Lowe, V. J., Knopman, D. S., … 
Petersen, R. C. (2017). Defining imaging biomarker cut points for brain aging and 
Alzheimer’s disease. Alzheimer’s & Dementia : The Journal of the Alzheimer’s 
Association, 13(3), 205–216. https://doi.org/10.1016/j.jalz.2016.08.005 
Jagust, W. (2018). Imaging the evolution and pathophysiology of Alzheimer disease. Nature 
Reviews Neuroscience, 1. https://doi.org/10.1038/s41583-018-0067-3 
Jagust, W., Gitcho, A., Sun, F., Kuczynski, B., Mungas, D., & Haan, M. (2006). Brain 
imaging evidence of preclinical Alzheimer’s disease in normal aging. Annals of 
Neurology, 59(4), 673–681. https://doi.org/10.1002/ana.20799 
Jagust, W. J., Landau, S. M., Shaw, L. M., Trojanowski, J. Q., Koeppe, R. A., Reiman, E. M., 
… Mathis, C. A. (2009). Relationships between biomarkers in aging and dementia. 
Neurology, 73(15), 1193–1199. https://doi.org/10.1212/WNL.0b013e3181bc010c 
Jansen, W. J., Ossenkoppele, R., Knol, D. L., Tijms, B. M., Scheltens, P., Verhey, F. R. J., … 
Zetterberg, H. (2015). Prevalence of cerebral amyloid pathology in persons without 
dementia: A meta-analysis. JAMA - Journal of the American Medical Association, 
313(19), 1924–1938. https://doi.org/10.1001/jama.2015.4668 
Jansen, W. J., Ossenkoppele, R., Tijms, B. M., Fagan, A. M., Hansson, O., Klunk, W. E., … 
Zetterberg, H. (2018). Association of Cerebral Amyloid-β Aggregation With Cognitive 
Functioning in Persons Without Dementia. JAMA Psychiatry, 75(1), 84. 
https://doi.org/10.1001/jamapsychiatry.2017.3391 
Janssen, R. J., Mourão-Miranda, J., & Schnack, H. G. (2018). Making Individual Prognoses 
in Psychiatry Using Neuroimaging and Machine Learning. Biological Psychiatry: 
Cognitive Neuroscience and Neuroimaging, 3(9), 798–808. 
https://doi.org/10.1016/J.BPSC.2018.04.004 
Jo, T., Nho, K., & Saykin, A. J. (2019). Deep Learning in Alzheimer’s Disease: Diagnostic 
Classification and Prognostic Prediction Using Neuroimaging Data. Frontiers in Aging 
Neuroscience, 11, 220. https://doi.org/10.3389/fnagi.2019.00220 
Johnson, K. A., Schultz, A., Betensky, R. A., Becker, J. A., Sepulcre, J., Rentz, D., … 
Sperling, R. (2016). Tau positron emission tomographic imaging in aging and early 
 168 
Alzheimer disease. Annals of Neurology, 79(1), 110–119. 
https://doi.org/10.1002/ana.24546 
Jollans, L., Boyle, R., Artiges, E., Banaschewski, T., Desrivières, S., Grigis, A., … Whelan, 
R. (2019). Quantifying performance of machine learning methods for neuroimaging 
data. NeuroImage, 199, 351–365. https://doi.org/10.1016/j.neuroimage.2019.05.082 
Jonsson, T., Atwal, J. K., Steinberg, S., Snaedal, J., Jonsson, P. V., Bjornsson, S., … 
Stefansson, K. (2012). A mutation in APP protects against Alzheimer‘s disease and age-
related cognitive decline. Nature, 488(7409), 96. https://doi.org/10.1038/nature11283 
Joshi, S., Shenoy, D., Vibhudendra Simha, G. G., Rrashmi, P. L., Venugopal, K. R., & 
Patnaik, L. M. (2010). Classification of Alzheimer’s disease and Parkinson’s disease by 
using machine learning and neural network methods. In ICMLC 2010 - The 2nd 
International Conference on Machine Learning and Computing (pp. 218–222). 
https://doi.org/10.1109/ICMLC.2010.45 
Jutten, R. J., Harrison, J., de Jong, F. J., Aleman, A., Ritchie, C. W., Scheltens, P., & Sikkes, 
S. A. M. (2017). A composite measure of cognitive and functional progression in 
Alzheimer’s disease: Design of the Capturing Changes in Cognition study. Alzheimer’s 
& Dementia: Translational Research & Clinical Interventions, 3(1), 130–138. 
https://doi.org/10.1016/J.TRCI.2017.01.004 
Jutten, R. J., Harrison, J., Lee Meeuw Kjoe, P. R., Opmeer, E. M., Schoonenboom, N. S. M., 
de Jong, F. J., … Sikkes, S. A. M. (2018). A novel cognitive-functional composite 
measure to detect changes in early Alzheimer’s disease: Test–retest reliability and 
feasibility. Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring, 10, 
153–160. https://doi.org/10.1016/J.DADM.2017.12.002 
Kang, J., Lemaire, H. G., Unterbeck, A., Salbaum, J. M., Masters, C. L., Grzeschik, K. H., … 
Müller-Hill, B. (1987). The precursor of Alzheimer’s disease amyloid A4 protein 
resembles a cell-surface receptor. Nature, 325(6106), 733–736. 
https://doi.org/10.1038/325733a0 
Karlaftis, V. M., Giorgio, J., Vértes, P. E., Wang, R., Shen, Y., Tino, P., … Kourtzi, Z. 
(2019). Multimodal imaging of brain connectivity reveals predictors of individual 
decision strategy in statistical learning. Nature Human Behaviour. 
https://doi.org/10.1038/s41562-018-0503-4 
Kero, M., Paetau, A., Polvikoski, T., Tanskanen, M., Sulkava, R., Jansson, L., … Tienari, P. 
J. (2013). Amyloid precursor protein (APP) A673T mutation in the elderly Finnish 
population. Neurobiology of Aging, 34(5), 1518.e1-1518.e3. 
 169 
https://doi.org/10.1016/j.neurobiolaging.2012.09.017 
Kim, W. S., Li, H., Ruberu, K., Chan, S., Elliott, D. A., Low, J. K., … Garner, B. (2013). 
Deletion of Abca7 increases cerebral amyloid-β accumulation in the J20 mouse model 
of Alzheimer’s disease. Journal of Neuroscience, 33(10), 4387–4394. 
https://doi.org/10.1523/JNEUROSCI.4165-12.2013 
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., … Långström, 
B. (2004). Imaging Brain Amyloid in Alzheimer’s Disease with Pittsburgh Compound-
B. Annals of Neurology, 55(3), 306–319. https://doi.org/10.1002/ana.20009 
Knopman, D. S., Jack, C. R., Wiste, H. J., Weigand, S. D., Vemuri, P., Lowe, V. J., … 
Petersen, R. C. (2013). Brain injury biomarkers are not dependent on β-amyloid in 
normal elderly. Annals of Neurology, 73(4), 472–480. https://doi.org/10.1002/ana.23816 
Knopman, D. S., Lundt, E. S., Therneau, T. M., Vemuri, P., Lowe, V. J., Kantarci, K., … 
Jack, C. R. (2019). Entorhinal cortex tau, amyloid-β, cortical thickness and memory 
performance in non-demented subjects. Brain, 142(4), 1148–1160. 
https://doi.org/10.1093/brain/awz025 
Krishnan, A., Williams, L. J., McIntosh, A. R., & Abdi, H. (2011). Partial Least Squares 
(PLS) methods for neuroimaging: A tutorial and review. NeuroImage, 56(2), 455–475. 
https://doi.org/10.1016/j.neuroimage.2010.07.034 
Krizhevsky, A., Sutskever, I., & Hinton, G. E. (2012). ImageNet Classification with Deep 
Convolutional Neural Networks. Retrieved from http://code.google.com/p/cuda-convnet/ 
Krut, J. J., Zetterberg, H., Blennow, K., Cinque, P., Hagberg, L., Price, R. W., … Gisslén, M. 
(2013). Cerebrospinal fluid Alzheimer’s biomarker profiles in CNS infections. Journal 
of Neurology, 260(2), 620–626. https://doi.org/10.1007/s00415-012-6688-y 
Landau, S. M., Harvey, D., Madison, C. M., Reiman, E. M., Foster, N. L., Aisen, P. S., … 
Jagust, W. J. (2010). Comparing predictors of conversion and decline in mild cognitive 
impairment. Neurology, 75(3), 230–238. 
https://doi.org/10.1212/WNL.0b013e3181e8e8b8 
Landau, Susan M, Fero, A., Baker, S. L., Koeppe, R., Mintun, M., Chen, K., … Jagust, W. J. 
(2015). Measurement of longitudinal β-amyloid change with 18F-florbetapir PET and 
standardized uptake value ratios. Journal of Nuclear Medicine : Official Publication, 
Society of Nuclear Medicine, 56(4), 567–574. 
https://doi.org/10.2967/jnumed.114.148981 
Langbaum, J. B., Hendrix, S. B., Ayutyanont, N., Chen, K., Fleisher, A. S., Shah, R. C., … 
Reiman, E. M. (2014). An empirically derived composite cognitive test score with 
 170 
improved power to track and evaluate treatments for preclinical Alzheimer’s disease. 
Alzheimer’s & Dementia, 10(6), 666–674. https://doi.org/10.1016/J.JALZ.2014.02.002 
LaPoint, M. R., Chhatwal, J. P., Sepulcre, J., Johnson, K. A., Sperling, R. A., & Schultz, A. 
P. (2017). The association between tau PET and retrospective cortical thinning in 
clinically normal elderly. NeuroImage, 157, 612–622. 
https://doi.org/10.1016/j.neuroimage.2017.05.049 
Leal, S. L., Lockhart, S. N., Maass, A., Bell, R. K., & Jagust, W. J. (2018). Subthreshold 
amyloid predicts tau deposition in aging. Journal of Neuroscience, 38(19), 4482–4489. 
https://doi.org/10.1523/JNEUROSCI.0485-18.2018 
Leandrou, S., Petroudi, S., Kyriacou, P. A., Reyes-Aldasoro, C. C., & Pattichis, C. S. (2018). 
Quantitative MRI Brain Studies in Mild Cognitive Impairment and Alzheimer’s 
Disease: A Methodological Review. IEEE Reviews in Biomedical Engineering, 11, 97–
111. https://doi.org/10.1109/RBME.2018.2796598 
Lecun, Y., Bengio, Y., & Hinton, G. (2015, May 27). Deep learning. Nature. Nature 
Publishing Group. https://doi.org/10.1038/nature14539 
Lemere, C. A., Blusztajn, J. K., Yamaguchi, H., Wisniewski, T., Saido, T. C., & Selkoe, D. J. 
(1996). Sequence of deposition of heterogeneous amyloid β-peptides and APO E in 
down syndrome: Implications for initial events in amyloid plaque formation. 
Neurobiology of Disease, 3(1), 16–32. https://doi.org/10.1006/nbdi.1996.0003 
Lemere, Cynthia A., Lopera, F., Kosik, K. S., Lendon, C. L., Ossa, J., Saido, T. C., … 
Arango V., J. C. (1996). The E280A presenilin 1 Alzheimer mutation produces 
increased Aβ42 deposition and severe cerebellar pathology. Nature Medicine, 2(10), 
1146–1150. https://doi.org/10.1038/nm1096-1146 
Li, D., Iddi, S., Aisen, P. S., Thompson, W. K., & Donohue, M. C. (2019). The relative 
efficiency of time-to-progression and continuous measures of cognition in 
presymptomatic Alzheimer’s disease. Alzheimer’s & Dementia: Translational Research 
& Clinical Interventions, 5, 308–318. https://doi.org/10.1016/J.TRCI.2019.04.004 
Lindsey, R., Daluiski, A., Chopra, S., Lachapelle, A., Mozer, M., Sicular, S., … Potter, H. 
(2018). Deep neural network improves fracture detection by clinicians. Proceedings of 
the National Academy of Sciences of the United States of America, 115(45), 11591–
11596. https://doi.org/10.1073/pnas.1806905115 
Liu, K., Chen, K., Yao, L., & Guo, X. (2017). Prediction of Mild Cognitive Impairment 
Conversion Using a Combination of Independent Component Analysis and the Cox 
Model. Frontiers in Human Neuroscience, 11, 33. 
 171 
https://doi.org/10.3389/fnhum.2017.00033 
Liu, X., Faes, L., Kale, A. U., Wagner, S. K., Fu, D. J., Bruynseels, A., … Denniston, A. K. 
(2019). A comparison of deep learning performance against health-care professionals in 
detecting diseases from medical imaging: a systematic review and meta-analysis. The 
Lancet Digital Health, 1(6), e271–e297. https://doi.org/10.1016/S2589-7500(19)30123-
2 
Lowe, V. J., Curran, G., Fang, P., Liesinger, A. M., Josephs, K. A., Parisi, J. E., … Murray, 
M. E. (2016). An autoradiographic evaluation of AV-1451 Tau PET in dementia. Acta 
Neuropathologica Communications, 4(1). https://doi.org/10.1186/s40478-016-0315-6 
Maass, A., Landau, S., Baker, S. L., Horng, A., Lockhart, S. N., La Joie, R., … Jagust, W. J. 
(2017). Comparison of multiple tau-PET measures as biomarkers in aging and 
Alzheimer’s disease. NeuroImage, 157, 448–463. 
https://doi.org/10.1016/J.NEUROIMAGE.2017.05.058 
Maass, A., Lockhart, S. N., Harrison, T. M., Bell, R. K., Mellinger, T., Swinnerton, K., … 
Jagust, W. J. (2018). Entorhinal tau pathology, episodic memory decline, and 
neurodegeneration in aging. Journal of Neuroscience, 38(3), 530–543. 
https://doi.org/10.1523/JNEUROSCI.2028-17.2017 
Mak, E., Gabel, S., Mirette, H., Su, L., Williams, G. B., Waldman, A., … O’Brien, J. (2017). 
Structural neuroimaging in preclinical dementia: From microstructural deficits and grey 
matter atrophy to macroscale connectomic changes. Ageing Research Reviews, 35, 250–
264. https://doi.org/10.1016/j.arr.2016.10.001 
Marinescu, R. V., Oxtoby, N. P., Young, A. L., Bron, E. E., Toga, A. W., Weiner, M. W., … 
Consortium,  the E. (2018). TADPOLE Challenge: Prediction of Longitudinal Evolution 
in Alzheimer’s Disease. Retrieved from http://arxiv.org/abs/1805.03909 
Maroco, J., Silva, D., Rodrigues, A., Guerreiro, M., Santana, I., & de Mendonça, A. (2011). 
Data mining methods in the prediction of Dementia: A real-data comparison of the 
accuracy, sensitivity and specificity of linear discriminant analysis, logistic regression, 
neural networks, support vector machines, classification trees and random forests. BMC 
Research Notes, 4(1), 299. https://doi.org/10.1186/1756-0500-4-299 
Marquié, M., Normandin, M. D., Vanderburg, C. R., Costantino, I. M., Bien, E. A., Rycyna, 
L. G., … Gómez-Isla, T. (2015). Validating novel tau positron emission tomography 
tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Annals of Neurology, 78(5), 
787–800. https://doi.org/10.1002/ana.24517 
Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., & Beyreuther, 
 172 
K. (1985). Amyloid plaque core protein in Alzheimer disease and Down syndrome. 
Proceedings of the National Academy of Sciences of the United States of America, 
82(12), 4245–4249. https://doi.org/10.1073/pnas.82.12.4245 
Mateos-Pérez, J. M., Dadar, M., Lacalle-Aurioles, M., Iturria-Medina, Y., Zeighami, Y., & 
Evans, A. C. (2018). Structural neuroimaging as clinical predictor: A review of machine 
learning applications. NeuroImage: Clinical, 20, 506–522. 
https://doi.org/10.1016/j.nicl.2018.08.019 
Matsuda, H. (2016). MRI morphometry in Alzheimer’s disease. Ageing Research Reviews, 
30, 17–24. https://doi.org/10.1016/j.arr.2016.01.003 
Mazzeo, S., Santangelo, R., Bernasconi, M. P., Cecchetti, G., Fiorino, A., Pinto, P., … 
Magnani, G. (2016). Combining Cerebrospinal Fluid Biomarkers and 
Neuropsychological Assessment: A Simple and Cost-Effective Algorithm to Predict the 
Progression from Mild Cognitive Impairment to Alzheimer’s Disease Dementia. Journal 
of Alzheimer’s Disease, 54(4), 1495–1508. https://doi.org/10.3233/JAD-160360 
McIntosh, A. R., & Lobaugh, N. J. (2004). Partial least squares analysis of neuroimaging 
data: Applications and advances. NeuroImage, 23(SUPPL. 1), 250–263. 
https://doi.org/10.1016/j.neuroimage.2004.07.020 
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., 
… Phelps, C. H. (2011). The diagnosis of dementia due to Alzheimer’s disease: 
Recommendations from the National Institute on Aging-Alzheimer’s Association 
workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s & Dementia, 
7(3), 263–269. https://doi.org/10.1016/j.jalz.2011.03.005 
Michaud, T. L., Su, D., Siahpush, M., & Murman, D. L. (2017). The risk of incident mild 
cognitive impairment and progression to dementia considering mild cognitive 
impairment subtypes. Dementia and Geriatric Cognitive Disorders Extra, 7(1), 15–29. 
https://doi.org/10.1159/000452486 
Milan, L., & Whittaker, J. (1995). Application of the Parametric Bootstrap to Models that 
Incorporate a Singular Value Decomposition. Applied Statistics, 44(1), 31. 
https://doi.org/10.2307/2986193 
Monteiro, J. M., Rao, A., Shawe-Taylor, J., & Mourão-Miranda, J. (2016). A multiple hold-
out framework for Sparse Partial Least Squares. Journal of Neuroscience Methods, 271, 
182–194. https://doi.org/10.1016/j.jneumeth.2016.06.011 
Mormino, E. C., Betensky, R. A., Hedden, T., Schultz, A. P., Amariglio, R. E., Rentz, D. M., 
… Sperling, R. A. (2014). Synergistic Effect of β-Amyloid and Neurodegeneration on 
 173 
Cognitive Decline in Clinically Normal Individuals. JAMA Neurology, 71(11), 1379. 
https://doi.org/10.1001/jamaneurol.2014.2031 
Mullan, M., Crawford, F., Axelman, K., Houlden, H., Lilius, L., Winblad, B., & Lannfelt, L. 
(1992). A pathogenic mutation for probable Alzheimer’s disease in the APP gene at the 
N–terminus of β–amyloid. Nature Genetics, 1(5), 345–347. 
https://doi.org/10.1038/ng0892-345 
Murray, M. E., Graff-Radford, N. R., Ross, O. A., Petersen, R. C., Duara, R., & Dickson, D. 
W. (2011). Neuropathologically defined subtypes of Alzheimer’s disease with distinct 
clinical characteristics: A retrospective study. The Lancet Neurology, 10(9), 785–796. 
https://doi.org/10.1016/S1474-4422(11)70156-9 
Nelson, P. T., Head, E., Schmitt, F. A., Davis, P. R., Neltner, J. H., Jicha, G. A., … Scheff, S. 
W. (2011, May). Alzheimer’s disease is not “brain aging”: Neuropathological, genetic, 
and epidemiological human studies. Acta Neuropathologica. 
https://doi.org/10.1007/s00401-011-0826-y 
Nho, K., Risacher, S. L., Crane, P. K., DeCarli, C., Glymour, M. M., Habeck, C., … Saykin, 
A. J. (2012). Voxel and surface-based topography of memory and executive deficits in 
mild cognitive impairment and Alzheimer’s disease. Brain Imaging and Behavior, 6(4), 
551–567. https://doi.org/10.1007/s11682-012-9203-2 
Ossenkoppele, R., Jansen, W. J., Rabinovici, G. D., Knol, D. L., van der Flier, W. M., van 
Berckel, B. N. M., … Brooks, D. J. (2015). Prevalence of amyloid PET positivity in 
dementia syndromes: a meta-analysis. JAMA, 313(19), 1939–1949. 
https://doi.org/10.1001/jama.2015.4669 
Öst, M., Nylén, K., Csajbok, L., Öhrfelt, A. O., Tullberg, M., Wikkelsö, C., … Nellgård, B. 
(2006). Initial CSF total tau correlates with 1-year outcome in patients with traumatic 
brain injury. Neurology, 67(9), 1600–1604. 
https://doi.org/10.1212/01.wnl.0000242732.06714.0f 
Oulhaj, A., Wilcock, G. K., Smith, A. D., & De Jager, C. A. (2009). Predicting the time of 
conversion to MCI in the elderly: Role of verbal expression and learning. Neurology, 
73(18), 1436–1442. https://doi.org/10.1212/WNL.0b013e3181c0665f 
Palmqvist, S., Zetterberg, H., Blennow, K., Vestberg, S., Andreasson, U., Brooks, D. J., … 
Hansson, O. (2014). Accuracy of brain amyloid detection in clinical practice using 
cerebrospinal fluid β-Amyloid 42: A cross-validation study against amyloid positron 
emission tomography. JAMA Neurology, 71(10), 1282–1289. 
https://doi.org/10.1001/jamaneurol.2014.1358 
 174 
Palmqvist, S., Zetterberg, H., Mattsson, N., Johansson, P., Minthon, L., Blennow, K., … 
Hansson, O. (2015). Detailed comparison of amyloid PET and CSF biomarkers for 
identifying early Alzheimer disease. Neurology, 85(14), 1240–1249. 
https://doi.org/10.1212/WNL.0000000000001991 
Patterson, C. (2018). World Alzheimer Report 2018 - The state of the art of dementia 
research: New frontiers. 
Pellegrini, E., Ballerini, L., Hernandez, M. del C. V., Chappell, F. M., González-Castro, V., 
Anblagan, D., … Wardlaw, J. M. (2018). Machine learning of neuroimaging for assisted 
diagnosis of cognitive impairment and dementia: A systematic review. Alzheimer’s & 
Dementia: Diagnosis, Assessment & Disease Monitoring, 10, 519–535. 
https://doi.org/10.1016/J.DADM.2018.07.004 
Pereira, T., Ferreira, F. L., Cardoso, S., Silva, D., de Mendonça, A., Guerreiro, M., & 
Madeira, S. C. (2018). Neuropsychological predictors of conversion from mild cognitive 
impairment to Alzheimer’s disease: a feature selection ensemble combining stability and 
predictability. BMC Medical Informatics and Decision Making, 18(1), 137. 
https://doi.org/10.1186/s12911-018-0710-y 
Pereira, T., Lemos, L., Cardoso, S., Silva, D., Rodrigues, A., Santana, I., … Madeira, S. C. 
(2017). Predicting progression of mild cognitive impairment to dementia using 
neuropsychological data: a supervised learning approach using time windows. BMC 
Medical Informatics and Decision Making, 17(1), 110. https://doi.org/10.1186/s12911-
017-0497-2 
Pernet, C. R., Wilcox, R., & Rousselet, G. A. (2013). Robust Correlation Analyses: False 
Positive and Power Validation Using a New Open Source Matlab Toolbox. Frontiers in 
Psychology, 3, 606. https://doi.org/10.3389/fpsyg.2012.00606 
Petersen, R. C., Aisen, P. S., Beckett, L. A., Donohue, M. C., Gamst, A. C., Harvey, D. J., … 
Weiner, M. W. (2010). Alzheimer’s Disease Neuroimaging Initiative (ADNI): Clinical 
characterization. Neurology, 74(3), 201–209. 
https://doi.org/10.1212/WNL.0b013e3181cb3e25 
Petersen, Ronald C., Doody, R., Kurz, A., Mohs, R. C., Morris, J. C., Rabins, P. V., … 
Winblad, B. (2001). Current Concepts in Mild Cognitive Impairment. Archives of 
Neurology, 58(12), 1985. https://doi.org/10.1001/archneur.58.12.1985 
Petersen, Ronald C. (2009). Early diagnosis of Alzheimer’s disease: is MCI too late? Current 
Alzheimer Research, 6(4), 324–330. Retrieved from 
http://www.ncbi.nlm.nih.gov/pubmed/19689230 
 175 
Pontecorvo, M. J., Devous, M. D., Kennedy, I., Navitsky, M., Lu, M., Galante, N., … 
Mintun, M. A. (2019). A multicentre longitudinal study of flortaucipir (18F) in normal 
ageing, mild cognitive impairment and Alzheimer’s disease dementia. Brain, 142(6), 
1723–1735. https://doi.org/10.1093/brain/awz090 
Poorkaj, P., Bird, T. D., Wijsman, E., Nemens, E., Garruto, R. M., Anderson, L., … 
Schellenberg, G. D. (1998). Tau is a candidate gene for chromosome 17 frontotemporal 
dementia. Annals of Neurology, 43(6), 815–825. https://doi.org/10.1002/ana.410430617 
Prasher, V. P., Farrer, M. J., Kessling, A. M., Fisher, E. M. C., West, R. J., Barber, P. C., & 
Butler, A. C. (1998). Molecular mapping of Alzheimer-type dementia in Down’s 
syndrome. Annals of Neurology, 43(3), 380–383. https://doi.org/10.1002/ana.410430316 
Prince, M., Wimo, A., Guerchet, M., Gemma-Claire Ali, M., Wu, Y.-T., Prina, M., … Xia, Z. 
(2015). World Alzheimer Report 2015 The Global Impact of Dementia: An analysIs of 
prevalence, Incidence, cost and trends. Retrieved from 
www.alz.co.uk/worldreport2015corrections 
Radua, J., Canales-Rodríguez, E. J., Pomarol-Clotet, E., & Salvador, R. (2014). Validity of 
modulation and optimal settings for advanced voxel-based morphometry. NeuroImage, 
86, 81–90. https://doi.org/10.1016/j.neuroimage.2013.07.084 
Rafii, M. S., & Aisen, P. S. (2019). Alzheimer’s Disease Clinical Trials: Moving Toward 
Successful Prevention. CNS Drugs, 33(2), 99–106. https://doi.org/10.1007/s40263-018-
0598-1 
Rathore, S., Habes, M., Iftikhar, M. A., Shacklett, A., & Davatzikos, C. (2017, July 15). A 
review on neuroimaging-based classification studies and associated feature extraction 
methods for Alzheimer’s disease and its prodromal stages. NeuroImage. Academic Press 
Inc. https://doi.org/10.1016/j.neuroimage.2017.03.057 
Rebeck, W. G., Reiter, J. S., Strickland, D. K., & Hyman, B. T. (1993). Apolipoprotein E in 
sporadic Alzheimer’s disease: Allelic variation and receptor interactions. Neuron, 11(4), 
575–580. https://doi.org/10.1016/0896-6273(93)90070-8 
Resnick, S. M., & Sojkova, J. (2011). Amyloid imaging and memory change for prediction of 
cognitive impairment. Alzheimer’s Research & Therapy, 3(1), 3. 
https://doi.org/10.1186/alzrt62 
Rovelet-Lecrux, A., Hannequin, D., Raux, G., Le Meur, N., Laquerrière, A., Vital, A., … 
Campion, D. (2006). APP locus duplication causes autosomal dominant early-onset 
Alzheimer disease with cerebral amyloid angiopathy. Nature Genetics, 38(1), 24–26. 
https://doi.org/10.1038/ng1718 
 176 
Rowe, C. C., Ng, S., Ackermann, U., Gong, S. J., Pike, K., Savage, G., … Villemagne, V. L. 
(2007). Imaging β-amyloid burden in aging and dementia. Neurology, 68(20), 1718–
1725. https://doi.org/10.1212/01.wnl.0000261919.22630.ea 
Samper-González, J., Burgos, N., Bottani, S., Fontanella, S., Lu, P., Marcoux, A., … Colliot, 
O. (2018). Reproducible evaluation of classification methods in Alzheimer’s disease: 
Framework and application to MRI and PET data. NeuroImage, 183, 504–521. 
https://doi.org/10.1016/j.neuroimage.2018.08.042 
Sander, K., Lashley, T., Gami, P., Gendron, T., Lythgoe, M. F., Rohrer, J. D., … Årstad, E. 
(2016). Characterization of tau positron emission tomography tracer [ 18 F]AV-1451 
binding to postmortem tissue in Alzheimer’s disease, primary tauopathies, and other 
dementias. Alzheimer’s & Dementia, 12(11), 1116–1124. 
https://doi.org/10.1016/j.jalz.2016.01.003 
Schneider, P., Biehl, M., & Hammer, B. (2009). Adaptive Relevance Matrices in Learning 
Vector Quantization. Neural Computation, 21(12), 3532–3561. 
https://doi.org/10.1162/neco.2009.11-08-908 
Schöll, M., Lockhart, S. N., Schonhaut, D. R., O’Neil, J. P., Janabi, M., Ossenkoppele, R., … 
Jagust, W. J. (2016). PET Imaging of Tau Deposition in the Aging Human Brain. 
Neuron, 89(5), 971–982. https://doi.org/10.1016/j.neuron.2016.01.028 
Schöll, M., Maass, A., Mattsson, N., Ashton, N. J., Blennow, K., Zetterberg, H., & Jagust, W. 
(2019, June 1). Biomarkers for tau pathology. Molecular and Cellular Neuroscience. 
Academic Press Inc. https://doi.org/10.1016/j.mcn.2018.12.001 
Schultz, S. A., Gordon, B. A., Mishra, S., Su, Y., Perrin, R. J., Cairns, N. J., … Benzinger, T. 
L. S. (2018). Widespread distribution of tauopathy in preclinical Alzheimer’s disease. 
Neurobiology of Aging, 72, 177–185. 
https://doi.org/10.1016/j.neurobiolaging.2018.08.022 
Schwarz, A. J., Yu, P., Miller, B. B., Shcherbinin, S., Dickson, J., Navitsky, M., … Mintun, 
M. S. (2016). Regional profiles of the candidate tau PET ligand 18F-AV-1451 
recapitulate key features of Braak histopathological stages. Brain : A Journal of 
Neurology, 139(Pt 5), 1539–1550. https://doi.org/10.1093/brain/aww023 
Selkoe, D. J. (1991, April 1). The molecular pathology of Alzheimer’s disease. Neuron. Cell 
Press. https://doi.org/10.1016/0896-6273(91)90052-2 
Serrano-Pozo, A., Qian, J., Monsell, S. E., Blacker, D., Gómez-Isla, T., Betensky, R. A., … 
Hyman, B. T. (2014). Mild to moderate Alzheimer dementia with insufficient 
neuropathological changes. Annals of Neurology, 75(4), 597–601. 
 177 
https://doi.org/10.1002/ana.24125 
Shi, Y., & Holtzman, D. M. (2018, December 1). Interplay between innate immunity and 
Alzheimer disease: APOE and TREM2 in the spotlight. Nature Reviews Immunology. 
Nature Publishing Group. https://doi.org/10.1038/s41577-018-0051-1 
Shi, Y., Yamada, K., Liddelow, S. A., Smith, S. T., Zhao, L., Luo, W., … Holtzman, D. M. 
(2017). ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model 
of tauopathy. Nature, 549(7673), 523–527. https://doi.org/10.1038/nature24016 
Silva, D., Guerreiro, M., Santana, I., Rodrigues, A., Cardoso, S., Maroco, J., & De 
Mendonça, A. (2013). Prediction of long-term (5 years) conversion to dementia using 
neuropsychological tests in a memory clinic setting. Journal of Alzheimer’s Disease, 
34(3), 681–689. https://doi.org/10.3233/JAD-122098 
Singh, R., Kalra, M. K., Nitiwarangkul, C., Patti, J. A., Homayounieh, F., Padole, A., … 
Digumarthy, S. R. (2018). Deep learning in chest radiography: Detection of findings and 
presence of change. PLOS ONE, 13(10), e0204155. 
https://doi.org/10.1371/journal.pone.0204155 
Singh, V., Chertkow, H., Lerch, J. P., Evans, A. C., Dorr, A. E., & Kabani, N. J. (2006). 
Spatial patterns of cortical thinning in mild cognitive impairment and Alzheimer’s 
disease. Brain : A Journal of Neurology, 129(Pt 11), 2885–2893. 
https://doi.org/10.1093/brain/awl256 
Sintini, I., Martin, P. R., Graff-Radford, J., Senjem, M. L., Schwarz, C. G., Machulda, M. M., 
… Whitwell, J. L. (2019). Longitudinal tau-PET uptake and atrophy in atypical 
Alzheimer’s disease. NeuroImage: Clinical, 23. 
https://doi.org/10.1016/j.nicl.2019.101823 
Smith, C. D., Chebrolu, H., Wekstein, D. R., Schmitt, F. A., Jicha, G. A., Cooper, G., & 
Markesbery, W. R. (2007). Brain structural alterations before mild cognitive 
impairment. Neurology, 68(16), 1268–1273. 
https://doi.org/10.1212/01.wnl.0000259542.54830.34 
Spasov, S., Passamonti, L., Duggento, A., Liò, P., & Toschi, N. (2019). A parameter-efficient 
deep learning approach to predict conversion from mild cognitive impairment to 
Alzheimer’s disease. NeuroImage, 189, 276–287. 
https://doi.org/10.1016/j.neuroimage.2019.01.031 
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., … 
Phelps, C. H. (2011). Toward defining the preclinical stages of Alzheimer’s disease: 
Recommendations from the National Institute on Aging-Alzheimer’s Association 
 178 
workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s & Dementia, 
7(3), 280–292. https://doi.org/10.1016/J.JALZ.2011.03.003 
Spillantini, M. G., Van Swieten, J. C., & Goedert, M. (2000). Tau gene mutations in 
frontotemporal dementia anti parkinsonism linked to chromosome 17 (FTDP-17). 
Neurogenetics. https://doi.org/10.1007/s100489900084 
Steiger, J. H. (1980). Tests for comparing elements of a correlation matrix. Psychological 
Bulletin, 87(2), 245–251. https://doi.org/10.1037/0033-2909.87.2.245 
Strozyk, D., Blennow, K., White, L. R., & Launer, L. J. (2003). CSF Aß 42 levels correlate 
with amyloid-neuropathology in a population-based autopsy study. Neurology, 60(4), 
652–656. https://doi.org/10.1212/01.WNL.0000046581.81650.D0 
T., S., C., R., F., A., N., M., K., B., H., Z., … Zetterberg, H. (2014). Diagnostic performance 
of cerebrospinal fluid total tau and phosphorylated tau in Creutzfeldt-Jakob disease: 
Results from the Swedish Mortality Registry. JAMA Neurology, 71(4), 476–483. 
https://doi.org/10.1001/jamaneurol.2013.6455 LK  - 
http://ze6dt7rj9y.search.serialssolutions.com?sid=EMBASE&issn=21686149&id=doi:1
0.1001%2Fjamaneurol.2013.6455&atitle=Diagnostic+performance+of+cerebrospinal+fl
uid+total+tau+and+phosphorylated+tau+in+Creutzfeldt-
Jakob+disease%3A+Results+from+the+Swedish+Mortality+Registry&stitle=JAMA+N
eurol.&title=JAMA+Neurology&volume=71&issue=4&spage=476&epage=483&aulast
=Skillb%C3%A4ck&aufirst=Tobias&auinit=T.&aufull=Skillb%C3%A4ck+T.&coden=
&isbn=&pages=476-483&date=2014&auinit 
Tabert, M. H., Manly, J. J., Liu, X., Pelton, G. H., Rosenblum, S., Jacobs, M., … Devanand, 
D. P. (2006). Neuropsychological prediction of conversion to alzheimer disease in 
patients with mild cognitive impairment. Archives of General Psychiatry, 63(8), 916–
924. https://doi.org/10.1001/archpsyc.63.8.916 
Tang, E. Y. H., Harrison, S. L., Errington, L., Gordon, M. F., Visser, P. J., Novak, G., … 
Stephan, B. C. M. (2015). Current Developments in Dementia Risk Prediction 
Modelling: An Updated Systematic Review. PLOS ONE, 10(9), e0136181. 
https://doi.org/10.1371/journal.pone.0136181 
Tanveer, M., Richhariya, B., Khan, R. U., Rashid, A. H., Khanna, P., Prasad, M., & Lin, C. 
T. (2020). Machine Learning Techniques for the Diagnosis of Alzheimer’s Disease. 
ACM Transactions on Multimedia Computing, Communications, and Applications, 
16(1s), 1–35. https://doi.org/10.1145/3344998 
Tanzi, R. E., Gusella, J. F., Watkins, P. C., Bruns, G. A. P., St. George-Hyslop, P., Van 
 179 
Keuren, M. L., … Neve, R. L. (1987). Amyloid β protein gene: CDNA, mRNA 
distribution, and genetic linkage near the Alzheimer locus. Science, 235(4791), 880–
884. https://doi.org/10.1126/science.2949367 
Tapiola, T., Alafuzoff, I., Herukka, S. K., Parkkinen, L., Hartikainen, P., Soininen, H., & 
Pirttilä, T. (2009). Cerebrospinal fluid β-amyloid 42 and tau proteins as biomarkers of 
Alzheimer-type pathologic changes in the brain. Archives of Neurology, 66(3), 382–389. 
https://doi.org/10.1001/archneurol.2008.596 
Thung, K.-H., Yap, P.-T., Adeli, E., Lee, S.-W., & Shen, D. (2018). Conversion and time-to-
conversion predictions of mild cognitive impairment using low-rank affinity pursuit 
denoising and matrix completion. Medical Image Analysis, 45, 68–82. 
https://doi.org/10.1016/J.MEDIA.2018.01.002 
Thung, K. H., Yap, P. T., Adeli, E., Lee, S. W., & Shen, D. (2018). Conversion and time-to-
conversion predictions of mild cognitive impairment using low-rank affinity pursuit 
denoising and matrix completion. Medical Image Analysis, 45, 68–82. 
https://doi.org/10.1016/j.media.2018.01.002 
Topol, E. J. (2019). High-performance medicine: the convergence of human and artificial 
intelligence. Nature Medicine, 25(1), 44–56. https://doi.org/10.1038/s41591-018-0300-7 
Tosun, D., Landau, S., Aisen, P. S., Petersen, R. C., Mintun, M., Jagust, W., … Alzheimer’s 
Disease Neuroimaging Initiative. (2017). Association between tau deposition and 
antecedent amyloid-β accumulation rates in normal and early symptomatic individuals. 
Brain : A Journal of Neurology, 140(5), 1499–1512. 
https://doi.org/10.1093/brain/awx046 
van der Kant, R., Goldstein, L. S. B., & Ossenkoppele, R. (2020, January 1). Amyloid-β-
independent regulators of tau pathology in Alzheimer disease. Nature Reviews 
Neuroscience. Nature Research. https://doi.org/10.1038/s41583-019-0240-3 
van Maurik, I. S., Vos, S. J., Bos, I., Bouwman, F. H., Teunissen, C. E., Scheltens, P., … van 
der Flier, W. M. (2019). Biomarker-based prognosis for people with mild cognitive 
impairment (ABIDE): a modelling study. The Lancet Neurology, 18(11), 1034–1044. 
https://doi.org/10.1016/S1474-4422(19)30283-2 
Vogel, J. W., Vachon-Presseau, E., Pichet Binette, A., Tam, A., Orban, P., La Joie, R., … 
Villeneuve, S. (2018). Brain properties predict proximity to symptom onset in sporadic 
Alzheimer’s disease. Brain, 141(6), 1871–1883. https://doi.org/10.1093/brain/awy093 
Wang, L., Benzinger, T. L., Su, Y., Christensen, J., Friedrichsen, K., Aldea, P., … Ances, B. 
M. (2016). Evaluation of Tau imaging in staging Alzheimer disease and revealing 
 180 
interactions between β-Amyloid and tauopathy. JAMA Neurology, 73(9), 1070–1077. 
https://doi.org/10.1001/jamaneurol.2016.2078 
Wang, Y., Haaksma, M. L., Ramakers, I. H. G. B., Verhey, F. R. J., Flier, W. M., Scheltens, 
P., … Melis, R. J. F. (2019). Cognitive and functional progression of dementia in two 
longitudinal studies. International Journal of Geriatric Psychiatry, gps.5175. 
https://doi.org/10.1002/gps.5175 
Wei, W., Poirion, E., Bodini, B., Tonietto, M., Durrleman, S., Colliot, O., … Ayache, N. 
(2020). Predicting PET-derived Myelin Content from Multisequence MRI for Individual 
Longitudinal Analysis in Multiple Sclerosis. NeuroImage, 117308. 
https://doi.org/10.1016/j.neuroimage.2020.117308 
Weiner, M. W., Veitch, D. P., Aisen, P. S., Beckett, L. A., Cairns, N. J., Cedarbaum, J., … 
Trojanowski, J. Q. (2015). 2014 Update of the Alzheimer’s Disease Neuroimaging 
Initiative: A review of papers published since its inception. Alzheimer’s and Dementia, 
11(6), e1–e120. https://doi.org/10.1016/j.jalz.2014.11.001 
Weiner, M. W., Veitch, D. P., Aisen, P. S., Beckett, L. A., Cairns, N. J., Green, R. C., … 
Trojanowski, J. Q. (2017). Recent publications from the Alzheimer’s Disease 
Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials. 
Alzheimer’s and Dementia, 13(4), e1–e85. https://doi.org/10.1016/j.jalz.2016.11.007 
Whitwell, J. L., Przybelski, S. A., Weigand, S. D., Knopman, D. S., Boeve, B. F., Petersen, 
R. C., & Jack, C. R. (2007). 3D maps from multiple MRI illustrate changing atrophy 
patterns as subjects progress from mild cognitive impairment to Alzheimer’s disease. 
Brain, 130(7), 1777–1786. https://doi.org/10.1093/brain/awm112 
Wilkosz, P. A., Seltman, H. J., Devlin, B., Weamer, E. A., Lopez, O. L., DeKosky, S. T., & 
Sweet, R. A. (2010). Trajectories of cognitive decline in Alzheimer’s disease. 
International Psychogeriatrics, 22(2), 281–290. 
https://doi.org/10.1017/S1041610209991001 
Wolpert, D. H., & Macready, W. G. (1997). No free lunch theorems for optimization. IEEE 
Transactions on Evolutionary Computation, 1(1), 67–82. 
https://doi.org/10.1109/4235.585893 
Woo, C.-W., Chang, L. J., Lindquist, M. A., & Wager, T. D. (2017). Building better 
biomarkers: brain models in translational neuroimaging. Nature Neuroscience, 20(3), 
365–377. https://doi.org/10.1038/nn.4478 
Yesavage, J. A. (1988). Geriatric depression scale. Psychopharmacol Bull, 24(4), 709–711. 
Young, A. L., Marinescu, R. V., Oxtoby, N. P., Bocchetta, M., Yong, K., Firth, N. C., … 
 181 
Furst, A. J. (2018). Uncovering the heterogeneity and temporal complexity of 
neurodegenerative diseases with Subtype and Stage Inference. Nature Communications, 
9(1), 4273. https://doi.org/10.1038/s41467-018-05892-0 
Young, A. L., Oxtoby, N. P., Daga, P., Cash, D. M., Fox, N. C., Ourselin, S., … Alzheimer’s 
Disease Neuroimaging Initiative. (2014). A data-driven model of biomarker changes in 
sporadic Alzheimer’s disease. Brain, 137(9), 2564. 
https://doi.org/10.1093/BRAIN/AWU176 
Zhang, D., Shen, D., & Initiative, A. D. N. (2012). Predicting Future Clinical Changes of 
MCI Patients Using Longitudinal and Multimodal Biomarkers. PLoS ONE, 7(3), 
e33182. https://doi.org/10.1371/journal.pone.0033182 
Zhou, T., Thung, K.-H., Liu, M., Shi, F., Zhang, C., & Shen, D. (2018). Multi-modal 
Neuroimaging Data Fusion via Latent Space Learning for Alzheimer’s Disease 
Diagnosis (pp. 76–84). Springer, Cham. https://doi.org/10.1007/978-3-030-00320-3_10 
Zhu, X., Suk, H. Il, Lee, S. W., & Shen, D. (2016). Canonical feature selection for joint 
regression and multi-class identification in Alzheimer’s disease diagnosis. Brain 
Imaging and Behavior, 10(3), 818–828. https://doi.org/10.1007/s11682-015-9430-4 
 
 
 
 
 
 
 
 
 
 
